Filing under Rule 425 under the Securities Act

of 1933 and deemed filed under Rule 14a-12 of

the Securities Exchange Act of 1934

Filed by: Pershing Square Capital Management, L.P.

Subject Company: Valeant Pharmaceuticals International, Inc.

SEC File No. of Valeant Pharmaceuticals International, Inc.: 001-14956


LOGO

ADVANCING ALLERGAN
HOME WEBCAST NOMINEES SHAREHOLDER MATERIALS NEWS RELEASES
PROPOSED BY-LAWS
VALEANT AND ALLERGAN: CREATING VALUE TOGETHER
On April 22, 2014, Valeant Pharmaceuticals International and Pershing Square Capital Management announced their joint bid for Allergan. As Allergan’s largest shareholder, Pershing Square is working to maximize value for all Allergan shareholders. To date, Allergan has been unwilling to engage in discussions with Valeant or Pershing Square, which have twice increased their bid. The combination of Valeant and Allergan is not only financially compelling, it also creates a company better positioned to develop and advance new drugs around the world. Because Allergan’s Board of Directors has consistently refused to negotiate, on June 18, 2014, Valeant commenced an exchange offer for the common stock of Allergan and is taking its May 30th proposal directly to Allergan stockholders.
MEET THE NOMINEES
Betsy Atkins Cathleen P. Black Fredric N. Eshelman Steven J. Shulman David A. Wilson John J. Zillmer
Learn more about Pershing Square’s nominees to the Board of Directors.
CLICK FOR BIOS
HOW TO CALL A SPECIAL MEETING
SHAREHOLDERS
DTC PARTICIPANTS
FORMS TO COMPLETE TO BECOME A PROPOSING PERSON AND CALL A SPECIAL MEETING OF SHAREHOLDERS
Solicitation Statement Request Form to Call a Special Meeting Exhibit B-1—DTC Instruction Letter Exhibit B-2 – CEDE & Co. Meeting Request Exhibit C—Verification Letter Exhibit D—WHITE Proxy Card VIEW ALL FORMS
QUESTIONS
Why is Pershing Square asking shareholders to call a special meeting? What are you asking me to do? What steps must each Allergan shareholder take? What steps must each DTC Participant take? What is the record date for the calling of a special meeting? How many shares do you need you call a special meeting? SEE ALL FAQS
TIMELINE
Since Valeant Pharmaceuticals International and Pershing Square Capital Management announced their joint bid for Allergan April 22, Allergan’s Board of Directors has declined to engage with either Valeant or PSCM, its largest shareholder. This timeline traces the progression of the bid since its announcement and the steps Valeant and Pershing Square have taken to encourage productive discussions with the Allergan Board.
04-22-14
VALEANT AND PERSHING SQUARE ANNOUNCE BID TO ACQUIRE ALLERGAN
Valeant and Pershing Square announce bid to acquire Allergan ($48.30 + 0.83 share of VRX) Pershing Square’s Presentation. Allergan adopts a poison pill Read More
05-13-14
ALLERGAN REJECTS VALEANT’S BID
Allergan rejects Valeant’s bid; Pershing Square seeks list of Allergan stockholders and the next day files preliminary proxy to launch process to hold informal shareholder referendum on the bid.
05-19-14
PERSHING SQUARE URGES ALLERGAN INDEPENDENT DIRECTORS TO HIRE INDEPENDENT COUNSEL
Pershing Square urges Allergan independent directors to hire independent counsel, arguing Allergan’s CEO is conflicted because he will lose his leadership role at the company and likely his job as a result of the transaction Read More
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
July 17, 2014 Webcast
DOWNLOAD PRESENTATION
Calling for a Special Meeting of Allergan Shareholders
July      2014
Pershing Square Capital Management, L.P.
VIEW TRANSCRIPT
© 2014 Pershing Square Capital Management


Pershing Square Capital Management, L.P.
Calling
for
a
Special
Meeting
of
Allergan
Shareholders
July 17, 2014


1
Legal Disclaimer
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to Pershing
Square Capital Management, L.P.’s (“Pershing Square”)  solicitation of written requests to call a special meeting of shareholders of Allergan, Inc.
(“Allergan”) in connection with the proposal which Valeant Pharmaceuticals International, Inc. (“Valeant”) has made for a business combination
transaction with Allergan. In furtherance of this proposal and subject to future developments, Pershing Square has filed a definitive solicitation
statement with the Securities and Exchange Commission (the “SEC”) on July 11, 2014 (the “solicitation statement”), Valeant has filed a
registration statement on Form S-4 (the “Form S-4”) and a tender offer statement on Schedule TO (including the offer to exchange, the letter of
election and transmittal and other related offer materials) with the SEC on June 18, 2014 (together with the Form S-4, the “Schedule TO”),  and a
preliminary proxy statement on June 24, 2014 with respect to a meeting of Valeant shareholders.  Pershing Square and Valeant (and, if a
negotiated transaction is agreed, Allergan) may file one or more solicitation statements, registration statements, proxy statements, tender or
exchange offer documents or other documents with the SEC. This communication is not a substitute for the solicitation statement, the Schedule
TO, or any other solicitation statement, proxy statement, registration statement, prospectus, tender or exchange offer document or other document
Pershing Square, Valeant and/or Allergan may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY
HOLDERS OF VALEANT AND ALLERGAN ARE URGED TO READ THE SOLICITATION STATEMENT, PROXY STATEMENT(S),
REGISTRATION STATEMENT, PROSPECTUS, TENDER OR EXCHANGE OFFER DOCUMENTS AND OTHER DOCUMENTS FILED WITH
THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION. The solicitation statement is currently being mailed to stockholders of Allergan.  Any
definitive solicitation statement or proxy statement(s) or definitive tender or exchange offer documents (if and when available) will be mailed to
stockholders of Allergan and/or Valeant, as applicable.  Investors and security holders will be able to obtain free copies of the solicitation
statement and the Schedule TO and will be able to obtain free copies of these other documents filed with the SEC by Pershing Square and/or
Valeant through the web site maintained by the SEC at http://www.sec.gov.
Information regarding the names and interests in Allergan and Valeant of Pershing Square and persons related to Pershing Square who may be
deemed participants in any solicitation of Allergan or Valeant shareholders in respect of a Valeant proposal for a business combination with
Allergan is available in the solicitation statement.  The solicitation statement can be obtained free of charge from the sources indicated.


2
Legal Disclaimer (Cont.)
The information in this presentation is for informational purposes only, and this presentation shall not constitute an offer to sell or a solicitation of an
offer to purchase any security or investment product, nor does it constitute professional advice. This presentation and the information contained
herein is not investment advice or a recommendation or solicitation to buy or sell any securities. All investments involve risk, including the loss of
principal. Pershing Square recognizes that there may be confidential information in the possession of the companies discussed in this presentation
that could lead these companies to disagree with Pershing Square’s conclusions. The information contained in this presentation is subject in all
respects to the disclosure set forth in the reports filed by Allergan and Valeant with the SEC. Except where otherwise indicated, the information in this
presentation speaks only as of the date of this presentation. Permission to quote third-party reports in this presentation has been neither 
sought nor obtained, nor was consent obtained or sought with respect to third party statements referenced in this presentation.
This presentation is not all inclusive and may not contain all of the information that you require in order to evaluate Allergan and Valeant and the
transactions described in this presentation. You should review Valeant’s and Allergan’s most recent annual and quarterly reports and other reports
filed by Valeant and Allergan with the SEC. You should rely on your own independent analysis to assess the accuracy and completeness of all
information contained herein.  No representation, warranty or undertaking, expressed or implied, is or will be made and no responsibility or liability is or
will be accepted by Pershing Square or its affiliates or associates, or any of their respective directors, officers, employees, agents, shareholders or
advisors, as to, or in relation to, the accuracy or completeness of the information contained in the presentation, or any other information, errors therein
or omissions therefrom.
By presenting this information, none of Pershing Square or its affiliates or associates, or any of their respective directors, officers, employees, agents,
shareholders or advisors, is providing investment, legal, tax, financial, accounting or other advice to you or to any other party. None of Pershing
Square or its affiliates or associates, or any of their respective directors, officers, employees, agents, shareholders or advisors, is acting 
as an advisor or fiduciary in any respect in connection with providing this information.
Funds managed by Pershing Square and its affiliates are invested in Allergan common stock and other securities. Pershing Square manages funds
that are in the business of trading – buying and selling – securities and financial instruments. It is possible that there will be developments in the future
that cause Pershing Square to change its position regarding Allergan, Valeant and the proposed Valeant-Allergan business combination. Pershing
Square may buy, sell, cover or otherwise change the form of its investment in Allergan for any reason. Pershing Square hereby disclaims any duty to
provide any updates or changes to the analyses contained here including, without limitation, the manner or type of any Pershing 
Square investment.


3
Legal Disclaimer (Cont.)
Non-GAAP Financial Measures
This presentation includes certain non-GAAP financial measures, including but not limited to cash net income and EBITDA (collectively, “non-
GAAP financial measures”). These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial
measures prepared in accordance with GAAP. Pershing Square believes that the presentation of these financial measures enhances an investor’s
understanding of Valeant’s and Allergan’s financial performance. Pershing Square further believes that these financial measures are useful
financial metrics to assess operating performance from period to period by excluding certain items that it believes are not representative of
Valeant’s and Allergan’s respective core businesses. Pershing Square also believes that these financial measures provide investors with a useful
tool for assessing the comparability between periods of Valeant’s and Allergan’s respective abilities to generate cash from operations sufficient to
pay taxes, to service debt and to undertake capital expenditures. Pershing Square believes these financial measures are commonly used by
investors to evaluate companies’ performance. However, the use of these non-GAAP financial measures in this presentation may vary from that of
other companies in Valeant’s and Allergan’s industry. These non-GAAP financial measures should not be considered as alternatives to
performance measures derived in accordance with GAAP.


Legal Disclaimer (Cont.)
4
This presentation contains forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding Valeant’s offer to
acquire Allergan, Valeant’s financing of the proposed transaction, Valeant’s or Allergan’s expected future value and performance (including expected results of
operations and financial guidance), and the combined company’s future financial condition, operation results, strategy and plans.  Forward-looking statements may
be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,”
“opportunity,” “tentative,” “positioning,” “designed,” “create,” “predict,” “project,” “seek,” “ongoing,” “upside,” “increases” or “continue” and variations or similar
expressions and include but are not limited to beliefs expressed regarding future performance. These statements are based upon the current expectations and
beliefs of Pershing Square and are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results to differ
materially from those described in the forward-looking statements. These assumptions, risks and uncertainties include, but are not limited to, assumptions, risks
and uncertainties discussed in Valeant’s and/or Allergan’s most recent annual or quarterly reports filed with the SEC and the Canadian Securities Administrators
(the “CSA”) and assumptions, risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant’s filings with the SEC and the CSA.
Important factors that could cause actual results to differ materially from the forward-looking statements we make in this presentation are set forth in other reports
or documents that Valeant and/or Allergan file from time to time with the SEC or the CSA, and include, but are not limited to:
the ultimate outcome of any possible transaction between Valeant and Allergan, including the possibilities that Valeant will not pursue a transaction with Allergan
and that Allergan will reject a transaction with Valeant;
if a transaction between Valeant and Allergan were to occur, the ultimate outcome and results of integrating the operations of Valeant and Allergan, the ultimate
outcome of Valeant’s pricing and operating strategy applied to Allergan and the ultimate ability to realize synergies;
the effects of the business combination of Valeant and Allergan, including the combined company’s future financial condition, operating results, strategy and plans
the effects of governmental regulation on Valeant’s and Allergan’s business or potential business combination transaction;
ability to obtain regulatory approvals and meet other closing conditions to the transaction, including all necessary stockholder approvals, on a timely basis;
Valeant’s and Allergan’s ability to sustain and grow revenues and cash flow from operations in their respective markets and to maintain and grow their respective
customer bases, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
the impact of competition from other market participants;
the development and commercialization of new products;
the availability and access, in general, of funds to meet Valeant’s and Allergan’s debt obligations prior to or when they become due and to fund their operations
and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets; 
Valeant’s and Allergan’s ability to comply with all covenants in their respective indentures and credit facilities any violation of which, if not cured in a timely manner,
could trigger a default of their respective other obligations under cross-default provisions; and
the risks and uncertainties detailed by Valeant and Allergan with respect to their respective businesses as described in their respective reports and documents
filed with the SEC.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers
are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  None
of Pershing Square or any of its affiliates or associates, or any of their respective directors, officers, employees, agents, shareholders or advisors undertakes any
obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes.


5
Executive Summary
There are two principal reasons we are calling for a
special meeting
1)
To fix the special meeting provisions in Allergan’s bylaws,
which are unduly onerous and anti-shareholder
2)
To remove directors and propose the appointment of new
directors  who will engage with Valeant on its compelling
and certain offer to acquire Allergan at a 50%+ premium to
Allergan’s unaffected share price


6
I
A Special Meeting is Warranted Given Allergan’s Record of Poor                      
Corporate Governance
The Current Offer Justifies Board Engagement and Meets Investors’
“Asking Price”
The Valeant Offer Satisfies the Prevailing M&A Proxy Fight Analytical Framework
Investors and Research Analysts Are Confident in Valeant’s Operating Model
and the Strategic Combination
Risks in Allergan’s Business Model
Allergan’s History of Poor Cost Management
Allergan’s Poor Track Record of Allocating Capital
II
III
IV
V
VI
VII
Table of Contents
Allergan’s Shareholder Unfriendly Compensation Policies
VIII
We Believe There is Significant Downside to Allergan’s Standalone Stock Price
IX


I. A Special Meeting is Warranted Given
Allergan’s Record of Poor Corporate
Governance
7


8
To date, Allergan’s board has responded extremely
poorly to Valeant’s highly compelling and certain offer
Has refused to engage with Valeant
Has refused to meet with Pershing Square, Allergan’s
largest shareholder, without management present
Has attacked Valeant’s business model and management
with claims unsupported by factual evidence
A Special Meeting is Warranted Given Allergan’s
Record of Poor Corporate Governance


9
Members of the board of directors of a Delaware
corporation faced with a takeover bid are required to
inform themselves of all material information about a
transaction and then act with care in evaluating it
By failing to authorize the board’s advisors to meet with
Valeant to address any of the board’s stated concerns
about Valeant, the board and its advisors have failed to
do properly consider the Valeant transaction
A Special Meeting is Warranted Given Allergan’s
Record of Poor Corporate Governance (Cont.)
The board’s actions have deprived shareholders of the
opportunity to consider this offer


10
This board’s recent behavior is consistent with
Allergan’s past poor corporate governance
Shareholders deserve the right to elect a board who will
protect their interests as owners of the company
Shareholders also deserve the right to call a special
meeting free of onerous provisions and impediments
We have proposed a special meeting, which Allergan has
sought to suppress, to enfranchise shareholders
A Special Meeting is Warranted Given Allergan’s
Record of Poor Corporate Governance (Cont.)


ISS 2014 US Proxy Voting Guidelines:
“In terms of day-to-day governance, shareholders may lose an important right—
the ability to remove directors or initiate a shareholder resolution without having to
wait for the next scheduled meeting—if they are unable to call a timely special
meeting.  Shareholders could also be powerless to respond to a beneficial offer if
a bidder cannot call a special meeting.
Over the past few years…companies have responded to shareholder resolutions
seeking the right to call special meetings by offering management proposals with
stricter requirements…Such restrictions can be used as anti-takeover devices-
impeding the removal of incumbent board members or delaying a takeover
attempt of the company—and, therefore, run counter to the stated intention of
allowing shareholders to call special meetings.”
“Limitations on written consent are clearly contrary to shareholder interests…
Beneficial tender offers may also be precluded because of a bidder’s inability to
take action by written consent.”
11
ISS Supports Special Meeting and Written Consent Rights as
Important Tools for Empowering Shareholders to Respond to   
Attractive Offers


“But the value of a shareholder meeting is precisely that it provides a definitive,
authentic, and unassailable answer to the question of what shareholders want.
Not every shareholder is in agreement on every issue, to be sure—but
shareholders in general, and institutional shareholders in particular, accept that
the shareholder vote is the premier mechanism for the owners of the company to
settle significant questions about the company’s future.”
“Engagement can be a very effective mechanism for providing the board with
insight; for settling complex questions about the company’s future, however, it
lacks the definitive authority of the shareholder vote itself.”
ISS analysis on Darden Restaurants (April 24, 2014):
ISS recommendation: FOR the Consent to Request a Special Meeting
12
ISS Supports Special Meeting and Written Consent Rights as
Important Tools for Empowering Shareholders to Respond to   
Attractive Offers (Cont.)


25% of the vote required
Timing restrictions
Unduly onerous disclosure
requirements to make request
Restrictions on “similar items”
Restriction on stock sales by
shareholders requesting a
special meeting
13
2012
Shareholder
Proposal
(% of votes cast)
(1)
Call special meetings with
10% of the vote
(55.3%)
2013
2014
Mgmt Rec.
ISS Rec.
Right to act by
written consent
(50.2%)
Separation of
Chairman / CEO
(50.5%)
AGAINST
AGAINST
AGAINST
FOR
FOR
FOR
Placed on ballot a year later but
with substantial restrictions
Placed on ballot a year later but
with substantial restrictions
No action taken, to date
Mgmt
Response
25% of the vote required
Timing restrictions
Restrictions on “similar
items”
N/A
Restrictions
(1)
Votes FOR as % of votes [FOR + AGAINST]
GL Rec.
FOR
FOR
FOR
Allergan has Used Procedural Restrictions to
Neuter Mechanisms for Shareholder Action


14
Allergan’s Special Meeting Provision Provides a
Heavily Restricted Right
Requirement
for
shareholders
themselves
to
become
RECORD
OWNERS
Special
meetings
may
not
consider
any
“Similar
Items”
covered
at a
meeting in the previous year
By
which
the
Allergan
board
seeks
to
PROHIBIT
THE
ELECTION
OF
NEW
DIRECTORS
at
a
special
meeting,
even
if
current
Allergan
directors
are
removed
(1)
Unduly onerous disclosure requirements (with ongoing duty to update) for
requesting
shareholders
(e.g.,
2-year
trading
data,
relationships
with
AGN
employees
and
competitors)
Highly unusual requirement for Cede & Co. to itself submit individual
signed meeting requests (rather than granting the usual omnibus proxy)
The board determines, in sole discretion, whether meeting requests are
compliant
(1)
A
shareholder
derivative
lawsuit
is
pending
in
Delaware
challenging
the
Allergan
board’s
attempted
application
of
“Similar
Items”
to
replacing
directors
( In
re
Allergan,
Inc. Stockholder Litigation ).
To frustrate shareholder action, Allergan designed unnecessary
restrictions to calling a special meeting


25%
of the voting power of the company’s common stock required to
request a special meeting
The
meeting
request
must
be
“IN
PROPER
FORM” ,
meaning
the
requesting shareholders must make certain concessions including:
Representations
that
they
INTEND
TO
HOLD
THEIR
SHARES
through
the
date
of the special meeting
Acknowledgements that a sale of their Allergan shares prior to the meeting date
will constitute a corresponding reduction of shares in support of the special
meeting request, even if shares are repurchased prior to the meeting
Shareholders requesting the special meeting must continue to hold at
least
of
the
company’s
shares
until
the
special
meeting
date
or
the meeting may be cancelled
15
Allergan’s Special Meeting Provision Provides a
Heavily Restricted Right (Cont.)
To frustrate shareholder action, Allergan designed unnecessary
restrictions to calling a special meeting
25%


Allergan’s Special Meeting Provision Provides a
Heavily Restricted Right (Cont.)
Allergan’s special meeting timing restrictions effectively limit the special
meeting window to only one meeting per year within a narrow three and one
half-month period
Allergan’s board can delay a special meeting by up to 120 days from the date
requested
No requests are allowed from 90 days prior to the anniversary of the previous
AGM until the adjournment of the next AGM
Illustrative Timeline:
Oct
Aug
Sep
Jun
Jul
May 7:
Assumes request is
made the first day
after the AGM
Nov
Dec
Jan
Mar
Apr
May
Feb
Management can delay
up to 120 days
Special meeting
window
May 6:
Anniversary of
previous AGM
90-days prior to
anniversary of AGM
Solicitation period:
a. ~2 weeks for SEC
clearance
b.
~4 weeks for proxy
solicitation
~3.5 months
To frustrate shareholder action, Allergan designed unnecessary
restrictions to calling a special meeting
16


17
Allergan’s bylaws as written provide onerous burdens
There are, however, misperceptions that need to be addressed
Shareholders
are
required
to
represent
that
they
intend
to
hold
shares through the special meeting
Shareholders are still permitted to sell their shares after
announcing their intention to hold them, but any shares sold will
not count towards the 25% requirement to call a special meeting
While the sale of a share revokes that share from the special
meeting solicitation, the remainder of that investor’s position will
continue to qualify in support of the meeting
Misperceptions Regarding Calling a
Special Meeting


18
25% of the company’s shares are required to request a record date to
act by written consent
Similar unduly onerous disclosure requirements (with ongoing duty to
update) for requesting a record date as those to request a special
meeting
Action by written consent cannot cover “Similar Items”
considered at
a meeting in the previous 12 months, including the election of
directors, or any business to be presented at a meeting to be held
within 90 days
No consents can be dated or delivered until 90 days after delivery of
the request for a record date
Stockholders cannot act by written consent if the Allergan board
calls
a meeting to present a substantially “Similar Item”
A special meeting will allow shareholders to remedy these
problematic governance provisions as quickly as possible
Allergan’s Written Consent Provision Provides the
Illusion of Shareholder Rights


19
On April 22
nd
, the same day that Valeant first announced its proposal,
Allergan adopted a poison pill that limits shareholder communication
On June 6
th
, Pershing Square asked Allergan to clarify, among other
things, that the solicitation and receipt of proxies would not trigger
the pill
In
Allergan’s
June
11
th
reply, Allergan refused to respond directly on
this issue
Only after Pershing Square commenced an action in Delaware court
regarding this issue did management confirm that the solicitation of
proxies and certain related activities would not trigger the pill
Allergan’s Board has Taken Steps to Obstruct a
Special Meeting
Allergan’s board and management used ambiguity regarding the
poison pill to discourage the solicitation of proxies


20
Allergan shareholders must comply with a series of up
to four procedural steps, each requiring extensive
disclosure and documentation, to submit a request to
call a special meeting
The Allergan board has launched a revocation campaign
against calling a special meeting
To support a revocation, shareholders need only submit
a simple proxy card providing their name and checking a
box in one step
Allergan’s Board has Taken Steps to Obstruct a
Special Meeting (Cont.)
It takes up to four procedural steps to call a special meeting but
only one step to support a revocation
Steps
4
1
Allergan management is soliciting against a fundamental right it
has supposedly granted shareholders


Allergan
states
that
the
distraction
and
time
and
financial
cost
of
holding a meeting are the reasons why a special meeting should not
be held
These costs would go away if Allergan would immediately engage
with Valeant regarding the proposed transaction
21
Allergan’s Argument Against Holding a
Special Meeting
Allergan Schedule 14A filed July 15, 2014


22
Allergan has Ignored its Own
Corporate Governance Guidelines
Despite this clearly stated guideline, Allergan has refused any opportunity to discuss the
Valeant proposal with the lead independent director without Mr. Pyott being present
Pershing Square first requested a discussion with Mr. Gallagher on April 23  .  Allergan
complied but included Mr. Pyott on the call
During the call, Mr. Ackman requested a meeting with Mr. Gallagher in executive session,
which Mr. Gallagher rejected
Mr. Ackman proposed a subsequent conversation with Mr. Gallagher, but Mr. Gallagher
refused to provide any contact details
Mr. Ackman offered to speak with Mr. Gallagher with the board’s counsel present, but Mr.
Gallagher again refused
On May 13
th
, Mr. Pyott told Mr. Ackman that he was the only member of the board
authorized to speak with shareholders
[Emphasis added]
Allergan’s 2014 proxy supplement
Allergan’s 2014 proxy statement
rd


23
Shareholder proposal passed
at 2014 AGM to separate
CEO/Chairman roles
Lengthy tenure may
impact independence and
objectivity
No “skin in the game”,
limited alignment with
investors
(1)
ISS recommended AGAINST the re-election of Mr. Gallagher at the 2014 AGM for failing as Corporate Governance and Compliance Committee Chair to fully implement a shareholder proposal that received majority support
at the 2013 AGM to amend the corporate charter to allow shareholders to act by written consent.  Although the Board did include such a proposal at the 2014 AGM, it included a restriction limiting agenda items and a
requirement that 25 percent of the outstanding shares are required to request a record date.
(1)
Members of Corporate Governance
Committee received lower than average
shareholder support at the 2014 AGM
Allergan’s Board is Characterized by Long Tenures,
Low Stock Ownership, and Weak Governance
Shares Held
Committees
2014 AGM
Name
Title
Board
Tenure (Y)
Age
Shares
(000's)
% O/S
Audit /
Finance
Corp.
Gov.
Org. &
Comp.
Sci. &
Tech.
% Votes
ISS Rec.
GL Rec.
David E.I. Pyott
CEO / Chairman
16
60
234.2
<0.1%
91.4%
FOR
FOR
Michael R. Gallagher
Lead Director
16
68
39.2
<0.1%
C
C
66.7%
AGAINST
AGAINST
Deborah Dunsire, M.D.
Director
8
51
38.0
<0.1%
M
M
95.0%
FOR
FOR
Trevor M. Jones, Ph.D.
Director
10
71
7.5
<0.1%
M
C
88.5%
FOR
AGAINST
Louis J. Lavigne, Jr.
Director
9
65
20.0
<0.1%
M
M
94.9%
FOR
FOR
Peter J. McDonnell, M.D.
Director
1
55
5.6
<0.1%
M
M
88.3%
FOR
AGAINST
Timothy D. Proctor
Director
1
64
5.6
<0.1%
M
M
94.0%
FOR
FOR
Russell T. Ray
Director
11
66
27.2
<0.1%
C
M
94.2%
FOR
FOR
Henri A. Termeer
Director
0
68
2.5
<0.1%
M
M
95.0%
FOR
FOR
Source:
Name, title, tenure, age and committees per Allergan’s proxy statement filed with the SEC March 26, 2014; Shares held per FactSet; ISS recommendation per April 23, 2014 ISS report; Glass Lewis recommendation per April
13, 2014 Glass Lewis report; and vote results per Allergan’s Form  8-K filed with the SEC May 9, 2014.


ISS Has Identified a High Possibility of
Governance Risk at Allergan
24
Source: Institutional Shareholder Services.
(1)         May 28, 2014 ISS Governance QuickScore Profile.
This May, ISS awarded Allergan a governance QuickScore of 8,
indicating
a
HIGH
POSSIBLILITY
OF
GOVERNANCE
RISK
(1)
The board did not adequately address a shareholder proposal supported by the majority of
shares voted
ISS recommended AGAINST the re-election of Mr. Gallagher at the 2014 AGM for failing
as Corporate Governance and Compliance Committee Chair to fully implement the
2013 shareholder proposal to allow action by written consent; Gallagher received
33.3% withhold votes
8 of 9 of directors received shareholder approval rates below the average (95%) level at the
most recent shareholder meeting
3 directors received below 90% of the vote
3 of 8 of the non-executive directors on the board have lengthy tenure
The roles of Chairman and CEO have not been separated even though a majority of
shareholders voting approved a proposal to separate at Allergan’s 2014 AGM
Shareholder
rights
(9
/10;
10
is
the
lowest
ISS
ranking)
The company has a poison pill in effect with a 10% trigger threshold
25% of share capital is needed to convene a special meeting or act by written consent
Board
structure
(10
/10;
10
is
the
lowest
ISS
ranking)
There are material restrictions on shareholders’ right to call special meetings or
act by written consent


25
The existence of a poison pill makes it impossible for shareholders to
take advantage of Valeant’s exchange offer for Allergan shares
Without a special meeting, Allergan’s board could disenfranchise
shareholders on this transaction until the company’s next AGM
Allergan could delay the company’s 2015 AGM beyond next May
In the meantime, we believe there is significant risk to shareholder
value at Allergan
Valeant may be forced to or choose to abandon the transaction
Allergan’s board could take value-destructive actions to thwart the
Valeant offer
The special meeting provides shareholders an important
opportunity to:
Create a path to completion of a compelling offer
Rectify onerous bylaw and charter provisions that disenfranchise
shareholders
Why a Special Meeting is Necessary to Protect
Shareholder Rights


At the Special Meeting, shareholders can vote to remove
Allergan directors 
Pershing Square will propose to remove six of Allergan’s nine
directors, to be replaced with new candidates Pershing Square
has identified
If the Allergan board refuses to appoint these new directors,
shareholders of 10% or more can seek a summary election
§ 223
(c)
provides
in
relevant
part:
A Viable Path to Effect a Deal
26
at
the
time
of
filling
any
vacancy
or
any
newly
created
directorship,
the
directors then in office shall constitute less than a majority of the whole
board (as constituted immediately prior to any such increase), the Court of
Chancery may, upon application of any stockholder or stockholders holding
at least ten percent of the voting stock
. . . summarily order an election to be
held to fill any such vacancies or newly created directorships, or to replace
the directors chosen by the directors then in office
.
.
. ”
“If,
under Delaware General Corporation Law § 223 (c)


27
Receipt of 25%+ support for the special meeting will put
pressure on the board to engage with Valeant
A director’s removal is not just embarrassing but permanently
impairs
the
removed
director’s
“career”
as
a public company
director
Because negotiating the best price for Allergan with Valeant
and other possible buyers could take several months, we
would be prudent to begin negotiations shortly
In our experience, when boards see the writing on the wall,
they do the right thing
A More Sensible Path to Get There Sooner…


28
Allergan shareholders get paid sooner
Reduces shareholder exposure to Allergan operational and
deal risk
Reduces risk of financing and equity market instability
An executed merger agreement legally binds Valeant
Allergan will likely have a fiduciary out in a merger agreement
so alternative deals are still possible
Compelling Reasons for Near-Term Engagement


29
Betsy Atkins (61)
Chief Executive Officer of Baja LLC
Cathleen P. Black (70)
Senior Advisor at RRE Ventures LLC
Pershing Square is Proposing a Slate of Qualified and
Independent Nominees to Protect Shareholder Interests
Fredric N. Eshelman (65)
Principal of Eshelman Ventures, LLC
CEO of Baja LLC, an independent venture capital firm focused on technology, renewable sciences, and sciences, since 1994
Co-founded several successful high tech and consumer companies, including Ascend Communications, which was sold to
Lucent Technologies in 1999 for $24 billion
Formerly CEO and Chairman of Clear Standards, an on-demand enterprise energy management sustainability software
company,
from
2008
to
2009,
at
which
time
it
was
acquired
by
SAP
AG.
Former
Chairman
of
the
Board
of
Directors
of
Third
Screen Media, a company that was eventually sold to AOL
Has served as a director of Polycom, Inc. since April 1999, Schneider Electric, SA since April 2011, HD Supply Holdings, Inc.
since September 2013, and Ciber Inc. since July 2014. Formerly served on the Boards of Directors of Human Genome
Sciences Inc., HealthSouth Corporation, Vonage Holdings Inc., Towers Watson & Co., Reynolds American Inc., SunPower
Corporation, and Chico’s FAS, Inc. Has agreed she will remain on only three other boards if elected to Allergan’s board
Senior Advisor at RRE Ventures LLC, an early stage venture capital firm, since 2011, and has served on the boards of two of
RRE Ventures LLC’s portfolio companies, Yieldbot Inc. and Bark & Co Inc. She is also a board member of PubMatic, Inc.
Previously served as President of Hearst Magazines and also served as a director of the Hearst Corporation from January
1996 until late 2010. Served as President of USA Today from October 1983 until June 1991 and was a board member of the
parent company, Gannett Co.
Served as a director of Vibrant Media Inc., a global leader of in-content contextual technology, from October 2012 until 2013,
served as an independent director of International Business Machines Corp. from 1995 until 2010, and served as a director
of The Coca-Cola Company from 1992 until 2010
Principal at Eshelman Ventures, LLC, which is a fund that invests primarily in early-stage healthcare
Served as Founding Chairman of Furiex Pharmaceuticals, Inc., a drug development company, from its founding in 2009 until
the sale of the company to Forest Laboratories LLC in July 2014 for $1.5 billion. Founded Pharmaceutical Product
Development (PPD), an international contract research organization, and served as the CEO of PPD until 1989 and from
July 1990 until July 2009, Vice Chairman of its board of directors from July 1993 until July 2009, and Executive Chairman
from
July
2009
until
its
sale
to
private
equity
in
2011
for
$3.9
billion.
From
1989
until
1990,
Dr.
Eshelman
was
Senior
Vice
President of Development at Glaxo, Inc. and served on the board of the U.S. subsidiary of Glaxo Holdings plc.
Currently serves as director on several private company boards. Served on the board of Princeton Pharma Holdings LLC
from February 2008 until May 2010, when it was acquired by Valeant Pharmaceuticals International, Inc.


30
Steven J. Shulman (63)
David A. Wilson (73)
John J. Zillmer (58)
Pershing Square is Proposing a Slate of Qualified and
Independent Nominees to Protect Shareholder Interests
Managing Director of Shulman Ventures, Inc.
Former President and CEO of the Graduate Management Admission Council, a not-for-profit association dedicated to
creating access to graduate management and professional education, a position he held from 1995 until December 2013
Has served as a Director for CoreSite Realty Corporation since 2010 and Barnes & Noble, Inc. since 2010. Served as a
Director for Terra Industries, Inc. from 2009 until 2010 and Laureate Education, Inc. from 2002 until 2007.
Worked in various capacities for Ernst & Young LLP from 1978 until 1994. Also held faculty positions at Queen’s
University from 1968 until 1970, the University of Illinois at Urbana Champaign from 1970 until 1972, the University of
Texas from 1972 until 1978, and Harvard University’s Graduate School of Business from 1976 until 1977
Former President and CEO of the Graduate Management Admission Council
Former Executive Chairman of Univar, Inc., a position he held from May 2012 until December 2012. Served as Director,
President and CEO of Univar, Inc. from 2009 to May 2012.
Served
as
Chairman
and
CEO
of
Allied
Waste
Industries,
Inc.
from
2005
until
2008,
at
which
time
Allied
Waste
Industries, Inc.
merged with Republic Services, Inc. Served as Executive VP of ARAMARK Corporation from 2000 until 2004
Has
served
as
a
Director
of
Veritiv
Corporation
since
June
2014,
Reynolds
American
Inc.
since
2007
and
Ecolab
Inc.
since
2006. Has also served as Director of Liberty Capital Partners, Investment Arm, a private equity and venture capital firm
specializing in startups, early stage, growth equity, buyouts, and acquisitions, since June 2004
Former President, CEO and Director of Univar, Inc.
Managing Director of Shulman Ventures Inc., a private equity firm, and has been a strategic advisor to Water Street
Healthcare Partners, a health care private equity firm, since 2008
Served as Chairman of Health Management Associates Inc. from 2013 until January 2014, and served as Chairman and
CEO of Magellan Health Services, Inc. from 2003 until 2009
Founded and was Chairman and CEO at Internet Healthcare Group, LLC, a health care services and technology venture
fund, from 1999 until 2003, and served as the Chairman, President and CEO of Prudential Healthcare, Inc. from 1997-1999
Has served as Chairman of CareCentrix, Inc. since 2008, Access MediQuip, LLC since 2009, and Accretive Health, Inc.
since 2014, and has served on numerous privately held company boards


31
In addition to providing a forum to vote on the
proposed transaction, the special meeting will allow
shareholders the opportunity to fix Allergan’s
egregious special meeting bylaws
If Allergan’s special meeting bylaws are allowed to
stand, they will be widely promoted by “defense”
firms and will likely be widely adopted in Corporate
America 


32
We encourage shareholders considering supporting the
Pershing Square special meeting consent solicitation to
contact D.F. King, our proxy solicitor, with any questions
about the process:
Ed McCarthy
D.F. King
(212) 269-5550
emccarthy@dfking.com


II. The Current Offer Justifies Board
Engagement and Meets Investors’
“Asking Price”
33


34
On April 22
nd
, Valeant announces initial offer to acquire Allergan for 0.83
Valeant shares and $48.30 per share in cash 
On May 12
th
, Allergan rejects initial Valeant offer
On May 27
th
, Allergan publishes presentation attacking Valeant’s
business model and management team
Allergan
publishes
subsequent
presentations
on
June
10
th
and
July
14
th
On May 28
th
, Valeant raises cash component of offer to $58.30 per share
plus a contingent value right for DARPin
On May 30
th
, in response to investor feedback, Valeant raises cash
component
of
the
offer
to
$72.00
per
share
and
commits
to
not
raise
offer
again
without
substantial
engagement
from
Allergan
Valued at Valeant’s current share price, the current offer implies a ~50%+
premium to Allergan’s unaffected trading price and 23x+ EBITDA multiple
On June 23
rd
, Allergan’s board unanimously rejects Valeant’s revised bid
and describes the bid as “grossly inadequate”
History of the Transaction
Pershing Square is Allergan’s largest investor with 9.7% ownership


35
Source:
Company filings and FactSet as of 7/14/14.
Note:
Mean and median values do not include proposed Allergan / Valeant transaction.
Roche / Genetech and Novartis / Alcon transactions excluded because they were
multi-stage acquisitions.
(1)
Total includes upfront and contingent payments at face value.
(2)
(3)
AstraZeneca / MedImmune unaffected date of 4/12/07.
(4)
Valeant / Allergan unaffected date of 4/10/14.
(5)
Sanofi-Aventis / Genzyme unaffected date of 7/1/10.
(6)
Based on most recent offer on 7/14/14.
(7)
Schering financials converted using 3/23/06 exchange rate of 1.198 USD / EUR.
(8)
Bayer / Schering unaffected date of 3/13/06.
(9)
Pfizer / Wyeth unaffected date of 1/22/09.
(10)
Pharmaceutical M&A transactions over $15 billion in last 10 years (ranked by upfront premium paid)
(7)
(10)
(4)
(5)
(3)
(8)
(10)
(9)
The Offer is Compelling Even When Valued at Valeant’s
Current
Share
Price:
The
“Look-Through”
Value
of
the
Deal
(6)
Transaction Value
Premium to
Implied EV /
Implied EV /
Date
($ in billions)
Form of
Unaffected Price
LTM Revenue
(2)
LTM EBITDA
(2)
Acquiror
/
Target
Announced
Upfront
/
Total
(1)
Consideration
Upfront
/
Total
(1)
Upfront
/
Total
(1)
Upfront
/
Total
(1)
/
4/23/07
$16
Cash
54%
11.3x
NM
/
4/21/14
$53
+
CVR
Cash / Stock
48%
+
CVR
7.9x
+
CVR
22.8x
+
CVR
/
2/16/11
$20
/
$24
Cash
48%
/
76%
4.8x
/
5.8x
17.9x
/
21.4x
/
6/20/14
$56
Cash & Stock
42%
10.9x
25.9x
/
3/9/09
$41
Cash & Stock
34%
2.5x
10.3x
/
3/23/06
$20
Cash
33%
2.9x
12.2x
/
1/25/09
$68
Cash & Stock
29%
2.8x
8.2x
/
2/18/14
$25
Cash & Stock
27%
6.5x
34.3x
Mean
$35
$36
38%
42%
6.0x
6.1x
18.1x
18.7x
Median
$25
$25
34%
34%
4.8x
5.8x
15.0x
16.8x
Forest Laboratories LTM revenue and EBITDA pro forma for Aptalis acquisition.
Implied EV based on total transaction value including contingent payments.


36
Proper Way to Value the Proposed Transaction
Valued on an unaffected basis, this transaction is a merger
between a $42 billion equity market cap company, Valeant, and a
$35
billion
company,
Allergan
1
Allergan shareholders will own 44% of the combined company
In such a stock transaction, one cannot value the offer using the
current market value of the acquirer’s common stock
Investors must use the projected value of the combined entity,
considering any cost and revenue synergies, strategic benefits of
the transaction, and likely changes to the multiple investors assign
to the earnings of the combined company in their valuation
Compare this transaction to one where target company
shareholders will own a minimal amount of the combined
company
In
that
case,
this
logic
does
not
apply,
and
investors
could
use
the
current market value of the acquirer's stock to value the offer
(1) Reflects Allergan’s market capitalization as of April 10, 2014, the day before Pershing Square began its rapid accumulation program, and Valeant’s market capitalization as of
April 21, 2014, the day before Valeant announced its bid to acquire Allergan.


37
Valeant management believes the transaction delivers immediate
accretion
of
~25%
to
Valeant’s
2014
EPS
on
a
pro
forma
basis
(1)
We believe transaction uncertainty created by Allergan’s
obstructionism has kept Valeant’s stock price from reflecting the
transaction’s benefits
We believe merger arbitrage activity has affected Valeant’s stock
price
Short interest is 4x the average level prior to deal announcement
Arbitrage investors require compensation for uncertainty and time
value of money
We believe Valeant’s current stock price does not reflect the
anticipated value of the combined entity, including synergies,
and therefore serves as a poor measure to evaluate the offer
We Believe Valeant’s Current Stock Price Does
Not Reflect the Full Value of the Offer
Based on EPS of $8.55-$8.80 standalone and $10.69-$11.00 pro forma (Valeant management estimates – May 28, 2014 and June 2, 2014, respectively).
(1)


We believe Allergan’s board has erred in using Valeant’s current
stock price to value the transaction
We believe a valuation that takes into account the fair value of
the
combined company, of which Allergan investors will own ~44%, is
the proper methodology for valuing the offer
Per Share
Cash
Consideration
Per Share
Equity
Consideration
$72
$151
$223
$10.85 x 16.8 p/e = $182 per share
38
Using the Fair Value of the Combined Company
Implies a Considerably Higher Offer Value
Valeant
Stock
Price
Exchange
Ratio
$182
0.83
Total
(1)
Source
=
Management
estimate,
Valeant
June
2
presentation
(2)
Source
=
Management
estimate,
Valeant
May
28
presentation
Equity Consideration
Calculation
nd
th
Pro-Forma
2014
EPS
=
$10.85
(1)
Blended
Unaffected
2014
P/E
Multiple
=
16.8x
(2)


39
Independent Investment Research Validates Pershing
Square’s Valuation Methodology


40
Independent Investment Research Validates Pershing
Square’s Valuation Methodology (Cont.)
Louise Chen, Guggenheim; “Pershing Square and VRX Getting More Aggressive on
Consummating AGN Deal”, June 2, 2014:
“We also think it is compelling that AGN shareholders can get
the $180 deal they wanted now (without assuming an increase
in VRX’s stock price) and this excludes the DARPin CVR as
well as any potential upside from an increase in VRX’s stock
price driven by certainty of a deal. We estimate AGN shares
could be worth as much as $225 if the Street appropriately
values the combined entity, and it would be hard for AGN to
trump this with other potential options, in our view .


Investor View of
Value -
J.P. Morgan
Survey
(1) 
41
J. P. Morgan’s May 16
th
May 20
th
survey suggests investors are
seeking a $160 to $200 per share acquisition price:
Following Allergan’s May 12
th
revised long-term plan announcement,
J.P. Morgan conducted a survey of 123 Allergan investors
~77% of those surveyed believe an offer of $160-$200 per share will be
sufficient
Based on the surveyed investors’
expected value of the combined
company, Valeant’s current offer is worth $188-$221
Combined Company
Stock Price
$140
$180
Implied Offer Value
$188
$221
We Believe the Current Offer Meets Investors’
“Asking Price”
(1)
60% of survey respondents believe the combined company
would be worth $140 to $180 per share


42
Pharmaceutical M&A transactions over $15 billion in last 10 years (ranked by upfront premium paid)
Even More Compelling Deal When Valued at the Fair Value
of the Combined Company:  The “Fair Value”* of the Deal
*: Assumes fair value of $223 per
share as per page 38av c
+-.
Transaction Value
Premium to
Implied EV /
Implied EV /
Date
($ in billions)
Form of
Unaffected Price
LTM Revenue
(2)
LTM EBITDA
(2)
Acquiror
Target
Announced
Upfront
/
Total
(1)
Consideration
Upfront
/
Total
(1)
Upfront
/
Total
(1)
Upfront
/
Total
(1)
4/21/14
$70
+
CVR
Cash / Stock
91%
+
CVR
10.6x
+
CVR
30.3x
+
CVR
4/23/07
$16
Cash
54%
11.3x
NM
2/16/11
$20
/
$24
Cash
48%
/
76%
4.8x
/
5.8x
17.9x
/
21.4x
6/20/14
$56
Cash & Stock
42%
10.9x
25.9x
3/9/09
$41
Cash & Stock
34%
2.5x
10.3x
3/23/06
$20
Cash
33%
2.9x
12.2x
1/25/09
$68
Cash & Stock
29%
2.8x
8.2x
2/18/14
$25
Cash & Stock
27%
6.5x
34.3x
Mean
$35
$36
38%
42%
6.0x
6.1x
18.1x
18.7x
Median
$25
$25
34%
34%
4.8x
5.8x
15.0x
16.8x
/
/
/
/
/
/
/
/
/
(7)
(10)
(4)
(5)
(3)
(8)
(10)
(9)
(6)
Source:
Company filings and FactSet as of 7/14/14.
Note:
Mean and median values do not include proposed Allergan / Valeant transaction.
Roche / Genetech and Novartis / Alcon transactions excluded because they were 
multi-stage acquisitions.
(1)
Total includes upfront and contingent payments at face value.
(2)
Implied EV based on total transaction value including contingent payments.
(3)
Valeant / Allergan unaffected date of 4/10/14.
(4)
AstraZeneca / MedImmune unaffected date of 4/12/07.
(5)
Sanofi-Aventis / Genzyme unaffected date of 7/1/10.
(6)
Based on most recent offer on 7/14/14.
(7)
Schering financials converted using 3/23/06 exchange rate of 1.198 USD / EUR.
(8)
Bayer / Schering unaffected date of 3/13/06.
(9)
Pfizer / Wyeth unaffected date of 1/22/09.
(10)
Forest Laboratories LTM revenue and EBITDA pro forma for Aptalis acquisition.


Dow Jones
04/10/2014
07/14/2014
% Change
Implied AGN
share price
Look-Through Price as
a % premium to
implied price
Fair Value as
a % premium to
implied price
S&P 500
1,833.1
1,977.1
7.9%
$125.79
37.1%
77.3%
S&P 1500 Pharma
523.0
564.7
8.0%
$125.93
37.0%
77.1%
Dow Jones
16,170.2
17,055.4
5.5%
$123.01
40.2%
81.3%
Allergan Proxy Peers
100.0
111.4
11.4%
$129.92
32.8%
71.6%
43
Source:
FactSet.
(1)
Implied Allergan share price based on relative change in index price from unaffected price of $116.63 on April 10, 2014.
(2)
Per Allergan proxy statement dated March 26, 2014 (Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Eli Lilly, Endo Health Solutions,
Gilead Sciences, Johnson & Johnson, St. Jude Medical, Stryker Corporation, and Valeant Pharmaceuticals). Excludes Forest  Laboratories due to acquisition by Actavis
on July 1, 2014.
(2)
Peer movements since the unaffected date imply a 33% to 72%
premium over a standalone Allergan today
(1)
Even Adjusted For Peer Movements, the Offer is
a Large Premium


The Offer Represents a Large Premium to Analysts’
Pre-bid 12-Month Price Targets
The
offer
is
a
28%
to
65%
premium
to
analysts’
12-month
price
targets prior to Valeant’s initial public offer
Fair Value
Median
Look-Through Price
(1)
(1)
$130
$138
$145
$150
$125
$142
$135
$135
$109
$130
$135
$125
$140
$145
$124
$140
$130
$132
Prior to 4/21/2014
Broker
12-Month Target Price
Bank of America
Barclays
BMO Capital Markets
Buckingham Research Group
Cowen and Company
Credit Suisse
Goldman Sachs
Guggenheim Securities LLC
JPMorgan
Piper Jaffray
RBC Capital Markets
Sanford C. Bernstein & Co
Sterne, Agee & Leach
Stifel
SunTrust Robinson Humphrey
Susquehanna Financial Group
UBS
William Blair & Co
Median
12 mo.
Price Target
$172.50 offer as a %
premium
$223 offer as a %
premium
Median
$135.00
27.8%
65.2%
Source:
Bloomberg, FactSet.
Note:
$172.50/share offer based on closing prices as of July 14, 2014.
(1)
Currently advising Allergan on the Valeant proposal.
44


Valeant’s revised proposal offers substantial value to AGN
shareholders and is highly superior to AGN’s standalone value
What Valeant’s proposal offers:
$72 of cash per share
$9.01 of Valeant 2014 earnings
per AGN share
(1)
+ DARPin CVR
What standalone AGN offers:
$0 cash
2014 EPS Guidance = $5.69
Or, if $72 of cash is reinvested in
additional VRX shares at $121/share:
$15.46 of Valeant 2014 earnings
per AGN share
(2)
+ DARPin CVR
(1)
$9.01= 0.83 x 10.85 2014 Pro Forma VRX EPS
(2)
$15.46 = 1.425 x 10.85 2014 Pro Forma VRX EPS
272% increase in earnings  
per AGN share
45
How Some Large Shareholders Are Thinking
About The Transaction


The Valeant proposal offers ~$15.50 of EPS in 2014. Allergan
offers ~$14 of EPS in 2019
What Valeant’s proposal offers:
What standalone AGN offers:
2019 EPS Guidance = ~$14
$0 cash
If $72 of cash is reinvested in
additional VRX shares at $121/share:
2014 $15.46 earnings per AGN
share
(1)
+ DARPin CVR
(1)
$15.46 = 1.425 x 10.85 2014 Pro Forma VRX EPS
46
We Believe Valeant Offers More Value in One Year than
Standalone Allergan is Projected to Offer in Five Years


III. The Valeant Offer Satisfies the
Prevailing M&A Proxy Fight Analytical
Framework
47


Descriptions
Score
Transaction
premium
48% premium to Allergan's unaffected closing share price of $116.63 on April 10,
2014 (see page 101 for unaffected price chart), the final trading day before
Pershing Square started to rapidly accumulate shares
Transaction
multiple
7.9x EV/LTM Revenue
22.8x EV/LTM EBITDA
43.0x LTM P/E
Unaffected
standalone price
Offer represents ~33% -
40% premium over Allergan’s standalone price today
Analyst price
targets
Valeant/Pershing Square's cash and stock offer is a 28% premium to the median
Allergan equity research analyst price target prior to Valeant/Pershing Square’s
initial public offer
(1)
Deal spread
Currently trading 3.2% below the offer
(2)
Long-term investor
feedback
Fundamental investors reportedly seeking $180 take-out price
Source:
Company SEC filings, Bloomberg, FactSet.
(1)
Based on analyst price targets prior to April 21, 2014.
(2)
Based on closing price of $167.02 as of July 14, 2014 close.
48
Adequacy of the Offer Scorecard:
Look-Through Price


Descriptions
Score
Transaction
premium
91% premium to Allergan's unaffected closing share price of $116.63 on April 10,
2014 (see page 101 for unaffected price chart), the final trading day before
Pershing Square started to rapidly accumulate shares
Transaction
multiple
10.6x EV/LTM Revenue
30.3x EV/LTM EBITDA
56.3x LTM P/E
Unaffected
standalone price
Offer represents ~72% -
81% premium over Allergan’s standalone price today
Analyst price
targets
Valeant/Pershing Square's cash and stock offer is a 65% premium to the median
Allergan equity research analyst price target prior to Valeant/Pershing Square’s
initial public offer
(1)
Deal spread
Currently trading 25.1% below the offer
(2)
Long-term investor
feedback
Fundamental investors reportedly seeking $180 take-out price
Source:
Company SEC filings, Bloomberg, FactSet.
(1)
Based on analyst price targets prior to April 21, 2014.
(2)
Based on closing price of $167.02 as of July 14, 2014 close.
49
Adequacy of the Offer Scorecard:
Fair Value


Certainty of the
offer
Adequacy of the
offer
Appropriateness
of the board’s
response
Partnership with Pershing Square and action to date indicate Valeant is a
serious buyer
No financing contingency; Tender offer launched; Sale of assets to
comply in advance with likely HSR issues; Initiated HSR review
Investors and research analysts endorse Valeant’s operating model and
the strategic merits of the deal
Offer is compelling by transaction multiples and premiums
The offer represents an attractive premium to the “unaffected”
standalone price today absent Valeant’s offer, as well as to the 12-
month analyst price targets before the initial bid
Offer
meets
the
“asking-price”
of
long-term
investors
Downside risk is significant
To date, the Allergan board has not responded properly by refusing to
engage with Valeant to perform due diligence on the transaction
proposal, and by attempting to thwart Pershing Square’s special
meeting process to determine the will of shareholders
50
The Valeant Offer is Certain and Attractive


IV. Investors and Research Analysts Are
Confident in Valeant’s Operating Model and
the Strategic Combination
51
*
*
*
*
*
*
*
*
*
*
****************************


52
Substantial Overlap of Ownership
The large percentage of Allergan shareholders who also own
Valeant stock reflects their confidence in Valeant’s currency
“We
believe
this
deal
will
eventually
go
to
AGN
shareholders,
who
are
interested
in
maximizing
value.
Given
the
reported
over
50%
overlap
in
VRX/AGN
shareholders,
we
believe
that
most
AGN
shareholders
are
familiar
enough
with
Valeant’s
business
model
to
invest
in
the
combined
entity.”
Alex Arfaei, BMO; “New Offer in Line With Our Expectations; Good Sale of Assets, Impressive
Presentation”, May 28, 2014:


53
Research Analysts’
Recommendations Suggest
that Valeant’s Stock is Undervalued
Source:
Bloomberg.
Note:
Most recent recommendations and price targets as of July 14, 2014.
Median analyst price target of $168 per share represents a 39%
premium to Valeant’s current share price
Broker
Price Target
Rec.
Aegis Capital Corp.
$180
Buy
BMO Capital Markets
$165
Outperform
Canaccord Genuity Corp
$168
Buy
Cantor Fitzgerald
Buy
CIBC World Markets
$160
Sector Outperform
CRT Capital Group
$170
Buy
FBR Capital Markets
$153
Outperform
Guggenheim Securities LLC
$178
Buy
Jefferies
$154
Buy
JPMorgan
$180
Overweight
Morningstar, Inc
Buy
Paradigm Capital Inc
$175
Buy
Piper Jaffray
$151
Neutral
Stifel
$165
Buy
Susquehanna Financial Group
$170
Positive
TD Securities
$160
Buy


Goldman Sachs was Very Bullish on Valeant Prior to Becoming
Allergan’s Advisor and Suspending Analyst Coverage
As noted in Allergan’s recent 14D-9, Goldman Sachs has
underwritten $22.35 billion of equity and debt offerings for
Valeant
54
Twelve days before Valeant’s initial offer for Allergan,
Goldman Sachs published a final research report on
Valeant, with a Buy rating, a $164 price target, and
placement on the firm’s “Conviction List”


55
Research Analysts Are Confident in Valeant’s
Operating Model and the Strategic Combination
“We
believe
that
Valeant
is
in
a
strong
position,
both
with
respect
to
its base business and relative to the strategic growth opportunity that
exists across the Pharmaceutical industry”
Lennox Gibbs, TD Securities; “Increased Clarity and a New Bid”, May 29, 2014:
“The CEO’s extensive management consulting experience may
provide unique insight into how to best avoid mistakes made by larger
companies in the industry. For the last several years, since the
merger with Biovail, Valeant has executed on an ambitious business
development strategy that is unique among peers.”
William Tanner, FBR; “Allergan Bid Upped Again, and Pershing Square Goes All In for Stock--
Looks Like a Best and Final Offer to Us”, June 2, 2014:


56
Research Analysts Are Confident in Valeant’s Operating
Model and the Strategic Combination (Cont.)
“Whether the acquisition happens or not, however, we believe that
the
Valeant business model remains valid and we do not believe that Allergan
management’s allegations regarding Valeant’s strategy are valid.”
Raghuram Selvaraju, Aegis Capital; “Valeant Ups the Ante in Allergan Acquisition Bid”, May
28, 2014:
“We don’t think that Valeant promotionally starves its brands, but rather
makes selective investments in highest value programs like Luzu and local
DTC…the roll-up strategy is difficult, and Valeant’s execution know-how and
experience
is
an
intangible
asset
that
will
continue
to
drive
value,
in
our
view.”
Irina Rivkind Koffler, Cantor Fitzgerald; “We Like Standalone Business, with AGN Upside;
Maintain BUY, Increase PT to $209”, June 2, 2014:
“Valeant has a strong track record of creating value by acquiring
firms with
solid product portfolios and investing only in late-stage/low-risk R&D.
Management has proven that M&A can lead to better returns than early-stage
R&D given Valeant’s ability to strip out costs.”
Stephanie Price, CIBC; “Growth on Steroids: Initiating Coverage at Sector Outperformer”, May
20, 2014:


57
Research Analysts Are Confident in Valeant’s Operating
Model and the Strategic Combination (Cont.)
“75% believe Valeant’s $2.7 Bn synergy target for a potential AGN acquisition
is realistic.”
Chris Schott, J. P. Morgan; “Buyside Survey Results Suggest Broad Expectation of a VRX-
AGN Transaction”, May 23, 2014:
“We see the opportunity for significant cost synergies with this deal given the
overlap in the VRX and AGN businesses and the possibility of tax
savings
given VRX's mid-single digit corporate tax rate.”
“Media-reported cost savings target of ~$2.5 bn would represent ~68% of
AGN's combined 2014 SG&A and R&D expenses but we believe this could
be achieved given the significant overlap in the two companies cosmetic and
ophthalmology businesses and VRX's strong track record in achieving
synergies from previous acquisitions. Simply removing this level
of expenses
from our AGN model by 2016 would suggest a DCF valuation for AGN
of
over $230/share, with additional upside possible when tax synergies are
factored in.”
Vamil Divan, MD, Credit Suisse; “VRX Takeout Could Complete a Rapid AGN Turnaround”,
April 21, 2014:


(1)
Measured as of May 30 th , 2014, other shareholders were offered an exchange ratio of 1.38 VRX shares per one AGN share. This ratio assumes AGN shareholders reinvested their cash consideration
in VRX stock at the then current market price of $131 per share.
(2)
~$600mm is measured as of May 30, 2014.
Pershing Square’s All Equity Commitment Demonstrates
Confidence in the Value of the Combined Company
Pershing Square has committed to take all stock in the
transaction at an exchange ratio of 1.22659 VRX shares
per one AGN share
Pershing Square’s exchange ratio is inferior to the offer
available to other Allergan shareholders
(1)
This commitment transferred ~$600 million of immediate
value to other shareholders in the transaction
(2)
Only if the value of the combined company reaches $180
per share will the value of Pershing Square’s offer equal
that of other holders
Pershing Square’s all stock election increased cash
available to other shareholders by ~$2 billion
58


V. Risks in Allergan’s Business Model
59
*
*
*
*
*
*
*
*
*
*
*****************************


Risks in Allergan’s Business Model
60
Highly concentrated product portfolio
Large exposure to upcoming patent expirations
Large price increases have significantly
contributed to revenue growth
Limited to any disclosure about early-stage R&D


Highly Concentrated Portfolio
61
Allergan’s top four drugs account for 64% of total revenue
Source: Sales for top drugs per Valeant management estimates. Total AGN sales per consensus estimates as of June 19, 2014.
Botox
32%
Restasis
16%
Lumigan
Franchise
9%
Alphagan
Franchise
7%
Other
Products
36%


High Exposure to Patent Cliffs
Allergan is currently benefiting from a window of patent
exclusivity, but by 2027 Allergan will lose exclusivity on
products comprising ~37% of current revenue
Products maintaining exclusivity or durability                 
(currently marketed products only, shown as a % of 2014E revenue)
Source:
Allergan
management
commentary,
Wall
Street
research,
Pershing
Square
estimates.
Total
2014E
sales
are
as
per
Wall
Street
consensus
estimates.
Note:
Assumes
100%
of
revenue
lost
in
year
of
patent
expiration.
Uses
year
of
patent
expiration
in
the
U.S.
as
a
proxy
for
global
patent
expirations,
except
for
Ganfort
which
uses
the
year
of
patent
expiration
in
the
EU
since
the
drug
is
not
marketed
in
the
U.S.
Assumptions
for
year
of
patent
expiry
by
drug
are
Restasis
2024,
Alphagan
2022,
Lumigan
2027,
Aczone
2016,
Ganfort
2022,
Ozurdex
2024,
Latisse
2024,
Lastacaft
2029.
Patent
data
per-Allergan
10-K
and
FDA
orange
book.
62


Risk of successful patent challenges greatest for “Life
Extension”
patents
Allergan recently received negative news on Latisse, which
employs the same active ingredient used in another AGN
product, Lumigan 
Allergan loses Latisse patent fight, jeopardizing up to $200M in
sales
“The U.S. Court of Appeals for the Federal Circuit in Washington has
deemed a pair of Latisse patents invalid, paving the way for Novartis'
Sandoz unit and the generics maker Apotex to sell their copies. The patents
on Latisse--a variation of Allergan's Lumigan, used to treat glaucoma--cover
ways to apply the drug to promote eyelash growth. But that growth is a
‘known potential side effect’
of glaucoma treatments, the court ruled,
rendering Allergan's patent claims obvious.”
-
Fierce Pharma; June 11, 2014
63
Generics Manufacturers May Challenge       
Existing Patents


Patent Cliffs + Concentration = High Risk
64
In 2013, Allergan’s stock fell by 19% within one week, in large
part due to increased risk of loss of exclusivity for Restasis,
one of Allergan’s largest products
6/20/13: FDA
issues guidance
on Restasis
generic pathway
Source: Bloomberg.
Share Price Performance of AGN from 5/1/13 to 6/30/13


Acuvail
Elestat
Lastacraft
Betagan
Zymaxid
Pricing has Driven Growth
65
Allergan has relied on large price increases to drive revenue
growth, both historically and in 2014
7-9% Price
Increases in 2014
10%+ Price
Increases in 2014
Alphagan
Combigan
Lumigan
Restasis
Aczone
Tazorac
Avage
Azalex
Source: Wolters Kluwer: Medi-Span Price Rx and Valeant management estimates.
100%+ Price
Increases in 2014
Pred-G
Pred Miled
FML Forte
Bleph-10


60%
85%
64%
18%
Allergan Durable
% of Portfolio
Valeant Durable
% of Portfolio
Allergan Top 4
Products
Valeant Top 10
Products
Valeant has a Lower Risk Product Portfolio
66
Valeant’s portfolio is both more durable and more diversified
Durability
Product Concentration
Source: Valeant management estimates.


60%
74%
64%
29%
Standalone
Allergan
PF Allergan +
Valeant
Standalone
Allergan
PF Allergan +
Valeant
67
The combined drug portfolio is expected to be more durable and
more diversified
Source: Valeant management estimates.
Durability
Product Concentration: Top 4
Drugs % of Total Sales
More durable
More
diversified
We Believe a Combination with Valeant Reduces
Portfolio Risk


Allergan’s Black Box R&D Model
68
No project-level expense guidance 
No guidance on expected returns from R&D
investment
Limited visibility of R&D creates uncertainty
History of losses outside of low-risk projects
Compensation program promotes R&D spending
without providing accountability for return on
investment


Limited Project Level R&D Guidance
69
Despite a major forecasted increase in R&D spending, Allergan
has not provided guidance on major areas of increased
expenditure and the expected return on investment
“Also, as a quick reminder, I have explained on several occasions
that in the coming five or so years, there will be a major step-up in
R&D from roughly $1 billion-plus this year to roughly $1.5 billion
some five years from now.”
David Pyott, Allergan Chairman and CEO; Q2 2013 Earnings Call, July 31, 2013:
“And
then
as
a
second
question,
just
wondering
if
--
one
of
the
criticisms that we've heard of Allergan, at least as it relates to
pipeline and the revelation of Phase II data, just wondering if there
will be more disclosure around that going forward, or are we going to
stick to sort of the same process of disclosure you simply -
-
primarily providing information for Phase III products at medical
meetings?”
Seamus Fernandez, Leerink Swann; May 12, 2014 Special Call:


70
Limited Project Level R&D Guidance
While the sales potential from Allergan’s R&D pipeline remains opaque,
peers such as Astra Zeneca give more detailed disclosure:
Source: Astra Zeneca May 2014 investor presentation.


Limited Visibility of R&D Creates Uncertainty
71
“Given you had to set back both these expectations of products
[Latisse for Scalp and DARPin] since you talked about last year at
your R&D day. How should we think about your commitment to this
growth and are you going to have to look elsewhere to drive this? Or
are you still confident that you can grow Allergan organically from a
revenue and earnings standpoint?”
Shibani Malhotra, RBC Capital Markets; Q1 2013 Earnings Call, May 1, 2013:
Lack of visibility and risk inherent in an early-stage R&D model
creates uncertainty for Allergan investors


72
Allergan’s experience with DARPin demonstrates lack of visibility
and risk inherent in an early stage R&D model
“Scott, I don't mean to beat a dead horse, but if you could just provide
us a little bit more color on what the magnitude of the benefit you saw
over LUCENTIS. You said you did see that in some patients, maybe
not in others. And what gives you confidence that the program will be
delayed one to two years versus just a complete bust?”
Jami Rubin, Goldman Sachs; Q1 2013 Earnings Call, May 1, 2013:
“But if that's the case, I guess I'm a little curious, why were you so
bullish on this product four months ago, five months ago? It made it
seem like you had enough data to be very bullish on the product and
now you're kind of saying, ‘Well, maybe, we didn't have enough
information?’”
Marc Goodman, UBS; Q1 2013 Earnings Call, May 1, 2013:
Limited Visibility of R&D Creates        
Uncertainty -
DARPin
AGN shares fell 13% the day of Allergan’s Q1 2013 earnings call


History of Losses Outside of Low-Risk Projects
73
Source: Valeant April 2014 investor presentation.


74
Source: Valeant April 2014 investor presentation.
History of Losses Outside of Low-Risk Projects


Incentives Matter
David Pyott is eligible to receive a bonus up to 25% of his base
salary
if the company exceeds its annual R&D spending target
The R&D target rewards Allergan executives for R&D spending
irrespective of the returns on that investment
By contrast, at Merck, management is compensated for achieving
pipeline ROI and NPV goals
Poorly Designed R&D Reinvestment Compensation Target
Allergan
Management
Annual
Bonus
Targets
(March
26,
2014
Proxy)
David Pyott, Allergan Chairman and CEO; Q3 2009 Earnings Call:
75
“Of course, R&D is not about the expenditure but it is about
results.”
“Of course, R&D is not about the expenditure but it is about
results.”


Allergan’s June 30th Pipeline Update Highlighted Flawed
R&D Strategy And Misunderstanding of Evolving Markets
Despite spending $1.3 billion on product acquisitions and $2.8 billion
on R&D over the last three years, it remains unclear whether Allergan
has any late-stage programs capable of moving the needle
Anti-VEGF DARPin
Efficacy
data,
to
date,
lack
sufficient
clinical
differentiation
vs.
incumbents
Significant safety concerns persist and may ultimately preclude adoption
Two entrenched market leaders with same the mechanism-of-action (anti-VEGF) limit market
penetration if approved
Broad use of Avastin a major threat to marginally differentiated, late entrants
Anti-PDGF,
gene
therapy
and
combination
products
in
others’
pipelines
competing
for
increasingly crowded AMD market
Semprana/Levadex
Overpaid for an asset that lacks clinical differentiation
Approval delays eroding opportunity as generics and new branded products enter market
Development of highly effective prophylactics (GCRP mAbs) may shrink opportunity
Ozuredex
Narrow label limits use to select patient sub-populations
Potential new competitor, Iluvien, as early as year-end 2014
Bimatoprost Sustained-Release
Use will be limited to patients who prefer injection in eyeball to daily drops
Outstanding pricing question: similar to generics or branded agents?
76


77
Marketed anti-VEGF Ab for wet AMD
Key pipeline product candidates for wet AMD
Source: Company filings, Clinical publications and Wall Street equity research.
(1)
Data taken from Phase 3 ANCHOR study involving Q4W Lucentis
The Crowded Competitive Landscape Raises Significant
Questions About DARPin’s Market Potential That Are Amplified By
Program Delays And Marginal Phase 2 Data
(2)
Data taken from Phase 3 VIEW-2 study comparing Q4W Eylea with Q4W Lucentis
(3)
Data taken from 2011 CATT study that was conducted by the NEI comparing Q4W Avastin with
Q4W Lucentis
Product
Company
Developmental
Status
MOA
Combo With
VEGF?
Efficacy
Dosing regimen
Safety profile
AGN 150998
(Anti-VEGF
DARPin)
Allergan/
Molecular Partners
Phase 2b
Pan anti-VEGF
DARPin
No
2.0mg dose: +8.2 letters at 16 weeks
1.0mg dose: +6.3 letters at 16 weeks
(vs +5.3 letters w/ Lucentis)
Doses at the start of trial and after 4 and
8 weeks
(vs additional doses after 12 and 16
weeks w/ Lucentis)
2.0 mg dose: Ocular Inflammation in 8%
of patients
1.0 mg dose: Ocular inflammation in
13% of patients
Fovista
Novartis/
Ophthotech
Phase 3
Anti-PDGF
aptamer
Yes
1.5mg Fovista/Lucentis: +10.6 letters at
24 weeks
(vs +6.5 letters w/ Lucentis alone)
Currently investigating once a month
regimen for first 12 months, followed by
once every two months regimen for next
12 months
No imbalances in AEs or SAEs (ocular
or systemic) and no difference in
intraocular pressure between arms
ESBA-1008
Novartis/
Alcon
Phase 2
Pan-VEGF
inhibitor
No
Phase 2 efficacy data expected in
4Q2014
Currently investigating 7 injections vs 8
injections w/ Eylea in Phase 2 study
Phase 1/2 trial showed that doses were
well tolerated as assessed by the
absence of adverse events within 7
days of injection
ALG-1001
Allegro Ophthalmics
Phase 1/2
Integrin
inhibitor
No
+5 letters sustained for 3-4 months
demonstrated in subset of 15 wAMD
patients
Currently investigating regimen of three
monthly injections in six-month dose-
ranging study
No serious or significant adverse events
reported in Phase 1 human safety study
with DME patients
Ava-101
Avalanche
Phase 1/2
Anti-VEGF
No
Low dose: +8.7 letters after 52 weeks
High dose: +6.3 letters after 52 weeks
Currently investigating safety and
efficacy of a single injection in dose-
escalating study
Phase 2a top-line data expected in mid
2015
DE-120
Santen
Phase 1/2
Dual
VEGF/PDGF
inhibitor
No
Phase 1/2 efficacy data expected in
2Q2014
Currently investigating in dose-
escalating, sequential-cohort Phase 1/2
study
Phase 1/2 safety data expected in
2Q2014
Efficacy
Product
Company
Loss of <15 letters in
VA at 52 weeks
Gain of >15 letters in
VA at 52 weeks
Mean change in VA from
baseline at 52 weeks
Dosing regimen
Safety profile
Lucentis
(1)
Roche/
Novartis
91%
31%
+6.3 letters
Once a month
Arteriothrombotic: 4.7%
Death: 1.4%
Eylea
(2)
Regeneron/
Bayer/
Santen
95%
31%
+8.9 letters
(vs +9.4 letters w/ Lucentis)
Once a month for first 3 months,
then every 2 months thereafter
Arteriothrombotic: 3.3%
(vs 3.2% for Lucentis in head-to-head)
Avastin*
(3)
Roche
94%
31%
+8.0 letters
(vs +8.5 letters w/ Lucentis)
Once a month and PRN
Arteriothrombotic: 2.1%
(vs 2.3% for Lucentis in head-to-head)
Death: 1.4%
(vs 1.3% for Lucentis in head-to-head)
*Avastin usage for wet AMD is off-label


VI. Allergan’s History of Poor
Cost Management
78
XXXXXXXX


Allergan’s SG&A spending is well above other specialty and
global pharmaceutical companies
SG&A Expense as % of Total Revenue (2013)
Avg. (ex-AGN) = 26.2%
79
Over 800 bps above next highest peer
and over 1,200 bps above peer average
Source: Company filings, Pershing Square estimates.
Allergan’s Elevated SG&A Expense
38.5%
30.4%
29.5%
27.5%
26.5%
26.0%
22.4%
21.4%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
Allergan
Shire
UCB SA
Pfizer
Merck
Merck
KGaA
Valeant
Actavis


Jami Rubin, Goldman Sachs; Q4 2013 Earnings Call, February 5, 2014:
Analysts Recognize the Cost Opportunity but have
Repeatedly Questioned Management's Commitment
to Solving the Problem
“You've talked about bringing your SG&A down to 35% over the last
couple
of
years.
But
[I]
understand
why
you
are
spending
as
much
as
you
did in terms of SG&A, but are you still thinking of taking the SG&A
amount down to 35%? And what do you mean by medium-term and near-
term because it's been four years now you've been saying that. How
should we be thinking about it?”
“But in your contingency plans, I would imagine that there will be a lot of
room to restructure, given how high your SG&A ratio is. Can you talk
about how variable your costs are and how realistic it would be to bring
down those costs…?”
Shibani Malhotra, RBC Capital Markets; Q4 2011 Earnings Call, February 2, 2012:
Jami Rubin, Goldman Sachs; Q2 2013 Earnings Call, July 31, 2013:
“And do you see a scenario where you could bring your SG&A ratio to
the low 30s from, what 37%, 38%?”
80


“Maybe
a
last
comment
on
SG&A,
we’ve
said
for
some
time
now,
we
expect
this
to
gradually
trend
down
into
the
mid-30s.
As
a
company,
we’ve
historically
been
very
high.”
David Pyott, Allergan Chairman and CEO; Q3 2010 Earnings Call, Nov. 1, 2010:
“Going back to SG&A leverage, we've always stated that
our target in the midterm is the mid-30s, so I'd reiterate
that. And clearly, this is not by cutting. It just means the
rate of increase for SG&A is lower than the rate of sales
growth.”
David Pyott, Allergan Chairman and CEO; Q4 2013 Earnings Call, Feb. 5, 2014:
81
“Well,
clearly,
we’ve
stated
over
the
years
that
gradually,
the
SG&A
rates
will
come
down
into
the
mid-30s.”
David Pyott, Allergan Chairman and CEO; Q4 2011 Earnings Call, Feb. 2, 2012:
SG&A Ratio
2010: 40%
2011: 40%
2013: 39%
Source: Company filings.
Allergan Management has Admitted that SG&A is
“Very High”
but has not Made Meaningful Progress
Solving the Problem


“I think this will be more a case of evolution versus revolution.”
David Pyott, Allergan Chairman and CEO; Response on Q3 2010 Earnings Call:
“And one more big-picture question, I guess, for David. You talked a
little bit about going to SG&A levels of sort of 35% over time, anything
structurally that you're planning for next year?”
David Buck, Buckingham; Question on Q3 2010 Earnings Call, November 1, 2010:
“You're quite right that we've had very high SG&A ratios relative
to the
rest of the industry…
So the good news is that we have a lot more room
for
maneuver
than
most
companies,
and
that
will
be
helpful
as
we
start
doing that form of scenario planning.”
David Pyott, Allergan Chairman and CEO; Q2 2013 Earnings Call, July 31, 2013:
Allergan Management has Admitted that SG&A is
“Very High”
but has not Made Meaningful Progress
Solving the Problem (Cont.)
82


VII. Allergan’s Poor Track Record of
Allocating Capital
83


Allergan has a Poor Track Record of
Allocating Capital
84
Flawed capital allocation framework
Questionable business development track record
Excess cash balances


“For David and for Jeff, what's your philosophy on having a net cash
position and whether you think that's ideal?”
“Can management better serve investors by maybe being more
aggressive with cash deployment and maybe even taking advantage
of some of these lower rates near term?”
Gregg
Gilbert,
BofA
Merrill
Lynch;
Q1
2012
Earnings
Call,
May
2,
2012:
Frank Pinkerton, SunTrust Robinson; Q1 2011 Earnings Call, May 4, 2011:
“My question is with respect to your capital allocation strategies.
Wondering if you could provide an update now especially given your
large cash balance and also your decision to potentially divest your
obesity franchise.”
Louise Chen, Guggenheim Securities; Q3 2012 Earnings Call, October 30, 2012:
85
Analysts have Repeatedly Questioned Allergan’s
Capital Allocation Strategy


“I was wondering though if you and the board are open to deals that create
economic value and add to franchise value even if they don't meet that [10%]
revenue growth threshold?”
Gregg Gilbert, Bank of America; Question on Q3 2013 Earnings Call, October 29, 2013:
David Pyott, Allergan Chairman and CEO; Response on Q3 2013 Earnings Call:
Allergan’s interest in acquisitions seems to be motivated by
growth for growth’s sake rather than shareholder value creation
“…we would have no interest in buying, and I'll exaggerate, a product or a
company
that
were
only
growing
2%
or
3%,
because
all
we
do
would
be
diluting our already really strong internal performance.”
David Pyott, Allergan Chairman and CEO; Q4 2013 Earnings Call, February 5, 2014:
86
Flawed Capital Allocation Framework: M&A
“Then your question on profile of potential companies, clearly, we're looking to
franchises that have growth potential because Allergan is a growth company.”


87
Capital return program is not designed to create shareholder value
Allergan’s buyback program aims only to offset the dilution from stock
based compensation –
Valuation is not a consideration
Did not buy back shares last year when the stock fell to the $80-$90 per
share range and stayed in that range for several months
“Well, maybe ending with the easiest part. On share repurchase, over a long
period of time, our goal has been to hold the share count roughly flat. We'll go
up and down at the margin quarter-to-quarter, so the treasury is on the other
side, if you like of the dilution caused by employees appropriately exercising
their stock options.”
David Pyott, Allergan Chairman and CEO; Q4 2013 Earnings Call, February 5, 2014:
Flawed Capital Allocation Framework:         
Share Buybacks


“And I think you as investors would prefer that we find good-return
assets like that versus the very modest levels of return we can get by
investing in the capital markets where, obviously, right now, the
returns are very, very low indeed.”
David Pyott, Allergan Chairman and CEO; Q3 2012 Earnings Call, October 30, 2012:
“We have sufficient liquidity on our balance sheet that enables us to
be proactive with respect to business development activities. Finding
smaller opportunities that are very focused, you've noted, I'm sure,
that we've been fairly active and aggressive in those areas. Finding
that larger opportunity is a bit tougher and we're very disciplined how
we go about it.”
Jeff Edwards, Allergan CFO; Q1 2011 Earnings Call, May 4, 2011:
88
Management has Highlighted M&A as a Primary
Use of Cash in the Past


Allergan has Historically Not Been Able to
Identify Attractive Acquisition Targets
89
“It would seem obvious to many of us that you should be hoping or
seeking to leverage your balance sheet more aggressively. But when
we talked to investors, some argue that there aren't actually many
assets available in your therapeutic categories or in aesthetic and
derm. So it's an issue that you'd like to be more aggressive, but can't
find the assets?”
Ken Cacciatore, Cowen & Company; Q3 2013 Earnings Call, October 29, 2013:
Between 2011 and 2013, Allergan generated $4.4bn of cash from
operations but invested only $1.3bn of cash in acquisitions 


Allergan’s Acquisition Track Record is
Questionable –
Inamed
90
In 2005, Allergan acquired Inamed Corporation for $3.3 billion
At the time of the acquisition, the obesity intervention business or LAP-
BAND franchise represented approximately 30% of total Inamed sales
Post-acquisition, LAP-BAND was shown to be less effective than
alternative therapies and insurers stopped covering it
In 2013, Allergan sold its obesity intervention business for $110
million and recorded a $408 million pre-tax loss on the sale
~80% of the net book value
(1)
of the business was written off
In addition, sales in Inamed’s largest division, Natrelle breast
aesthetics, profoundly disappointed with sales falling ~36% below
Wall Street analyst expectations by 2010
(2)
Allergan sold nearly a third of the largest business it ever acquired for
3.3% of the aggregate purchase price
Source: Company filings, press releases.
(1) Based on the book value as of 12/31/2012 related to the obesity intervention business unit.
(2) 2010 actual sales compared to analysts revenue consensus on the same year sales as of three months after the acquisition in 2006.
As the only major acquisition during David Pyott’s tenure, Inamed is not
an encouraging example of management’s M&A acumen


Allergan’s Acquisition Track Record is
Questionable –
Sanctura Franchise
In September 2007, Allergan acquired Esprit Pharma, whose only major
product line was the Sanctura franchise, for $371 million in cash
Allergan management stated that they expected peak-year revenue from
Sanctura XR, a replacement for the original Sanctura formulation, of
between $300 million and $400 million
Generic manufacturers challenged Allergan’s patents on Sanctura XR in
2009, and filed applications to market generic equivalents
In the third quarter of 2010, Allergan recorded an impairment charge
related to the Sanctura franchise of $369.1 million, or 99.6% of the initial
purchase price
(1)
In April of 2012, a Delaware judge ruled in favor of the generic
manufacturers and declared Allergan’s Sanctura XR patents invalid
Three years after Allergan acquired Sanctura, the company recorded an
impairment charge equal to the entire $371 million purchase price
Source: Company filings, press releases.
(1) Allergan 2013 10-K.
91


(1) Based on Allergan management estimate of peak-year sales of $500 million.
Allergan’s Acquisition Track Record is
Questionable –
MAP Pharmaceuticals (Levadex)
Forty-six days after Allergan spent $872 million to acquire Levadex, the
FDA rejected Allergan’s second request to market the drug
In January 2011, Allergan and MAP Pharmaceuticals (“MAP”) established a
50/50 partnership to develop Levadex
The FDA rejected the companies’
first request to market Levadex in March
2012, citing concerns about manufacturing of the product’s inhaler
On March 1
st
, 2013, Allergan acquired MAP for $872 million
On April 16
th
, 2013, the FDA rejected Allergan’s second request to market
Levadex, citing nearly identical concerns about the inhaler
In order to improve the quality of the inhaler device, Allergan spent an
additional $20 million to acquire Exemplar Pharma, maker of the inhaler
On
June
30
th
,
2014,
Allergan
reported
that
the
FDA
had
rejected
Levadex
a
third time
While Levadex is likely to be approved at some point, Allergan has lost at least
three
years
of
peak-year
market
exclusivity,
an
estimated
$1.5bn
of
sales
,
and
has allowed a competing product to enter their product launch window
92
(1)


Allergan’s Acquisition Track Record is
Questionable –
MAP Pharmaceuticals (Levadex)
93
“And then David and Scott, I assume that Allergan is very confident in the
provability of the product on taxpayers sooner but can you talk maybe more
broadly how you --
or specifically, how you protected shareholders of Allergan in
the event of an undesired FDA outcome?”
David Pyott, Allergan Chairman and CEO; Response on January 23, 2013 M&A Call:
“I think on my side, if I look at the risk of delay beyond the PDUFA date, this is just
normal with any program that exists whether it's our internal program or an
external. And of course, in this instance, we have been the partner of MAP from
the very beginning. So our team and their team has worked hand in glove. So
we're very well informed.”
Gregg Gilbert, BofA Merrill Lynch; Question on January 23, 2013 M&A Call:
Allergan management took an inappropriate risk by buying MAP weeks
before the Levadex FDA decision, despite working closely with MAP for
years on the Levadex project
Analysts were appropriately concerned about an adverse FDA outcome:


94
The largest acquisitions of Pyott’s tenure have all disappointed 
Allergan’s Largest Acquisitions, Using
~$5 Billion of Capital, Have All Disappointed
Semprana (Levadex)
3/23/06
99.6% of purchase price written
off as impairment charge
80% of net book value written off
Three FDA CRLs and resulting
multi-year delay has significantly
impaired the value of the asset
Sales have fallen >30% short of
expectations at the time of the
acquisition
$3.3Bn
*
$371M
$3.3Bn
*
$872M
10/16/07
3/1/13
3/23/06
Date
Tx value
*Lap-Band and Natrelle were acquired as part of the Inamed acquisition


VIII. Allergan’s Shareholder Unfriendly
Compensation Policies
95


Allergan’s Poorly Designed Executive
Compensation Program
Based on ISS executive compensation analysis, only 13% of David
Pyott’s total compensation in 2013 was tied to performance
ISS recently cautioned that the CEO’s level of long-term incentive
compensation was high relative to peers and was not conditioned on
specific performance goals
By contrast, 68% of Valeant CEO Michael Pearson’s total compensation
in 2013 was performance-based incentive pay
In 2013, David Pyott received total compensation of $14.1 million while
delivering 1-year TSR of 21.3%, in a year in which the S&P 500 TSR
was 32.4%
The median total compensation received by CEO’s in Allergan’s proxy
peer group was $14.5 million while delivering 1-year TSR of 65.8%
By contrast, Michael Pearson received total compensation of $7.0
million while delivering 1-year TSR of 96.4%, nearly three times the TSR
of the S&P 500
Source: 2014 ISS reports of Allergan and its peer group as defined by the company in its proxy statement dated March 26, 2014.
96


97
Inadequate TSR Trigger (on one-time grants)
In 2012, CEO Pyott was granted 165,000 restricted stock units to
“recognize over a decade of outstanding performance”
To achieve maximum
vesting, total shareholder return must be 9% over
a five year period
9% is below the 10% minimum
TSR Valeant must achieve for any of
management’s restricted stock to vest
Time-Vested Stock Options
Time-vested options comprise nearly all of senior management’s long-
term equity compensation
The options have no performance trigger 
The options are issued at the money, making them valuable even if
Allergan’s share price growth is meager over the life of the option
Allergan’s Poorly Designed Executive
Compensation Program (Cont.)


Allergan Management was Granted Options only
Months before Revised Guidance was Announced
Management’s 2014 options grant was struck at an Allergan
share price of $124 in February 2014, three months before
management chose to announce its revised guidance
98
This implies one of the following:
Management was under-reporting the profit potential of the
business at the time of the options grant, or
Management’s current estimate of Allergan’s long-term earnings
is unrealistically high
In February, David Pyott was granted 257,756 options worth a
Black-Scholes
value
of
$13
million
1
These options are worth $22 million at Allergan’s current $167
share price
1
(1) Option values calculated using a volatility of 27.5%.


Notably, management has not tied long-term compensation
to the new long-term financial plan
99
Annual Cash Incentive Compensation
Up to 200% of base salary possible if  
goals are achieved
Long-Term Incentive Compensation
50% time-vested stock options
50% performance share units;
three-year annualized Total
Shareholder Return (TSR) vesting
Annualized
TSR (IRR)
% of
PSUs
vesting
Michael Pearson &        
Howard Schiller
Valeant is “all in”
on aligning compensation with
performance –
we challenge Allergan to do the same
Allergan Has Revised Its Long-Term Plan But Not Its
Compensation Policy
<10%
0%
10%
100%
20%
200%
30%
300%
Source: Valeant 2014 proxy statement.
Valeant
Management
Compensation
Structure
:


100
IX. We Believe There is Significant
Downside to Allergan’s Standalone
Stock Price


Allergan’s
unaffected
share
price
is
$116.63,
the
closing
price
on
April
10
th
,
the day before Pershing Square began its rapid accumulation program
Allergan
share
price
and
volume
from
2/25/2014
to
7/14/2014
30% Downside to AGN Shares if they Revert to
the Unaffected Share Price
Note: Chart shows Allergan’s share price, volume, and the number of shares, delta-one options, and forwards purchased by Pershing Square from February 25, 2014, the day
Pershing Square began its purchases, to July 14, 2014. Share price and volume data are as per Capital IQ.
30% downside
to unaffected
share price of
$116.63
Apr. 9-10:
No
Pershing
purchases
101
Date Range
ADTV
1/1/2014  -
4/10/2014
4/11/2014  -
4/21/2014
4/22/2014  -
7/14/2014
2.6mm
6.8mm
4.1mm


High Trading Volume Since Initial Valeant Bid
102
Since Valeant’s initial bid, trading in AGN shares has exceeded
88% of the company’s float
April 22: Initial
VRX proposal
May 28: Second
VRX proposal
May 30: Third
VRX proposal
Source: Bloomberg, company filings.
Note:
%
of
float
traded
excludes
shares
owned
by
Pershing
Square
and
Valeant.


103
88%
(1)
of Allergan’s float has changed hands since the initial
VRX bid, likely indicating that many long-term AGN investors
have sold shares
We believe selling shareholders recognize that the standalone
value of Allergan is below the current AGN share price
We believe selling shareholders also recognize that value-
destructive actions taken by Allergan management to scuttle the
Valeant deal remain a risk
Recent buyers of Allergan shares likely support the transaction
Recent buyers have paid >$160 per share
We believe these buyers likely support the Valeant transaction
and believe in the value creation of the business combination
We believe that recent sellers of AGN shares include long-term
investors who fear that Allergan’s board and management will
not act to maximize shareholder value
(1) % of float traded excludes shares owned by Pershing Square and Valeant.
Long-Term Investors See Risk


$172.50
(1)
Look-Through Price
104
Source:
FactSet.
(1)
As of July 14, 2014.
Includes 252k shares sold
by David Pyott
at $123.12
per share (not
10b5-1), for
total proceeds of $31mm
43%
premium
$76mm
$12mm
$27mm
$53mm
$56mm
$65mm
$21mm
$15mm
$76mm
$12mm
$223 Fair Value
84%
premium
Allergan Insiders have Sold a Significant Number of
Shares at Prices Much Lower than the Current Offer
Allergan Insider Annual Open Market Sales
1,054K Shares
338K Shares
622K Shares
156K Shares
623K Shares
176K Shares
628K Shares
689K Shares
192K Shares
108K Shares
$72 
$83 
$92 
$103 
$121 
2010
2011
2012
2013
Q1 2014
Non-10b5
-1 Shares Sold (000's)
10b5
-1 Shares Sold (000's)
Weighted Average Sale Price


$138.0
$49.7
$75.8
$81.3
$192.9
$62.8
$70.8
$19.8
$298.1
$70.5
$170.0
$27.1
$87.2
$90.1
$31.6
$40.6
105
Source:
FactSet, 2013 –
Q1 2014.
Note:
Market cap based on basic shares outstanding.
(1)
Market
cap
as
of
July
14,
2014.
FRX
shown
as
of
closing
price
of
$99.00
on
June
30,
2014,
the
final
day
of
trading
prior
to
the
acquisition
by
Actavis
Plc.
23.4x
549,600 shares
WAP:  $115.29 per share
Peer Median
Market Cap
($Bn)
(1)
VRX management
exhibiting confidence in
business model
Allergan executives clearly had a far less bullish view of their
stock prior to the Valeant offer
$234mm
Allergan CEO/CFO Sales Compared to Peers
Since January 2013
$63mm
$50mm
$19mm
$16mm
$12mm
$8mm
$5mm
$3mm
$2mm
$2mm
$1mm
$0mm
$0mm
$0mm
$0mm
GILD
AGN
BIIB
BMY
PFE
ABT
CELG
STJ
JNJ
LLY
MRK
FRX
ABBV
AMGN
SYK
VRX


Allergan’s Revised Long-Term Financial Plan
On
May
12
th
,
in
reaction
to
Valeant’s
April
22
nd
bid,
Allergan management announced a new revised long-
term plan
106
We question the credibility and value creation
potential of this long-term plan


Higher Guidance Appears Driven by the Valeant Bid,
not a Fundamental Change in the Business
107
“And [on] many occasions, I've talked about our midterm growth
aspirations being around about 10% sales growth…”
David Pyott, Allergan Chairman and CEO; Q2 2013 Earnings Call, July 31, 2013:
“Beyond 2015, we believe we'll grow revenue at the double digits…”
David Pyott, Allergan Chairman and CEO; May 12, 2014 Special Call (After Valeant’s Proposal):
Management Revenue Guidance has not Materially Changed
Source:
Bloomberg Consensus.
Note:
Prior
to
new
plan
estimates
from
May
9  ,
2014
for
2014E-2015E
and
May
8  ,
2014
for
2016E-2017E.
Current
estimates
as
of
July
14  ,
2014.
$7.0Bn
$7.6Bn
$8.1Bn
$8.8Bn
$7.0Bn
$7.6Bn
$8.3Bn
$9.2Bn
0.5%
1.1%
2.5%
4.7%
2014E
2015E
2016E
2017E
Prior to New Plan
Current
th
th
th
Allergan Consensus Revenue Estimates, Before and After Revised Plan ($Bn, 2014E –2017E)


108
“Going
back
to
SG&A
leverage,
we've
always
stated
that
our
target
in
the midterm is the mid-30s, so I’d reiterate that.”
David Pyott, Allergan Chairman and CEO; Q4 2013 Earnings Call, February 5, 2014:
“Now we're really cranking this in terms of [SG&A] leverage. And by
the
end
of
this
period,
it
will
get
to
the
mid-
to
the
high-20s.”
David Pyott, Allergan Chairman and CEO; May 12, 2014 Special Call (After Valeant’s Proposal):
Source of Improved SG&A Ratio Unclear Given Modest Increase in Revenue Growth
And No Announced Major Cost Cuts
Higher Guidance Appears Driven by the Valeant Bid,
not a Fundamental Change in the Business (Cont.)


“Regarding
the
full
year
2014,
Allergan
estimates…
growth
of
between 12% and 15%, which is consistent with our aspiration of mid-
teens EPS growth.”
Jeff Edwards, Allergan CFO; Q4 2013 Earnings Call, February 5, 2014:
“…[we believe] we can achieve EPS growth of 20% on a compound
annual basis over the next five years.”
David Pyott, Allergan Chairman and CEO; May 12, 2014 Special Call (After Valeant’s Proposal):
What, besides the Valeant proposal, changed in the three months between Allergan’s
February
5
,
2014
Q4
earnings
conference
call
and
the
May
12
Special
Call?
109
If Allergan were being conservative about the fundamentals of the
business before the Valeant proposal, why then were insiders,
including Pyott, selling shares in Q1 2014?
Higher Guidance Appears Driven by the Valeant Bid,
not a Fundamental Change in the Business (Cont.)
th
th


Why is this the goal “now”?
How does raising guidance increase shareholder value?
“Our
goal
now
is
to
give
them
most
of
what
they
want…We
will
raise earnings guidance further.”
David
Pyott,
Allergan
Chairman
and
CEO;
June
23
rd
,
2014
-
Pyott as quoted by Reuters at the BIO International Convention; emphasis added
110
Higher Guidance Appears Driven by the Valeant Bid,
not a Fundamental Change in the Business (Cont.)


Certain
analysts
have
increased
their
near-term
price
targets
by
up
to
67%
based
on
a
24%
increase
in
EPS
five
years
from
now
111
Management’s increased guidance from a 15% EPS CAGR to a
20% EPS CAGR implies a 24% increase in 2019 EPS
+44%
+57%
+67%
+44%
+47%
Source:
Allergan June 10, 2014 investor presentation.
(1)
Represents midpoint of price target range.
The Revised Plan Does Not Support Certain
Standalone Analyst Price Target Increases…
(1)
(1)
$140
$115
$124
$135
$124
$202
$180
$207
$195
$183
$0
$50
$100
$150
$200
$250
BMO
BTIG
Buckingham
Guggenheim
Leerink Swann
Old Price Target
New Price Target


112
…Other Analysts Question Management’s Views on the
Standalone Value of Allergan
“Allergan asserts that its current 26.8x P/E multiple is ‘Due to
Accelerated EPS Outlook from Mid-teens to Revised Guidance of
20% Five-Year EPS CAGR,’
essentially saying that there is no take-
out premium in AGN stock related to the VRX offer. Given the stock’s
reaction following Valeant’s offers, we believe most investors would
disagree.”
Alex Arfaei, BMO; “Will Likely Go the Distance With AGN; But Should Gain More Support”,    
June 10, 2014:


113
Thoughts on Allergan’s Valuation Multiple
Some analysts have taken Allergan’s revised guidance and
applied
AGN’s
historical
average
P/E
multiple
of
22x
(1)
to
arrive
at a target price.  We believe this analysis is materially flawed
We believe AGN’s historic multiple priced in several
opportunities that will disappear under the revised guidance:
Opportunity
for
substantial
SG&A
and
R&D
savings,
starting
from
SG&A
ratio
that
is
over
1,200
bps
higher
than
the
peer
average
(2)
,
which are already captured in AGN’s revised guidance
Potential
to
reduce
AGN’s
relatively
high
tax
rate,
which
disappears without a tax inversion or sale to a foreign company
Premium
for
potential
take-out,
which
decreases
substantially
under a “go-it-alone”
approach, since few acquirers are willing to
engage in hostile transactions
(1)
Ten-year historical average twelve-month forward P/E multiple as per Bloomberg.
(2)
See page 79 for comparison of Allergan’s SG&A as a % of sales to peer companies.


114
Allergan’s history of poor cost management and
poorly designed management incentives should make
investors question the credibility of the revised or any
re-revised long-term plan


115
The Expected, Re-Revised Allergan Operating Plan
Allergan’s management has indicated they will re-revise their
long-term guidance at the time of their Q2 earnings
announcement
The re-revised plan is reactive both to the Valeant proposal and
to shareholder’s disappointment with the initial revised plan
presented in May
The new plan is not credible given management’s previous
statements and actions in addressing the considerable cost
opportunity at Allergan
Any new plan further validates Valeant’s assertion that Allergan
has significant waste in its SG&A and R&D spending
Allergan’s history of poor cost management indicate a lack of
appropriate management oversight by the Allergan board


116
“We
listened
carefully
to
investors’
perspectives
and
heard
that
they
would like to see us harnessing this financial strength to create even
more stockholder value by, among other suggestions, either
purchasing growth-oriented companies or technologies that fit our
strategy and operating model, and/or buying back Allergan stock.”
“As you know, historically we produced strong free cash flow as well
and we've managed to deploy a lion’s share of that free cash flow.
The number one priority is always business development, so M&A. By
all means we will continue looking aggressively for opportunities
across the therapeutic areas we presently do business, but also
looking for adjacencies or other specialty areas that could provide
significant value.”
David Pyott, Allergan CEO, 8-K filed May 19, 2014:
Jeff Edwards, Allergan CFO, Conference call, May 12, 2014:
Management is Considering Making Acquisitions
of its Own to Thwart an Attractive Bid


117
Why is Now the Right Time to Make a Large
Acquisition?
We are extremely skeptical that Allergan shareholders would
be better off paying a premium for another company than
receiving a 50%+ premium in a highly strategic merger
Given Allergan’s poor M&A history, we expect shareholders
will discount the value-creation potential of any acquisition
Unlike Valeant, Allergan has no experience integrating a large
acquisition
Shareholders will likely be especially leery of acquisitions of
pipeline assets, which are speculative in nature and have been
particularly value-destructive for Allergan in the past
Any
“value-creating”
acquisitions
would
have
most
likely
been
available for years before the Valeant bid


118
Source:
Reuters.
“Pyott has met with investors to talk about the company’s defense,
which
he
said
could
include
issuing
new
debt
to
buy
back
shares.
He
said Allergan could borrow up to $10 billion without affecting its
investment-grade rating, but he did not say how much the company
might spend on the buybacks.”
Caroline Humer and Deena Beasly of Reuters, July 1, 2014:
Management is Also Considering a Leveraged
Buyback


119
Allergan has indicated that the company is contemplating a
leveraged
buyback
of
up
to
$10
billion
,
compared
to
a
total
buyback of $2.4 billion from 2011 to Q1 2014
Allergan’s stock is currently trading at 29x 2014E earnings per
share,
vs.
18x
for
its
peers
(2)
Represents 24% premium over 12-month median price target of
$135 per share before initial Valeant bid
82% premium over the three-year average price of $92 per
share
A leveraged buyback of this scale will likely have to be
conducted at a material premium to AGN’s current price
A Large Buyback at the Currently Elevated Share
Price would be Value-Destructive
Source:
Interview with David Pyott (Reuters, July 1), Company filings and FactSet.
(1)
Represents Allergan’s maximum borrowing capacity while retaining investment-grade rating.
(2)
As of July 14, 2014. Peers from Allergan’s 2014 proxy (excluding Forest Laboratories).
(1)


120
Source: Company filings and Factset.
Allergan Share Buyback –
Too Little, Too Late
Why didn’t Allergan buy back stock at $80-90 per share last year?
2011
2012
2013
2014
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
3 year average price: $91.80
July 14   closing
price: $167.02
Amount repurchased
Stock price
82%
premium
$0.00
$20.00
$40.00
$60.00
$80.00
$100.00
$120.00
$140.00
$160.00
$180.00
$200.00
$0
$100
$200
$300
$400
$500
$600
$700
$800
$900
$1,000
$163
$136
$75
$88
$217
$332
$174
$185
$648
$0.7
$0.2
$1.4
$398
th


121
“Pyott said other drugmakers at the San Diego convention
‘understand that if we were to succumb to this, then somebody even
bigger is next on the menu, or at least a lot of them will be afternoon
snacks.’”
Is David Pyott more concerned about protecting shareholder
interests or preserving the privileges of fellow entrenched
pharmaceutical managements?
Deena Beasley of Reuters paraphrasing David Pyott at the BIO International Convention,
June 23, 2014:


122
Q&A
We encourage shareholders considering supporting the
Pershing Square special meeting consent solicitation to
contact D.F. King, our proxy solicitor, with any questions
about the process:
Ed McCarthy
D.F. King
(212) 269-5550
emccarthy@dfking.com


LOGO

ADVANCING ALLERGAN
Proposed Nominees
READ ANNOUNCEMENT
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
Betsy Atkins
Chief Executive Officer of Baja LLC
Betsy Atkins is a business executive and entrepreneur with substantial public company board experience known for her early stage investments in Yahoo and eBay and service as Chairman and CEO of Clear Standards, Inc, a leading provider of SaaS Software enterprise carbon management and sustainability solutions, which was acquired by SAP.
READ BIO
Cathleen P. Black
Senior Advisor at RRE Ventures LLC
Cathleen Black, a business executive and author, is a former New York City Schools Chancellor who served as chairman of Hearst Magazines for 15 years.
READ BIO
Fredric N. Eshelman
Principal at Eshelman Ventures, LLC
Fredric Eshelman, a pharmacist by training, built Pharmaceutical Product Development, Inc. from a one person start up into to a $4 billion contract research organization which was sold in 2011 to private equity. He also founded and served as executive chairman of Furiex Pharmaceuticals, Inc., which was sold earlier this year to Forest Labs. for up to $1.5 billion.
READ BIO
Steven J. Shulman
Managing Director of Shulman Ventures Inc.
Steve Shulman has extensive experience as a public company board member and executive.
READ BIO
David A. Wilson
Former President and Chief Executive Officer of the Graduate Management Admission Council
David Wilson is a world-renowned thought leader in the field of accounting with significant executive experience.
READ BIO
John J. Zillmer
John Zillmer is a well-known business executive with broad experience leading large industrial organizations.
READ BIO
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
Betsy Atkins
Chief Executive Officer of Baja LLC
Betsy Atkins, 61, has been the Chief Executive Officer of Baja LLC, an independent venture capital firm focused on technology, renewable sciences and life sciences, since 1994. She was formerly Chief Executive Officer and Chairman of Clear Standards, Inc., an on-demand enterprise energy management sustainability software company, from 2008 to 2009, at which time it was acquired by SAP AG.
Ms. Atkins has co-founded successful high tech and consumer companies, including Ascend Communications (formerly NASDAQ: ASDN). She is the former Chairman of the Board of Directors of Third Screen Media, a company that was eventually sold to AOL. Ms. Atkins was the CEO of NeutraCeutical Ingredients Pte. Ltd., from 1991 through 1993. She has also served on the Board of Directors of Human Genome Sciences Inc. (NASDAQ: HGSI), HealthSouth Corporation (NYSE: HLS), Vonage Holdings Inc. (NYSE: VG), Towers Watson & Co. (NYSE: TW), Reynolds American Inc. (NYSE: RAI), SunPower Corporation (NASDAQ: SPWR) and Chico’s FAS, Inc. (NYSE: CHS).
Ms. Atkins has served as a director of Polycom, Inc. (NASDAQ: PLCM) since April 1999 and is currently the Chairman of the Compensation Committee and a member of the Nominating and Governance Committee. She has been a director of Schneider Electric, SA. since April 2011. Ms. Atkins has also served as a director for HD Supply Holdings, Inc. (NASDAQ: HDS) since September 2013 and is a member of the Compensation Committee. Ms. Atkins served as a director for Wix.com Ltd. (NASDAQ: WIX) through July 2014, where she was a member of the Audit Committee and Chair of the Compensation Committee since October 2013. She has also served as a director of Ciber Inc. (NYSE: CBR) since July 2014 and is a member of the Compensation and Governance Committee.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
Cathleen P. Black
Senior Advisor at RRE Ventures LLC
Cathleen P. Black, 70, has served as a Senior Advisor at RRE Ventures LLC, an early stage venture capital firm, since 2011. She has served on the boards of two of RRE Ventures LLC’s portfolio companies, Yieldbot Inc. and Bark & Co Inc. as an independent board member and is also a board member of PubMatic, Inc., an advertising technology platform. Prior to that, Ms. Black served as President of Hearst Magazines, a division of the Hearst Corporation and one of the world’s largest publishers of monthly magazines, from January 1996 until late 2010. Ms. Black also served as a director of the Hearst Corporation from January 1996 until late 2010. Moreover, Ms. Black served as President of USA Today from October 1983 until June 1991 and was a board member of the parent company, Gannett Co., Inc. (NYSE: GCI).
In addition, Ms. Black served as a director of Vibrant Media Inc., a global leader of in-content contextual technology, from October 2012 until 2013, served as an independent director of International Business Machines Corp. (NYSE: IBM) from 1995 until 2010 and served as a director of The Coca-Cola Company (NYSE: KO) from 1992 until 2010.
Further, Ms. Black served as a director of NYC2012 Inc., a non-profit-organization created to promote New York City as a location for the 2012 Summer Olympics and as President of the Newspaper Association of America. Between January 2011 and April 2011, Ms. Black also served New York City as Chancellor of New York City Schools. Ms. Black is a member of the National Council of Foreign Relations, a trustee emeritus of The University of Notre Dame and a trustee of the Kent School.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
Fredric N. Eshelman
Principal at Eshelman Ventures, LLC
Fredric N. Eshelman, 65, is a principal at Eshelman Ventures, LLC, which is a fund that invests primarily in early-stage healthcare. He served as Founding Chairman of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development company, from its founding in 2009 until the sale of the company to Forest Laboratories LLC in July 2014. Mr. Eshelman also founded Pharmaceutical Product Development, Inc. (NASDAQ: PPDI), an international contract research organization. He served as the Chief Executive Officer of Pharmaceutical Product Development, Inc. until 1989 and from July 1990 until July 2009, Vice Chairman of its board of directors from July 1993 until July 2009 and Executive Chairman from July 2009 until its sale to private equity in 2011.
From 1989 until he rejoined Pharmaceutical Product Development, Inc. in 1990, Dr. Eshelman was Senior Vice President of Development at Glaxo, Inc. and served on the board of the United States subsidiary of Glaxo Holdings plc. Dr. Eshelman also currently serves as director on several private company boards. Dr. Eshelman also served on the board of Princeton Pharma Holdings LLC from February 2008 until May 2010, when it was acquired by Valeant Pharmaceuticals International, Inc.
Dr. Eshelman serves on the University of North Carolina System Board of Governors, including its Audit Committee. He also serves as a director of the North Carolina Biotechnology Center. Moreover, Dr. Eshelman serves on the University of North Carolina at Wilmington Board of Trustees and has served as an adjunct professor at University of North Carolina at Chapel Hill. The University of North Carolina Eshelman School of Pharmacy was so named to reflect his many contributions to the University of North Carolina and the profession of pharmacy.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
Steven J. Shulman
Managing Director of Shulman Ventures Inc.
Steven J. Shulman, 63, serves as the Managing Director of Shulman Ventures Inc., a private equity investment firm. Mr. Shulman has also served as a strategic advisor to Water Street Healthcare Partners, a private equity firm focused exclusively on health care, since 2008.
Mr. Shulman has served as Chairman of CareCentrix, Inc. since 2008, Access MediQuip, LLC since 2009 and Accretive Health, Inc. (NYSE: AH) since 2014. Mr. Shulman has also served as a director of HealthMarkets, Inc. since 2006, Facet Technologies since 2011, Oasis Outsourcing since 2012, MedImpact since 2013 and Quantum Health since 2013. Mr. Shulman has previously served on numerous other privately held company boards. Mr. Shulman served as Chairman of Health Management Associates Inc. (NYSE: HMA) from 2013 until January 2014. He also served as Chairman and Chief Executive Officer of Magellan Health Services, Inc. (NASDAQ: MGLN) from 2003 until 2009.
Mr. Shulman founded and served as Chairman and Chief Executive Officer at Internet Healthcare Group, LLC, from 1999 until 2003. He also served as the Chairman, President and Chief Executive Officer of Prudential Healthcare, Inc. from 1997 until 1999. Mr. Shulman co-founded and served as a director of Value Health, Inc. (NYSE: VH), a specialty managed care company in 1987, which went public in 1991 and was sold in 1997. During this time, he served in a number of senior operating positions including President of Pharmacy & Disease Management Group. Earlier in his career, Mr. Shulman held various leadership positions at Cigna Corporation (NYSE: CI) from 1983 to 1987 and at Kaiser Permanente from 1974 to 1983. Mr. Shulman served on the Board of Trustees of the Crohn’s and Colitis Foundation of America as well as the University of Hartford’s Art School. In addition, he serves on the Deans Council at SUNY at Stony Brook and as an incorporator at Hartford Hospital.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
David A. Wilson
Former President and Chief Executive Officer of the Graduate Management Admission Council
David A. Wilson, 73, is the former President and Chief Executive Officer of the Graduate Management Admission Council, a not-for-profit education association dedicated to creating access to graduate management and professional education that provides the Graduate Management Admission Test (GMAT), a position he held from 1995 through December 2013. Mr. Wilson served as Senior Advisor to the Graduate Management Admission Council from December 2013 until June 2014.
Mr. Wilson has served as a director of CoreSite Realty Corporation (NYSE: COR), since 2010, and is a member of the Compensation Committee and chair of the Audit Committee. He has also served Barnes & Noble, Inc. (NYSE: BKS) as a director and as chair of its Audit Committee since October 2010. Mr. Wilson served as a director at Terra Industries Inc. (formerly NYSE: TRA) from November 2009 until April 2010, where he served as member of the Audit Committee. Mr. Wilson also served as a director at Laureate Education, Inc. (formerly Sylvan Learning Systems, Inc.) (NASDAQ: LAUR), from 2002 until 2007, where he served on the audit committee.
From 1978 to 1994, Mr. Wilson worked in various capacities for Ernst & Young LLP (and its predecessor, Arthur Young & Company), including as Audit Principal, Audit Partner, Managing Partner, National Director of Professional Development, Chairman of Ernst & Young’s International Professional Development Committee and as a director of the Ernst & Young Foundation.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
« Back to Proposed Nominees
John J. Zillmer
John J. Zillmer, 58, is the former Executive Chairman of Univar, Inc., a leading global distributor of industrial and specialty chemicals and related services, a position he held from May 2012 to December 2012. He served as director, President and Chief Executive Officer of Univar, Inc. from September 2009 to May 2012.
Prior to joining Univar, Inc., Mr. Zillmer was Chairman and Chief Executive Officer of Allied Waste Industries, Inc. from May 2005 until December 2008, at which time Allied Waste Industries, Inc. merged with Republic Services, Inc. (NYSE: RSG). From May 2000 to January 2004, Mr. Zillmer served as Executive Vice President of ARAMARK Corporation (NYSE: ARMK), a company he joined in 1995.Mr. Zillmer has served as a director of Reynolds American Inc (NYSE: RAI), since July 2007 and has been the Chair of its Governance and Nominating Committee since 2011. He has also served as a director of Ecolab Inc. (NYSE: ECL), since May 2006. He has been a member of its Governance Committee since 2007, its Compensation Committee since 2011 and on its Audit Committee from 2007 to 2010.
Mr. Zillmer has also served as director and Chair of the Compensation and Governance Committee of Veritiv Corporation (NYSE: VRTV), since June 2014. He has also served as director of Liberty Capital Partners, Investment Arm, a private equity and venture capital firm specializing in startups, early stage, growth equity, buyouts, and acquisitions, since June 2004.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME WEBCAST NOMINEES SHAREHOLDER MATERIALS NEWS RELEASES PROPOSED BY-LAWS MEDIA CONTACTS
How To Call A Special Meeting – Shareholders
First, you should either transfer or purchase at least one share of Allergan common stock and deposit in record name on books of Allergan’s transfer agent, Wells Fargo Bank.
Second, you should complete, sign and date your Special Meeting Request Form and your WHITE Proxy Card.
Third, to effect the execution of the Cede & Co. Meeting Request and Verification Letter, you will need to:
arrange for your DTC participant(s) to instruct DTC to cause Cede & Co., as nominee of DTC, to sign and return the Cede & Co. Meeting Request to your DTC participant(s);
arrange for your DTC participant(s) to sign the Verification Letter with respect to your shares of Allergan common stock.
Fourth, once you receive the executed Cede & Co. Meeting Request and executed Verification Letter from your DTC participant, you should send the Cede & Co. Meeting Request and Verification Letter, along with the executed Special Meeting Request Form, WHITE Proxy Card and the record holder verification (copy of certificate or statement of ownership from Wells Fargo Bank, Allergan’s transfer agent), to D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 Attn: Krystal Scrudato (email:kscrudato@dfking.com Phone: (212) 269-5550).
©2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
How To Call A Special Meeting – DTC participant
First, once a DTC Participant is contracted by an Allegan shareholder, the DTC Participant should:
Instruct DTC to cause Cede & Co., as nominees of of DTC, to sign and return the Cede & Co. Meeting Request;
Sign the Verification letter with respect to that shareholder’s shares of Allegan common stock.
Second, upon receiving the executed Cede & Co. Meeting Request from Cede & Co., the DTC participant should return the executed Cede & Co. Meeting Request and executed Verification Letter to the shareholder.
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
http://advancingallergan.com/
Home
Webcast
Nominees
Shareholder Materials
News Releases
Proposed By-Laws
Media Contacts
Shareholder Materials
Forms To Complete To Become a Proposing Person And Call A Special Meeting of Shareholders
Solicitation Statement
Request Form to Call a Special Meeting
Exhibit B-1 – DTC Instruction Letter
Exhibit B-2 – CEDE & Co. Meeting Request
Exhibit C – Verification Letter
Exhibit D – WHITE Proxy Card
Proposed Director Consent
Exhibit F-1: Atkins
Exhibit F-2: Black
Exhibit F-3: Eshelman
Exhibit F-4: Shulman
Exhibit F-5: Wilson
Exhibit F-6: Zillmer
© 2014 Pershing Square Capital Management


SOLICITATION OF WRITTEN REQUEST FOR SPECIAL MEETING IN CONNECTION WITH THE

CALLING OF A SPECIAL MEETING OF SHAREHOLDERS OF

ALLERGAN, INC.

 

 

SOLICITATION STATEMENT

OF

THE REQUESTING SHAREHOLDER

 

 

To the Shareholders of Allergan, Inc.:

This Solicitation Statement (this “Solicitation Statement”), the enclosed form of Special Meeting Request attached as Exhibit A (the “Special Meeting Request Form”), the enclosed form of instruction letter to The Depository Trust Company (“DTC”) attached as Exhibit B-1 (the “DTC Instruction Letter”), the enclosed form of written request for a special meeting from DTC’s nominee attached as Exhibit B-2 (the “Cede & Co. Meeting Request”), the enclosed form of letter from the brokerage firm, bank nominee or other institution that is the holder of record of your shares of Company Common Stock (“DTC participant”) verifying your beneficial ownership of Company Common Stock attached as Exhibit C (the “Verification Letter”) and the accompanying WHITE Proxy Card attached as Exhibit D (the “WHITE Proxy Card”) are being furnished to you as a shareholder of Allergan, Inc., a Delaware corporation (the “Company” and/or “Allergan”), by and on behalf of PS Fund 1, LLC, a Delaware limited liability company (the “Requesting Shareholder,” “PS Fund 1,” “we,” “our” or “us”), for the purpose of soliciting revocable proxies from shareholders of the Company to empower us to deliver to the Company’s Secretary your Special Meeting Request Forms and Cede & Co. Meeting Requests to call a special meeting of the Company’s shareholders for the purposes described below (the “Special Meeting”), along with Verification Letters, as applicable.

Pursuant to the Company’s Amended and Restated Certificate of Incorporation, effective May 9, 2014 (the “Charter”), and the Company’s Amended and Restated Bylaws, effective May 9, 2014 (the “Bylaws”), the calling of the Special Meeting requires the written request of holders of record of at least 25% of the outstanding shares of common stock of the Company, par value $0.01 per share (“Company Common Stock”), at the time the request is validly submitted (the “Requisite Percentage”) subject to and in compliance with Article 10 of the Charter and Article II, Section 3 of the Bylaws.

In addition, pursuant to the Bylaws, one or more written requests must be signed by Proposing Persons (as defined in the Bylaws) that are holders of record of at least one share of Company Common Stock and have a combined Net Long Beneficial Ownership (as defined in the Bylaws) of at least the Requisite Percentage (such holders, the “Requisite Holders”).

The Special Meeting Request Forms, the DTC Instruction Letters, the Cede & Co. Meeting Requests, the Verification Letters and the WHITE Proxy Cards are being provided to you for the purpose of calling the Special Meeting. The DTC Instruction Letter and the Cede & Co. Meeting Request are to be completed by your DTC participant(s), upon your direction, and the Cede & Co. Meeting Request will be executed by Cede & Co., as DTC’s nominee, upon DTC’s receipt of a duly executed DTC Instruction Letter from your DTC participant(s) on your behalf. Beneficial owners of shares of Company Common Stock who wish to become Proposing Persons but do not currently hold any shares of Company Common Stock in record (certificated) form must transfer into the name of such Proposing Person, or purchase in the name of such Proposing Person, at least one share of Company Common Stock.

The date of this Solicitation Statement is July 11, 2014. This Solicitation Statement, the enclosed Special Meeting Request Form, the enclosed DTC Instruction Letter, the enclosed Cede & Co. Meeting Request, the enclosed Verification Letter and the accompanying WHITE Proxy Card are first being sent or given to shareholders on or about July 11, 2014.


Copies of the Bylaws and Charter can be found at: http://www.allergan.com/investors/corporate_governance_and_certificates.htm.

The Requesting Shareholder seeks to request that the Company call a special meeting of the Company’s shareholders to consider and vote upon the proposals set forth in the section of this Solicitation Statement titled “Plans for the Special Meeting.”

At this time, the Requesting Shareholder is soliciting your revocable proxy to empower us to deliver your Special Meeting Request Form and Cede & Co. Meeting Request, along with a Verification Letter, as applicable, to the Company’s Secretary, and is not currently seeking your proxy, consent, authorization or agent designation for approval of the Proposals or any other actions. In the event the Special Meeting is called, the Requesting Shareholder will send you proxy materials relating to the Proposals.

On April 22, 2014, Valeant first made an offer to the Board proposing a business combination of Allergan and Valeant. On May 30, 2014, Valeant publicly announced a revised proposal to merge with Allergan pursuant to which each share of Company Common Stock would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock (and has indicated it remains willing to add a contingent value right relating to sales of Allergan’s DARPin ® product if Allergan were to engage in negotiations with Valeant to work out the exact terms of the CVR). Please refer to the section of this Solicitation Statement titled “Background and Past Contacts” for more detailed information.

From April 10, 2014 (the day before Pershing Square began its rapid accumulation program) to the date of this Solicitation Statement, the Company’s stock price has increased by approximately 45%. We believe the market has spoken, and that shareholders see substantial value in Valeant’s revised proposal. To date, the Board has refused to engage with Valeant in any way regarding a merger with Valeant.

Therefore, the Requesting Shareholder is asking the Company’s shareholders to complete, sign and date the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card, to arrange for the execution of the Cede & Co. Meeting Request and Verification Letter by following the steps outlined below, and to return each of the Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter to D.F. King and Co., Inc. (“D.F. King”), which is assisting the Requesting Shareholder in this solicitation of requests to call the Special Meeting. To effect the execution of the Cede & Co. Meeting Request and Verification Letter, the Requesting Shareholder asks the Company’s shareholders to arrange for their DTC participant(s) to instruct DTC to cause Cede & Co., as nominee of DTC, to sign and return the Cede & Co. Meeting Request to the shareholder’s DTC participant(s), and for such DTC participant(s) to sign the Verification Letter with respect to such shareholder’s shares of Company Common Stock.

Upon receiving the executed Cede & Co. Meeting Request from Cede & Co., the DTC participant(s) should return the executed Cede & Co. Meeting Request and their executed Verification Letter to the shareholder, who should send the Cede & Co. Meeting Request and Verification Letter, along with the executed Special Meeting Request Form and WHITE Proxy Card, to D.F. King, who will gather such documents and provide them to the Requesting Shareholder for submission to the Company.

The Special Meeting Request Form and the Cede & Co. Meeting Request request that the Special Meeting be held as soon as possible, and in any event within 45 days, following the date on which Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters from the Requisite Holders are delivered to the Company’s Secretary.

We ask that the executed Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters be delivered as promptly as possible, by mail in the enclosed postage-paid envelope to D.F. King at the address below, and that you follow the instructions below with respect to any of your shares of Company Common Stock held through a DTC participant. Please note that, because Article II,

 

2


Section 3(a) of the Bylaws provides that special meeting requests from multiple shareholders may be aggregated and considered together only if they identify the same purposes and the same matters proposed to be acted on at a special meeting, we request that you not change the purposes or Proposals stated in the Special Meeting Request Forms or the Cede & Co. Meeting Requests.

If you have any questions about completing, executing and dating your Special Meeting Request Form or WHITE Proxy Card, causing your Cede & Co. Meeting Request or Verification Letter to be executed and returned to you or delivering each of the four documents to D.F. King, or otherwise require assistance, please contact D.F. King at the address and telephone numbers below. We encourage you to submit your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter, even if you cannot complete your Special Meeting Request Form or WHITE Proxy Card in full or you believe your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request or Verification Letter may be defective; however, we reserve the right not to submit any Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters if we believe that they do not comply with the Charter and Bylaws. If we believe that your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and/or Verification Letter does not so comply, or the Company notifies us of such non-compliance, we expect to contact you.

IMPORTANT

Please complete, sign and date the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card as soon as possible.

If any of your shares of Company Common Stock are held in the name of a brokerage firm, bank nominee or other institution, please arrange to have such DTC participant(s) complete and return the executed Cede & Co. Meeting Request and their executed Verification Letter to you by following the procedures set forth in the section of this Solicitation Statement titled “Procedures for Arranging for Execution of Cede & Co. Meeting Requests and Verification Letters”.

Pursuant to the Bylaws, if any portion of your shares of Company Common Stock is sold, or there is any other reduction in your Net Long Beneficial Ownership, prior to the date of the special meeting, your Special Meeting Request Form will be deemed revoked pursuant to the Bylaws to the extent of such sale or reduction. Therefore, we request that you not sell any portion of your shares, or otherwise reduce your Net Long Beneficial Ownership, until after the date of the special meeting.

If you have any questions about completing, executing and dating your Special Meeting Request Form or WHITE Proxy Card, causing your Cede & Co. Meeting Request or Verification Letter to be executed and returned to you or delivering each of the four documents to D.F. King, or otherwise require assistance, please contact:

D.F. King & Co., Inc.

48 Wall Street

New York, NY 10005

Toll-free: (800) 859-8511

Banks and brokers: (212) 269-5550

Please complete, sign and date the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card and, if any of your shares of Company Common Stock are held through a DTC participant, follow the instructions below to arrange for the execution of the Cede & Co. Meeting Request and the Verification Letter, and return all four documents to D.F. King in the enclosed postage-paid envelope today.

 

3


IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SOLICITATION OF WRITTEN REQUEST FOR SPECIAL MEETING. In addition to delivering printed versions of this Solicitation Statement, the Special Meeting Request Form, the WHITE Proxy Card, the DTC Instruction Letter, the Cede & Co. Meeting Request and the Verification Letter to all shareholders by mail, this Solicitation Statement, the Special Meeting Request Form, the WHITE Proxy Card, the DTC Instruction Letter, the Cede & Co. Meeting Request and the Verification Letter are also available on the Internet. You have the ability to access and print this Solicitation Statement, the Special Meeting Request Form, the WHITE Proxy Card, the DTC Instruction Letter, the Cede & Co. Meeting Request and the Verification Letter at http://www. advancingallergan.com. As a shareholder of Allergan, you may have received the Company’s revocation solicitation statement (the “Revocation Statement”) and the accompanying blue revocation card. Since only your latest dated proxy card will count, we urge you not to return any proxy/revocation card you receive from the Company. Remember, you can support the call of the Special Meeting only by submitting our WHITE Proxy Card and the other documents described herein. Please make certain that the latest dated proxy card you return is the WHITE Proxy Card.

THIS SOLICITATION IS BEING MADE BY THE REQUESTING SHAREHOLDER, AND NOT ON BEHALF OF THE COMPANY OR THE BOARD. AT THIS TIME, WE ARE NOT CURRENTLY SEEKING YOUR PROXY, CONSENT, AUTHORIZATION OR AGENT DESIGNATION FOR APPROVAL OF THE PROPOSALS OR ANY OTHER ACTIONS. WE ARE ONLY SOLICITING YOUR REVOCABLE PROXY TO EMPOWER US TO DELIVER TO THE COMPANY’S SECRETARY YOUR SPECIAL MEETING REQUEST FORM AND CEDE & CO. MEETING REQUEST TO CALL THE SPECIAL MEETING, ALONG WITH A VERIFICATION LETTER, AS APPLICABLE.

AFTER THE SPECIAL MEETING REQUEST FORMS, WHITE PROXY CARDS, CEDE & CO. MEETING REQUESTS AND VERIFICATION LETTERS HAVE BEEN DELIVERED, WE WILL SEND YOU PROXY MATERIALS URGING YOU TO VOTE IN FAVOR OF THE PROPOSALS.

YOUR SPECIAL MEETING REQUEST FORM, WHITE PROXY CARD, CEDE & CO. MEETING REQUEST AND VERIFICATION LETTER ARE IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN. WE URGE YOU TO COMPLETE, SIGN, DATE AND RETURN THE ENCLOSED SPECIAL MEETING REQUEST FORM AND THE ACCOMPANYING WHITE PROXY CARD AND, WITH RESPECT TO ANY OF YOUR SHARES OF COMPANY COMMON STOCK HELD THROUGH A DTC PARTICIPANT, TO FOLLOW THE PROCEDURES SET FORTH IN THE SECTION OF THIS SOLICITATION STATEMENT TITLED “PROCEDURES FOR ARRANGING FOR EXECUTION OF CEDE & CO. MEETING REQUESTS AND VERIFICATION LETTERS”.

BACKGROUND AND PAST CONTACTS

On September 10, 2012, J. Michael Pearson, Valeant’s Chairman of the Board and Chief Executive Officer, spoke to David Pyott, Allergan’s Chairman of the Board, President and Chief Executive Officer, about possibly combining the two companies. Mr. Pyott informed Mr. Pearson that he would discuss the possibility with the Board.

On September 25, 2012, Mr. Pyott called Mr. Pearson and indicated that he had spoken with the Board about a possible business combination with Valeant, and Allergan was not interested in a transaction at that time. As part of its general review of strategic opportunities, Valeant’s management continued to review numerous transaction alternatives with various pharmaceutical businesses and assets, including, from time to time, Allergan.

In September of 2013, Pershing Square Capital Management, L.P. (“Pershing Square”) hired William F. Doyle as a Senior Advisor.

 

4


On January 14, 2014, Mr. Doyle, a senior advisor at Pershing Square, spoke with Mr. Pearson, at a health care conference. They discussed Mr. Doyle’s work with Pershing Square and it was suggested that they have a subsequent discussion regarding the potential of Valeant and Pershing Square jointly engaging in merger and acquisition transactions. On January 31, 2014, Messrs. Pearson and Doyle had a follow-up meeting in which they exchanged public information about Valeant and Pershing Square. Messrs. Doyle and Pearson did not specifically discuss Allergan at either meeting.

On February 4, 2014, Mr. Pearson and G. Mason Morfit, then a director of Valeant, met with Mr. Doyle and William A. Ackman, the Chief Executive Officer of Pershing Square. They primarily discussed Valeant and Valeant’s business model. They also discussed what Pershing Square could do to encourage large public pharmaceutical companies to create more value for their stockholders, including by entering into different types of transactions with Valeant, though the structure that Valeant eventually used in connection with its offer for Allergan was not specifically discussed. Allergan was one of several companies mentioned, but was not discussed in detail.

On or around February 6, 2014, Mr. Ackman and Mr. Pearson had a telephone call in which they discussed, conceptually, a potential transaction structure in which Valeant would identify a target and disclose it confidentially to Pershing Square, after which Pershing Square could decide whether it was interested in working with Valeant. No specific targets were discussed on the telephone call. Around the same time, Mr. Pearson and Mr. Pyott agreed to meet the following weekend to follow up on their September 2012 discussions regarding the possibility of combining the two companies.

On February 7, 2014, Sullivan & Cromwell LLP (“Sullivan & Cromwell”), Valeant’s counsel, sent Pershing Square and Kirkland & Ellis LLP (“Kirkland & Ellis”), Pershing Square’s counsel, a draft confidentiality agreement that did not disclose the identity of Allergan. Between February 7, 2014 and February 9, 2014, representatives of Sullivan & Cromwell and Kirkland & Ellis exchanged drafts of and negotiated the confidentiality agreement.

On February 9, 2014, Valeant and Pershing Square entered into the confidentiality agreement, after which, Mr. Pearson called Mr. Ackman by telephone and informed him of Valeant’s interest in a potential transaction with Allergan. Later that day, the board of directors of Valeant (the “Valeant Board”), met telephonically and discussed, among other things, pursuing the acquisition of Allergan and doing so with Pershing Square.

On February 10, 2014, in connection with Allergan senior management’s meetings with analysts, Sanford B. Bernstein & Co. published a report of its discussions with Mr. Pyott, reporting that an acquisition of Allergan by Valeant “was not a good fit and shareholders would hesitate to take Valeant paper.” That same day, Bank of America Merrill Lynch analyst Gregg Gilbert issued a note stating that Allergan would not be interested in a transaction with Valeant.

On February 11, 2014, Pershing Square formed a new Delaware limited liability company, PS Fund 1, and Pershing Square, L.P., Pershing Square II, L.P., Pershing Square International, Ltd. and Pershing Square Holdings, Ltd (collectively, the “Pershing Square Funds”), which are investment funds managed by Pershing Square, entered into the original limited liability company agreement for PS Fund 1.

On February 13, 2014, representatives of Valeant and Pershing Square met to discuss a potential transaction involving Allergan. Representatives of Sullivan & Cromwell and Kirkland & Ellis also attended. Later that day, Sullivan & Cromwell sent Kirkland & Ellis a draft of an amended confidentiality agreement. Between February 13, 2014 and February 20, 2014, representatives of Sullivan & Cromwell and Kirkland & Ellis exchanged drafts of and negotiated the amended confidentiality agreement.

As a result of Mr. Pyott’s published statements to analysts, on February 14, 2014, the planned meeting between Messrs. Pearson and Pyott was cancelled.

 

5


On February 20, 2014, Valeant and Pershing Square entered into the amended confidentiality agreement, dated as of February 9, 2014. That same day, Kirkland & Ellis sent Sullivan & Cromwell a draft letter agreement related to the purchase of equity in Allergan. Between February 20, 2014 and February 25, 2014, representatives of Valeant, Pershing Square and their respective counsel exchanged drafts of and negotiated the letter agreement.

On February 21, 2014, the Valeant Board met in Toronto and discussed a potential transaction involving Allergan. Messrs. Ackman and Doyle attended a portion of the meeting, during which, among other things, Pershing Square’s role in a potential transaction was discussed.

On February 25, 2014, Pershing Square and Valeant entered into an agreement (the “Letter Agreement”) pursuant to which they agreed that a joint venture entity, PS Fund 1, would acquire shares of Company Common Stock and derivative instruments referencing Company Common Stock. Pursuant to the Letter Agreement, the parties thereto agreed, among other things, that:

 

    Valeant would not, while Valeant, Pershing Square and/or PS Fund 1 may be deemed a group, acquire beneficial ownership of Allergan equity, except in a business combination transaction with Allergan or as a result of transactions by Pershing Square, PS Fund 1 or any of their respective affiliates;

 

    PS Fund 1 would dissolve following the earliest to occur of several events, including the consummation of a business combination transaction with Allergan or at such time that Valeant informs Pershing Square or Allergan that it is no longer interested in pursuing a business combination transaction with Allergan;

 

    Income, gain and loss on $75.9 million in value of shares of Company Common Stock purchased by PS Fund 1 would be allocated to Valeant and the remaining net profit realized by PS Fund 1 would be allocated to funds advised by Pershing Square, except that Valeant would have a right to 15% of the net profits otherwise allocable to funds advised by Pershing Square if, before dissolution and at a time when a Valeant business combination proposal for Allergan is outstanding, a proposal for a third party business combination with Allergan is outstanding or made;

 

    Valeant would consult with Pershing Square before making any material decisions relating to a business combination with Allergan;

 

    Pershing Square would direct the management of PS Fund 1 (including the manner and timing of purchases and sales of Allergan equity) and would generally decide how PS Fund 1 votes any securities it owns, except that until the Termination Time (as defined in the Letter Agreement) PS Fund 1 would vote all of its shares of Company Common Stock in favor of a proposal by Valeant to acquire Allergan and other proposals supported by Valeant and against proposals reasonably likely to impair the ability of Valeant to consummate a business combination with Allergan, and, subject to limited exceptions, would not sell or otherwise reduce its economic ownership in Allergan equity;

 

    At the election of Valeant, immediately prior to consummation of a Valeant business combination with Allergan, Pershing Square would purchase, for $400 million, Valeant common shares at a per share price reflecting a 15% discount to the then current market price;

 

    If Valeant and Allergan consummate a business combination transaction that permits shareholders of Allergan to elect to receive Valeant common shares, Pershing Square would cause PS Fund 1 to elect to receive Valeant common shares for all shares of Company Common Stock over which it controls that election; and

 

    If Valeant and Allergan consummate a business combination transaction, Pershing Square would, on the date of consummation, hold Valeant common shares with a then current value of at least $1.5 billion and, for a period of at least one year after that consummation, it will not sell Valeant common shares unless after giving effect to the sale it continues to own at least $1.5 billion in value of Valeant common shares (and during that one year period it would not hedge its investment in that minimum number of shares).

 

6


Also on February 25, 2014, PS Fund 1 began acquiring securities of Allergan. Following the acquisition by PS Fund 1 of 597,431 shares of Company Common Stock, Valeant contributed $75.9 million to PS Fund 1 in respect of such shares. The Pershing Square Funds thereafter contributed to PS Fund 1 the remainder of the funds needed to fund the acquisition of securities of, and derivatives referencing, the Company. Between February 25 and April 21, 2014, representatives of Valeant and Pershing Square and their counsel participated in at least weekly phone calls to update Valeant on PS Fund 1’s trading.

On February 26, 2014, Sullivan & Cromwell sent Pershing Square and Kirkland & Ellis a draft of an amended and restated limited liability company agreement for PS Fund 1, including a Valeant entity as a member, and generally reflecting the terms of the Letter Agreement. Between February 25, 2014 and April 3, 2014, representatives of Sullivan & Cromwell and Kirkland & Ellis exchanged drafts of and negotiated the amended and restated limited liability company agreement of PS Fund 1.

On March 11, 2014 and March 12, 2014, the Valeant Board met and discussed various matters, including a potential transaction involving Allergan.

On March 17, 2014, representatives of Valeant and Pershing Square met to discuss the terms of a potential transaction with Allergan and to continue Pershing Square’s due diligence of Valeant’s business which also involved visits to certain Valeant operations and other oral and documentary due diligence.

On April 1, 2014, representatives of Valeant and Pershing Square met again to discuss Valeant’s and Allergan’s operations and the process for accomplishing the proposed transaction.

On April 3, 2014, Valeant Pharmaceuticals International (“Valeant USA”), Pershing Square and each of the Pershing Square Funds entered into the amended and restated limited liability company agreement of PS Fund 1, dated as of April 3, 2014, which generally reflected the terms of the Letter Agreement.

On April 7, 2014, the Valeant Board held a meeting in Toronto and discussed, among other things, pursuing an acquisition of Allergan and doing so with Pershing Square.

On April 8, 2014, PS Fund 1 reached beneficial ownership of 4.99% of Allergan’s outstanding stock and, as required by the Letter Agreement, stopped purchasing equity in Allergan pending Valeant approval to cross the 5% threshold. On April 10, 2014, Valeant provided approval for PS Fund 1 to purchase equity derivatives referencing Allergan that would result in PS Fund 1 beneficially owning more than 5% of Allergan’s outstanding stock.

On April 11, 2014, PS Fund 1 crossed the 5% Schedule 13D beneficial ownership threshold and began a rapid accumulation program. By April 21, 2014, PS Fund 1 had acquired beneficial ownership of approximately 9.7% of the outstanding shares of Company Common Stock.

Between April 13, 2014 and April 21, 2014, representatives of Valeant, Pershing Square and their advisors met and discussed the terms of Valeant’s initial proposal and their investor presentations in support of the proposal.

On April 21, 2014, Pershing Square and Valeant each filed a Schedule 13D disclosing their beneficial ownership of shares in Company Common Stock. Pershing Square’s Schedule 13D disclosed that Pershing Square had beneficially acquired for the account of PS Fund 1 an aggregate of 28,878,538 shares of Company Common Stock for total consideration of $3.217 billion, which had been contributed by the Pershing Square Funds and by Valeant USA pursuant to the Letter Agreement. That same evening, the Valeant Board met telephonically to determine whether to proceed with a proposal to acquire Allergan, and after deciding to do so, the appropriate terms of Valeant’s proposal. The Valeant Board approved the terms of the proposal and authorized Valeant to deliver a merger proposal letter to Allergan the next morning.

 

7


On April 22, 2014, Valeant made a public proposal to Mr. Pyott and the Board to acquire Allergan for a price comprised of $48.30 in cash and 0.83 Valeant common shares for each share of Company Common Stock based on the fully diluted number of shares of Company Common Stock outstanding. Pursuant to the terms of the proposal, Allergan shareholders would receive a substantial premium over Allergan’s unaffected stock price of $116.63 on April 10, 2014 (the day before Pershing Square began its rapid accumulation program) and would own approximately 43% of the combined company.

Later that day, Valeant and Pershing Square held an investor conference in which representatives of Valeant and Pershing Square delivered presentations describing the benefits of Valeant’s proposal. Beginning on April 22, 2014, representatives of Valeant met with Allergan stockholders and Valeant shareholders to discuss Valeant’s proposal.

On April 22, 2014, Allergan issued a press release in which it confirmed receipt of the proposal from Valeant and stated that the Board, in consultation with its financial and legal advisors, would carefully review and consider the proposal and pursue the course of action that it believes is in the best interests of the Company’s shareholders. The Company also adopted a shareholder rights plan (commonly referred to as a “Poison Pill”), effective April 22, 2014.

On April 23, 2014, Mr. Ackman emailed Matthew Maletta, Allergan’s Associate General Counsel and Secretary, to request an opportunity to speak with Michael R. Gallagher, the lead independent director of the Board, and Mr. Pearson spoke briefly with Mr. Pyott by telephone.

Mr. Maletta arranged a telephone call between Mr. Ackman and Mr. Gallagher, but later noted that Mr. Pyott and Jim Hindman, SVP of Investor Relations for Allergan, would be joining Mr. Gallagher on the call. While Mr. Ackman welcomed the opportunity to have a discussion with Mr. Pyott on April 24, 2014, Mr. Ackman’s purpose for the call was to speak with Mr. Gallagher, without management present, as the lead director who Mr. Ackman expected, based on Allergan’s proxy disclosures, to be the Board’s independent representative for shareholders in considering the Valeant proposal.

During the April 24, 2014 call, Mr. Ackman requested the opportunity to speak with Mr. Gallagher in executive session, which Mr. Gallagher rejected. Mr. Ackman then asked for Mr. Gallagher’s contact information so Mr. Ackman could contact Mr. Gallagher directly in the future. Mr. Gallagher was unwilling to provide Mr. Ackman with his contact information because Mr. Gallagher explained that he did not believe it was appropriate to speak to Mr. Ackman alone. Mr. Ackman then offered to speak with Mr. Gallagher with the Board’s counsel present on the call, and Mr. Gallagher also refused this request.

On May 1, 2014, early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, was granted with respect to the acquisition by PS Fund 1 of certain shares of Company Common Stock. Later that day, PS Fund 1 exercised its American-style call options to purchase Company Common Stock and also paid the applicable forward purchase price under the forward purchase contracts to purchase Company Common Stock. As a result, PS Fund 1 became Allergan’s largest shareholder. In total, Pershing Square contributed approximately $3.624 billion to PS Fund 1 to fund the acquisition of Company Common Stock through the purchase and ultimate settlement of derivative instruments.

On May 5, 2014, in response to news reports stating that the Company had begun to approach alternative business combination partners, Mr. Ackman sent a letter to Mr. Gallagher, encouraging the Board to begin discussions with Valeant regarding its proposal. Among other things, Mr. Ackman’s letter highlighted Pershing Square’s belief that (i) the strength of Allergan’s negotiating position with Valeant comes, in part, from the potential that Allergan may negotiate a more valuable transaction with a large global pharmaceutical company, (ii) the list of global pharmaceutical companies with the financial capacity to buy Allergan is limited, and even more limited when factors such as strategic fit and antitrust risk are considered, and (iii) unless Allergan were to identify and engage with a large global pharmaceutical company for a transaction in the very near future, the

 

8


odds of a transaction with such a counterparty are likely to decrease over time, the market and Valeant will likely learn of the lack of interest from alternative companies, and Allergan’s negotiating leverage with Valeant will decline. Indeed, in the days that followed such letter, news outlets reported that several global pharmaceutical companies, including Sanofi, Johnson & Johnson and Shire, had been contacted by Allergan and had declined to engage in a business combination transaction.

On May 8, 2014, Valeant reported its First Quarter 2014 Financial Results. On its earnings call with analysts, Howard B. Schiller, Valeant’s Executive Vice President and Chief Financial Officer, discussed Valeant’s meetings with Allergan stockholders and Valeant shareholders. Mr. Schiller announced that, while Valeant was waiting for a response to its proposal from the Board, Valeant and Pershing Square would commence a referendum to determine whether Allergan stockholders are supportive of a transaction with Valeant, although the referendum proposal was ultimately commenced only by Pershing Square.

On May 12, 2014, Mr. Pyott sent a letter to Mr. Pearson stating that the Board had rejected Valeant’s proposal.

Later on May 12, 2014, Mr. Ackman sent a letter (the “220 Request”) to Mr. Maletta, pursuant to Section 220 of the Delaware General Corporation Law (the “DGCL”) requesting a complete record or list of the holders of Company Common Stock.

On May 13, 2014, Valeant issued a public letter to Allergan stockholders in response to Allergan’s rejection of the proposal. Valeant announced that it would hold a webcast on May 28, 2014 to discuss why it believed that its proposal offered substantially superior value to Allergan’s standalone strategy. Valeant also announced that, based on feedback from Allergan’s stockholders, Valeant planned to improve its proposal during the May 28 webcast in order to demonstrate its commitment to complete the transaction.

Also on May 13, 2014, Pershing Square filed a preliminary proxy statement with the SEC announcing a meeting of Allergan stockholders in order to conduct a stockholder referendum in which stockholders would be given the opportunity to vote on a non-binding resolution (with the same terms as Proposal 7 described in this Solicitation Statement) to request that the Board promptly engage in good faith discussions with Valeant regarding Valeant’s proposal.

Also on May 13, 2014, Mr. Ackman spoke briefly by telephone with Mr. Pyott. Mr. Pyott only afforded 15 minutes for the call despite Mr. Ackman’s understanding that Mr. Pyott had spent considerably more time with other Allergan shareholders and despite the fact that Pershing Square is Allergan’s largest shareholder. During the call, Mr. Ackman asked several questions concerning Allergan’s rejection of the Valeant proposal, and why the Board did not meet with Valeant before doing so. Mr. Pyott would not answer these questions, but simply told Mr. Ackman that the Valeant proposal substantially undervalued Allergan. At the end of the call, Mr. Ackman again requested the opportunity to meet with Allergan’s independent directors. Mr. Pyott said that he was the only member of the Board that was authorized to speak with shareholders and rejected Mr. Ackman’s request to meet with the full Board.

On May 19, 2014, Mr. Ackman sent a letter to Mr. Gallagher, the designated point of contact for corporate governance issues relating to Allergan. Mr. Ackman stated that, because Mr. Pyott stood to lose his leadership position if Valeant’s proposal were consummated, Mr. Pyott would be unable to engage in unconflicted discussions with Valeant and Pershing Square regarding that proposal. Mr. Ackman also expressed his displeasure that Allergan had rejected Valeant’s proposal without conducting any private due diligence.

Later on May 19, 2014, Mr. Gallagher sent a letter to Mr. Ackman in which he confirmed receipt of Mr. Ackman’s prior letter and stated his disagreement with Mr. Ackman’s assertion regarding Mr. Pyott’s disabling conflict of interest in respect of Valeant’s proposal.

 

9


Also on May 19, 2014, representatives of Latham & Watkins LLP (“Latham”), on behalf of Allergan, sent a letter to representatives of Kirkland & Ellis, in response to the 220 Request, in which Latham stated that Allergan would make available to Pershing Square and certain of its affiliates such information set forth in the 220 Request that was currently available to Allergan.

On May 20, 2014, Valeant held its annual stockholder meeting. After the official business of the meeting concluded, Mr. Pearson made a presentation to Valeant shareholders during which he addressed, among other things, Valeant’s proposal and Valeant’s plans for its May 28 webcast. On May 20, 2014 and May 21, 2014, the Valeant Board met and discussed various matters, including the Allergan transaction.

On May 21, 2014, Mr. Ackman sent a letter to Mr. Gallagher confirming receipt of Mr. Gallagher’s May 19 letter and stating that Pershing Square was encouraged to hear that the Board had an “open mind” and would show a high degree of professionalism in its review of Valeant’s proposal, but that no effort had been made by the Board to reach out to Pershing Square or sit down with Valeant to discuss its proposal. Furthermore, Mr. Ackman noted Allergan’s negative characterization of Valeant’s proposal despite the immediate and long-term value that Valeant’s proposal represented for Allergan’s shareholders.

Later on May 21, 2014, Mr. Gallagher sent a letter to Mr. Ackman confirming receipt of Mr. Ackman’s prior letter and stating that the Board would carefully review any revised offer announced by Valeant.

On May 27, 2014, Allergan filed a presentation with the SEC in which it criticized Valeant’s business model and management team despite the fact that Allergan had failed to conduct any private due diligence on Valeant.

Later on May 27, 2014, representatives of Kirkland & Ellis sent a letter to representatives of Latham requesting that Latham produce those documents set forth in the 220 Request which were currently available to Allergan and to provide a list of those documents which Allergan would not be able to produce.

On May 28, 2014, executives of Valeant held an investor presentation in New York City during which Valeant publicly announced an improved proposal and Valeant’s willingness to sit down with the Board and Allergan management to engage in meaningful discussions regarding that proposal. Representatives of Valeant also presented on Valeant’s business model and refuted Allergan’s claims from its May 27 press release and presentation.

Also on May 28, 2014, Mr. Pearson sent a letter to Mr. Pyott outlining the improved proposal, which increased the cash component of Valeant’s proposal by $10.00 per share of Company Common Stock to $58.30, and included a contingent value right (the “CVR”) tied to sales of Allergan’s DARPin ® representing an additional $25.00 of value per share of Company Common Stock. In addition, Valeant committed to invest up to $400 million to develop DARPin ® and pay to Allergan shareholders 40% of the net sales of DARPin ® after recovery of Valeant shareholders’ investment in DARPin ® development expenses.

On May 28, 2014, Allergan confirmed receipt of Valeant’s revised proposal. Allergan stated that the Board would carefully review and consider the revised proposal and pursue the course of action that the Board believes is in the best interests of Allergan and all of its stockholders. However, Allergan’s May 27 press release and presentation suggested that Allergan would not be willing to negotiate with Valeant.

On May 29, 2014, at the Sanford C. Bernstein Strategic Decisions Conference in New York City, numerous large Allergan shareholders expressed to Mr. Ackman their support of a merger between Allergan and Valeant. These investors suggested that, if Valeant raised its offer to $180 in value per share of Company Common Stock based on Valeant’s current trading price, they would be supportive of a transaction.

On the morning of May 30, 2014, Mr. Ackman spoke by telephone with Mr. Pearson and conveyed to Mr. Pearson the substance of his conversations with other Allergan shareholders from the day before. Mr. Ackman indicated that, if Valeant would raise its bid for Allergan so that its value (based on then current

 

10


prices) approximated $180 per share of Company Common Stock, Pershing Square would accept a fixed exchange ratio of 1.22659 based on Allergan and Valeant closing prices on May 29, 2014. After considering Pershing Square’s proposal, Mr. Pearson contacted Mr. Ackman and said that he would recommend to the Valeant Board that Valeant raise its offer for Allergan on the terms discussed with Mr. Ackman, which the Valeant Board approved at a telephone meeting later that day.

Later in the afternoon on May 30, 2014, Valeant announced that it was making a revised proposal for Allergan under which each Allergan share would be exchanged for $72.00 in cash and 0.83 Valeant common shares, based on the fully diluted number of Allergan shares outstanding. The revised proposal also referenced Valeant’s continued willingness to include the CVR if Allergan were to engage in negotiations with Valeant to work out the exact terms. Under the revised proposal, Allergan stockholders would continue to be able to elect cash and/or Valeant stock, subject to proration. Pershing Square also separately agreed to exchange its Allergan shares for Valeant shares at a 1.22659 exchange ratio, based on closing stock prices of Allergan and Valeant on May 29, 2014, and receive no cash consideration.

Also on May 30, 2014, Mr. Pearson sent a letter to Mr. Pyott outlining the revised proposal to raise its offer for Allergan.

Allergan confirmed the receipt of Valeant’s revised offer on May 30, 2014. Allergan stated that the Board would carefully review and consider the revised proposal and pursue the course of action that the Board believes is in the best interests of Allergan and all of its stockholders and referenced its position set forth in its May 27 presentation. Allergan’s May 27 press release and presentation indicated that Allergan would likely not be willing to negotiate with Valeant.

On June 2, 2014, Valeant held an investor meeting and webcast to discuss its revised offer and announce its intention to commence an exchange offer on the terms of its revised offer. On the same day, Pershing Square filed a preliminary solicitation statement in respect of the Proposals. Pershing Square also indicated that it would no longer pursue its previously announced stockholder referendum in light of its plans to call a special meeting and in response to feedback Pershing Square received from other Allergan shareholders who urged Pershing Square to focus on calling a special meeting due to the more formal nature of the Special Meeting and the fact that certain proposals to be voted on at the Special Meeting would be binding on the Company.

On June 6, 2014, Pershing Square sent a letter (the “June 6 Letter”) to Arnold A. Pinkston, Executive Vice President, General Counsel and Assistant Secretary of Allergan, in which it asked Allergan to confirm, among other things, that actions taken in support of the PS Fund 1 solicitation and any subsequent application to the Delaware Court of Chancery that might be filed seeking an order requiring Allergan to hold a meeting for the election of directors would not result in Pershing Square being deemed an Acquiring Person under Allergan’s Poison Pill.

On June 10, 2014, Allergan announced that Mr. Pyott had sent a letter to Mr. Pearson, stating that the Board had rejected Valeant’s proposal.

On June 11, 2014, Pershing Square received a letter from Allergan’s counsel in which it declined to provide the confirmation requested in the June 6 Letter, other than to note that the mere solicitation and receipt of one or more revocable proxies by Pershing Square from other Allergan stockholders for the purpose of requesting a special meeting would not in and of itself result in Pershing Square being deemed an Acquiring Person under Allergan’s Poison Pill.

On June 12, 2014, PS Fund 1 commenced an action in the Delaware Court of Chancery seeking declaratory and other equitable relief, including a declaration that (i) the actions by PS Fund 1 and other Allergan stockholders solely for the purpose of exercising the right to call a special meeting in compliance with the requirements of the Bylaws will not trigger Allergan’s Poison Pill, or alternatively (ii) the relevant provisions of Allergan’s Poison Pill are invalid as a matter of law because they are inconsistent with the right to call a special

 

11


meeting that is granted to stockholders in the Charter (the “Poison Pill Lawsuit”). On the same day, PS Fund 1 filed a motion seeking to expedite the resolution of the litigation. On June 19, 2014, the Delaware Court of Chancery granted the motion to expedite and set a hearing date for July 7, 2014.

On June 18, 2014, Valeant commenced an exchange offer (the “Exchange Offer”) pursuant to which Valeant is offering to exchange, for each share of Company Common Stock, at the election of the applicable Allergan shareholder:

 

    $72.00 in cash and 0.83 common shares of Valeant (the “Standard Election Consideration”);

 

    an amount in cash equal to the implied value of the Standard Election Consideration (based on the average of the closing prices of common shares of Valeant as quoted on the New York Stock Exchange (the “NYSE”) on each of the five NYSE trading days ending on the 10th business day preceding the date of expiration of the exchange offer); or

 

    a number of Valeant common shares having a value equal to the implied value of the Standard Election Consideration (based on the average of the closing prices of Valeant common shares as quoted on the NYSE on each of the five NYSE trading days ending on the 10th business day preceding the date of expiration of the exchange offer),

subject in each case to the election and proration procedures described in the offer to exchange and in the related letter of election and transmittal.

On June 23, 2014, Allergan filed a Schedule 14D-9 with the SEC in which it recommended that Allergan shareholders not tender their shares of Company Common Stock in the Exchange Offer.

On June 24, 2014, Allergan issued a press release stating that its board of directors rejected Valeant’s offer.

On June 24, 2014, Valeant filed a proxy statement on Schedule 14A for the calling of a special meeting of Valeant shareholders to approve the issuance of Valeant common shares in connection with an acquisition of Allergan.

On June 27, 2014, Pershing Square issued a press release announcing that it had entered into a settlement with Allergan resolving the Poison Pill Lawsuit and confirming that Pershing Square’s actions in connection with the solicitation and receipt of revocable proxies to call a Special Meeting does not trigger Allergan’s Poison Pill. The court order effecting the settlement was signed on June 28, 2014 and filed with the SEC by Pershing Square on June 30, 2014.

PLANS FOR THE SPECIAL MEETING

If we, the Requesting Shareholder, with the support of other shareholders are successful in obtaining sufficient shareholder support to request that a Special Meeting be called pursuant to the Bylaws and the Special Meeting is called, we expect to present the following matters for a shareholder vote at the Special Meeting:

 

    Proposal 1: “RESOLVED, that the following six members of the current Board, Deborah Dunsire, M.D., Michael R. Gallagher, Trevor M. Jones, Ph.D., Louis J. Lavigne, Jr., Russell T. Ray and Henri A. Termeer, as well as any other person or persons elected or appointed to the Board without shareholder approval after the Company’s 2014 annual meeting and up to and including the date of the Special Meeting (other than any Group Nominee set forth herein), be and hereby are removed from office as directors of the Company.”

Article 7 of the Charter, along with Section 141(k) of the DGCL, provides that any director or the entire Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of the Company’s directors.

 

12


If Proposal 1 passes, only three directors will remain on the Board. We are seeking to remove Messrs. Deborah Dunsire, M.D., Michael R. Gallagher, Trevor M. Jones, Ph.D., Louis J. Lavigne, Jr., Russell T. Ray and Henri A. Termeer because we believe that they have not acted in the best interests of shareholders with respect to Valeant’s proposal to acquire the Company as evidenced by the Board’s failure to engage in good faith discussions with Valeant regarding its proposal to merge with Allergan, and its adoption of a poison pill in the face of such proposal.

We will, in accordance with SEC requirements, provide shareholders with a way to vote for removal of less than all of the directors listed in the foregoing resolution.

 

    Proposal 2 : “RESOLVED, that the shareholders of Allergan hereby request that the Board elect or appoint the following individuals to serve as directors of the Company, regardless of whether Proposal 1 is passed: Betsy S. Atkins, Cathleen P. Black, Fredric N. Eshelman, Ph.D., Steven J. Shulman, David A. Wilson and John J. Zillmer (individually a “Group Nominee” and collectively, the “Group Nominees”); provided , however , that if at any time prior to the date of the Special Meeting one or more Group Nominees are no longer willing or, as a result of death or incapacity, able to serve as directors of the Company and a majority of the then-remaining Group Nominees select replacements, those replacements (rather than the individuals they replaced), along with the Group Nominees who have not been replaced, shall then be considered the Group Nominees for all purposes.”

Pursuant to Article II, Section 6 of the Bylaws, such a proposal requesting that the Board elect or appoint such individuals as directors requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at such Special Meeting on such matter, a quorum being present.

Each Group Nominee named in this Proposal 2 has consented to be named in a proxy statement and to serve as a director of the Company, if elected. If the Group Nominees are elected, they intend to discharge their duties as directors of the Company consistent with all applicable legal requirements, including the general fiduciary obligations imposed upon corporate directors. If elected, each Group Nominee named in this Proposal 2 would serve as a director until the Company’s annual meeting in 2015. This Proposal 2 is nonbinding in nature and thus the Board will be under no legal obligation to take any action with respect to the shareholders’ request to appoint new directors (which action is necessary to effect such request), no matter how many votes are cast in favor of this Proposal 2. We will, in accordance with SEC requirements, provide shareholders with a way to vote for inclusion of less than all of the Group Nominees in the request contemplated by the foregoing resolution.

In the event that Proposal 1 passes and the above-named directors are removed from the Board creating six vacancies, but Proposal 2 does not pass or Proposal 2 passes but the Board refuses to implement the shareholders’ wishes and does not elect or appoint the Group Nominees, then pursuant to Article III, Section 5 of the Bylaws, Article 8 of the Charter and Section 223 of the DGCL, such vacancies may be filled by a majority vote of the then-remaining directors, even though less than a quorum. In the event that, at the time of filling any board vacancy, the directors then in office constitute less than a majority of the whole Board, we intend to exercise our rights pursuant to Section 223(c) of the DGCL which provides that the Delaware Court of Chancery may summarily order an election to be held to fill any such vacancies or to replace the directors chosen by the directors then in office. For additional information on our rights under Section 223(c) of the DGCL, see the section of this Solicitation Statement titled “Information Regarding the Nominees.”

 

13


    Proposal 3 : “RESOLVED, that Article II, Section 3 of the Bylaws be, and hereby is, amended to read as set forth in Section 3(A) of Exhibit E to the Solicitation Statement filed by PS Fund 1, LLC (“PS Fund 1”) on July 11, 2014 (the “Solicitation Statement”), in order to provide simplified mechanics for calling and determining the place, date and hour of any special meeting called at the request of the Company’s shareholders.”

Pursuant to Article II, Section 6 of the Bylaws, the amendment of the Bylaws requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at the Special Meeting on such matter, a quorum (which is a majority in voting interest of the shares of the Company) being present.

In order to simplify the mechanics for calling a special meeting, we are proposing amendments to the Bylaws that would eliminate certain procedural and informational requirements for calling a special meeting – which are set forth in the language marked as struck out in Article II, Section 3 of Exhibit E to this Solicitation Statement – that were originally adopted at the time of the Company’s 2013 annual meeting of shareholders. These requirements were summarized at the time of their adoption, in the Company’s Proxy Statement on Schedule 14A, filed with the SEC on March 8, 2013, as follows:

“no business may be conducted at the special meeting except as set forth in the Company’s notice of meeting; no stockholder special meeting request may be made during the period commencing 90 days prior to the first anniversary of the date of the immediately preceding annual meeting and ending on the date of the final adjournment of the next annual meeting; a special meeting request cannot cover business substantially similar to what was covered at an annual or special meeting held within one year, subject to certain exceptions; a special meeting will not be held if similar business is to be covered at an annual or special meeting called by the Board but not yet held; and the requesting stockholder’s notice must provide certain information regarding the business proposed to be conducted, and as to the stockholder giving notice and any person or entity acting in concert with the stockholder giving notice.”

In the event that Proposal 3 passes, the bylaw provisions quoted immediately above would be eliminated.

 

    Proposal 4 : “RESOLVED, that Article II, Section 3 of the Bylaws be, and hereby is, amended to add a new clause at the end (which shall be designated clause (B) if Proposal 3 above is passed and shall be designated clause (E) if Proposal 3 above is not passed) to read as set forth in Section 3(B) of Exhibit E to the Solicitation Statement, in order to provide mechanics for calling a special meeting if no directors or less than a majority of directors are then in office.”

Pursuant to Article II, Section 6 of the Bylaws, the amendment of the Bylaws requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at the Special Meeting on such matter, a quorum (which is a majority in voting interest of the shares of the Company) being present.

In the event that Proposal 1 passes and the above-named directors are removed from the Board creating six vacancies, but Proposal 2 does not pass or Proposal 2 passes but the Board refuses to implement the shareholders’ wishes and does not elect or appoint the Group Nominees, then, as discussed above, pursuant to Article III, Section 5 of the Bylaws, Article 8 of the Charter and Section 233(a) of the DGCL, such vacancies may be filled by a majority vote of the then-remaining directors, even though less than a quorum.

We are proposing amendments to the Bylaws that would facilitate the shareholders’ right to call a special meeting to elect the replacements of the removed directors in the event that, at the time of filling any board vacancy, the directors then in office constitute less than a majority of the whole Board, as contemplated by Section 223 of the DGCL.

 

14


    Proposal 5 : “RESOLVED, that Article II, Section 9 of the Bylaws be, and hereby is, amended to read as set forth in Section 9 of Exhibit E to the Solicitation Statement, in order to provide simplified mechanics for nominating directors or proposing business at any annual meeting.”

Pursuant to Article II, Section 6 of the Bylaws, the amendment of the Bylaws requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at the Special Meeting on such matter, a quorum (which is a majority in voting interest of the shares of the Company) being present.

In order to simplify the mechanics for nominating directors or proposing business at any annual meeting, we are proposing amendments to the Bylaws that would remove informational and procedural requirements for proposing business and nominating directors, which are set forth in the language marked as struck out in Article II, Section 9 of Exhibit E to this Solicitation Statement, such as:

 

    the shareholder must provide detailed information regarding the business proposed to be conducted, as to the shareholder and any person or entity acting in concert with the shareholder, and as to each nominee, including the disclosure by the shareholder and each nominee of any “Disclosable Interests” (as defined in the Bylaws), which requirements require greater disclosure than that required by the federal proxy rules and Delaware law;

 

    the shareholder must make representations regarding its intention to hold its shares through the date of the meeting, and must appear in person or by qualified representative to present the matters at the meeting; and

 

    the requesting shareholder must update and supplement all such information as of the record date for the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement.

 

    Proposal 6 : “RESOLVED, that, if Proposal 1 is passed, Article III, Section 2 of the Bylaws be, and hereby is, amended to read as set forth in Article III, Section 2 of Exhibit E to the Solicitation Statement, in order to fix the authorized number of directors of the Company at nine directors.”

Pursuant to Article II, Section 6 of the Bylaws, the amendment of the Bylaws requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at the Special Meeting on such matter, a quorum (which is a majority in voting interest of the shares of the Company) being present. According to Article 6 of the Charter, directors can only be elected at the annual meeting of shareholders.

If Proposal 1 is passed, and Proposal 2 passes and the Board implements the shareholders’ wishes and elects or appoints the Group Nominees, this Proposal 6 is designed to prevent the Board from taking other actions to nullify those actions, including by appointing to the Board several new directors affiliated with Company management.

 

    Proposal 7 : “RESOLVED, that any amendment to the Bylaws adopted without shareholder approval after the Company’s 2014 annual meeting and up to and including the date of the Special Meeting that changes the Bylaws in any way from the version that was publicly filed with the SEC on March 26, 2014 and became effective as of May 9, 2014 (other than any amendment to the Bylaws set forth herein) be, and hereby are, repealed.”

Pursuant to Article VII, Section 3 of the Bylaws, the repeal of amendments to the Bylaws requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at the Special Meeting on such matter, a quorum being present.

This Proposal 7 is designed to prevent the Board from taking actions to amend the Bylaws to attempt to nullify or delay the actions taken by, or proposed to be taken by, the shareholders pursuant to the Proposals or to create new obstacles to the consummation of the transactions contemplated by Valeant’s proposal.

 

15


    Proposal 8 : “RESOLVED, that the shareholders of Allergan hereby request that the Board promptly engage in good faith discussions with Valeant regarding Valeant’s offer to merge with the Company, without in any way precluding discussions the Board may choose to engage in with other parties potentially offering higher value.”

Pursuant to Article II, Section 6 of the Bylaws, such a proposal requesting that the Board promptly engage in good faith discussions with Valeant regarding Valeant’s proposal requires the vote of a majority in voting interest of the shareholders present in person or by proxy and entitled to vote at such Special Meeting on such matter, a quorum being present.

This Proposal 8 is designed to provide shareholders with the ability to demonstrate, in a coordinated and powerful manner, their support for the Company to engage in a meaningful dialogue with Valeant. While there are numerous ways the Board could implement this Proposal 8, examples of such meaningful engagement could include, without limitation, and in each case conducted in good faith:

 

    the participation in one or more substantive, face-to-face meetings between the chief executive and other senior-level officers of the Company and representatives of Valeant to address the terms of Valeant’s offer to merge with the Company;

 

    members of the Board making themselves available for face-to-face meetings with representatives of Valeant to discuss the terms of Valeant’s offer;

 

    discussions between the financial advisors of the Company and the financial advisors of Valeant;

 

    discussions between the legal advisors of the Company and the legal advisors of Valeant, including in respect of the proposed merger agreement between the companies; and

 

    the Company undertaking preliminary due diligence activities with respect to Valeant, including entering into a confidentiality agreement that would allow it to receive non-public information from Valeant.

This Proposal 8 is non-binding in nature and thus the Board will be under no legal obligation to take any action with respect to the shareholders’ request to engage with Valeant, no matter how many votes are cast in favor of this Proposal 8.

We will solicit votes in favor of the Proposals only by means of a proxy statement and proxy card once the Special Meeting Request Forms and Cede & Co. Meeting Requests to call the Special Meeting have been delivered, along with the Verification Letters, as applicable. If the Requesting Shareholder is successful in requesting that the Special Meeting be called as a result of the Requisite Holders completing, executing, dating and returning the enclosed Special Meeting Request Forms, Cede & Co. Meeting Requests and Verification Letters and the accompanying WHITE Proxy Cards to D.F. King, and the Requesting Shareholder delivering such Special Meeting Request Forms, Cede & Co. Meeting Requests, Verification Letters and WHITE Proxy Cards to the Company’s Secretary, then we will include in the Requesting Shareholder’s definitive proxy statement for such Special Meeting information regarding voting at such Special Meeting. The sole purpose of this solicitation, and the only effect of your return of the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card, and following the instructions below with respect to any of your shares of Company Common Stock held through a DTC participant, is to request the calling of the Special Meeting and to empower us to deliver your Special Meeting Request Form and Cede & Co. Meeting Request, along with a Verification Letter, as applicable, to the Company’s Secretary.

Accordingly, we urge you to join with us to request the call of the Special Meeting for the purpose of submitting the Proposals to shareholders for a vote thereon. To help us call the Special Meeting, please follow the instructions for delivering your Special Meeting Request Form, Cede & Co. Meeting Request, Verification Letter and WHITE Proxy Card described below.

 

16


WE URGE YOU TO COMPLETE, EXECUTE, DATE AND RETURN THE ENCLOSED SPECIAL MEETING REQUEST FORM AND THE ACCOMPANYING WHITE PROXY CARD TO D.F. KING, AND FOLLOW THE INSTRUCTIONS BELOW WITH RESPECT TO ANY OF YOUR SHARES OF COMPANY COMMON STOCK HELD THROUGH A DTC PARTICIPANT.

THE SPECIAL MEETING

Special Meeting Request Form and the WHITE Proxy Card . The Requesting Shareholder is asking the shareholders to complete, execute, date and return the enclosed Special Meeting Request Forms and the accompanying WHITE Proxy Cards to D.F. King, which is assisting us with this solicitation and, upon receiving your executed WHITE Proxy Cards, will deliver the executed written requests from the Requisite Shareholders (once received) to the Company’s Secretary to obligate the Company to call the Special Meeting of shareholders pursuant to the Bylaws. We are furnishing this Solicitation Statement, the Special Meeting Request Forms and the WHITE Proxy Cards to enable you and the Company’s other shareholders to support us in requesting the Special Meeting be called and held.

Cede & Co. Meeting Request . The Requesting Shareholder is also asking shareholders who wish to become Proposing Persons to arrange for their DTC participant(s) to instruct DTC to cause Cede & Co., as DTC’s nominee, to sign and return the Cede & Co. Meeting Request to their DTC participant(s) and for their DTC participant(s) to sign the Verification Letter with respect to their shares. Shareholders may do this by having their DTC participant(s) complete and sign the DTC Instruction Letter, included as Exhibit B-1 hereto, and send it to DTC. Upon DTC’s receipt of a completed DTC Instruction Letter executed by a DTC participant, Cede & Co. will sign and return the Cede & Co. Meeting Request to the DTC participant. The DTC participant should return the executed Cede & Co. Meeting Request from Cede & Co. along with their executed Verification Letter to the shareholder. The shareholder should then deliver the executed Cede & Co. Meeting Request and Verification Letter to D.F. King, which will gather such documents and provide them to the Requesting Shareholder for submission to the Company. Beneficial owners of shares of Company Common Stock who wish to become Proposing Persons but do not currently hold any shares of Company Common Stock in record (certificated) form must transfer into the name of such Proposing Person, or purchase in the name of such Proposing Person, at least one share of Company Common Stock.

Requisite Holders . For the Special Meeting to be properly requested in accordance with the Bylaws, Special Meeting Request Forms and Cede & Co. Meeting Requests in favor of the call of the Special Meeting must be executed by the Requisite Holders. If you are not already a shareholder of record and want to submit a Special Meeting Request, you must first arrange (through transfer or purchase) to become a stockholder of record of at least one share of Company Common Stock. If you need assistance in doing that, please contact Edward McCarthy at D.F. King & Co., (212) 269-5550, emccarthy@dfking.com .

On the date of filing of this Solicitation Statement, PS Fund 1 is the beneficial holder of 28,878,538 shares of Company Common Stock and the Requesting Shareholder is the beneficial owner of 28,878,638 shares of Company Common Stock. According to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9, as filed with the SEC on June 23, 2014 (as amended on June 24, 2014 and June 30, 2014, the “Company 14D-9”), there were 296,824,582 shares of Company Common Stock outstanding as of June 20, 2014.

Based on the number of shares outstanding, Special Meeting Requests and other required documents representing an aggregate of at least 74,206,146 shares of Company Common Stock, including the shares held by the Requesting Shareholder, will be required to request the call of the Special Meeting. The Requesting Shareholder anticipates submitting all of the Special Meeting Request Forms on the first business day after the Requesting Shareholder discloses that it believes that it has obtained sufficient Special Meeting Request Forms to call a Special Meeting.

 

17


The Special Meeting Request Form and Cede & Co. Meeting Request request that the Special Meeting be held as soon as possible, and in any event within 45 days, following the date on which Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters from the Requisite Holders are delivered to the Company’s Secretary. After the Special Meeting is called, we intend to solicit proxies from you in support of the Proposals by sending you a notice of the Special Meeting, a proxy statement and a proxy card for use therewith. At the Special Meeting, the shareholders will be asked to vote “For” the Proposals.

Record Date for Special Meeting . The record date for determining shareholders entitled to notice of, and to vote at, the Special Meeting shall be at the close of business on the day immediately preceding the day upon which notice of the Special Meeting is given to shareholders, unless the Board sets a different record date in accordance with Article VI, Section 5 of the Bylaws and Section 213 of the DGCL. In any event, such record date shall not be more than 60 nor less than 10 days before the date of the Special Meeting.

Time and Location of Special Meeting; Notice of Special Meeting . The Bylaws provide that all meetings of shareholders shall be held either at the principal office of the Company (which is 2525 Dupont Drive, Irvine, California, 92612) or at any other place that may be designated by the Board. Further, the Bylaws require the Company, in complying with a request to convene the Special Meeting, to provide shareholders written notice of the place, date and hour of the Special Meeting and to state the purpose for which the Special Meeting is called not less than 10 days nor more than 60 days before the date of the Special Meeting. If the Special Meeting is requested by the Requisite Shareholders, the Bylaws provide that the Board may (in lieu of calling the requested special meeting) present an identical or substantially similar item at another meeting of shareholders that is to be held 120 days from the date the Company’s Secretary receives such Special Meeting request. We will strongly discourage the Board from taking such action, which will effectively delay addressing the Proposals in a timely manner, and recommend that you do the same.

We expect to request, in any future proxy solicitation relating to the Special Meeting, authority (i) to initiate and vote for Proposals, (ii) to recess or adjourn the Special Meeting for any reason and (iii) to oppose and vote against any proposal to recess or adjourn the Special Meeting. In accordance with Rule 14a-4(c)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), should any other proposals be brought before the Special Meeting that we are not aware of within a reasonable time before the Special Meeting, we will vote proxies granted to us in the subsequent proxy statement furnished to shareholders on such matters in our discretion.

PROCEDURES FOR SUBMITTING SPECIAL MEETING REQUEST FORMS, WHITE PROXY

CARDS, CEDE & CO. MEETING REQUESTS AND VERIFICATION LETTERS

Pursuant to this Solicitation Statement, the Requesting Shareholder is requesting that the holders of the outstanding shares of Company Common Stock request that the Company’s Secretary call the Special Meeting and hold the Special Meeting as soon as possible by taking the following actions: (1) complete, execute and date the Special Meeting Request Form attached hereto as Exhibit A and the accompanying WHITE Proxy Card attached hereto as Exhibit D, by which you will empower us to deliver your executed Special Meeting Request Forms, Cede & Co. Meeting Requests and Verification Letters, as applicable, to the Company’s Secretary on your behalf, (2) direct your DTC participant to complete and deliver the DTC Instruction Letter attached hereto as Exhibit B-1 to DTC to cause Cede & Co. to execute and return the Cede & Co. Meeting Request attached as Exhibit B-2 hereto to your DTC participant, and direct your DTC participant to execute the Verification Letter and return the executed Cede & Co. Meeting Request and their executed Verification Letter to you and (3) deliver to D.F. King at the address set forth on the enclosed envelope your executed Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters. Please note that, because Article II, Section 3(a) of the Bylaws provides that special meeting requests from multiple shareholders may be aggregated and considered together only if they identify the same purposes and the same matters proposed to be acted on at the meeting, we request that you not change the purposes or Proposals stated in the Special Meeting Request Forms or Cede & Co. Meeting Requests.

 

18


As a shareholder of Allergan, you may have received the Company’s Revocation Statement and the accompanying blue revocation card. Since only your latest dated proxy card will count, we urge you not to return any proxy/revocation card you receive from the Company. Remember, you can support the call of the Special Meeting only by submitting our WHITE Proxy Card and the other documents described herein. Please make certain that the latest dated proxy card you return is the WHITE Proxy Card.

The enclosed Special Meeting Request Form reflects our good faith effort to identify all the information required by the Bylaws in connection with shareholders’ written request for a special meeting; however, the Bylaw requirements to call a special meeting are difficult to interpret. We expect that the Company will take actions seeking to frustrate the calling of the special meeting, including by claiming that Special Meeting Request Forms do not comply with the Bylaws in an attempt to avoid or delay the call of the Special Meeting. We encourage you to submit your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter, even if you cannot complete your Special Meeting Request Form or WHITE Proxy Card in full or you believe your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request or Verification Letter may be defective; however, we reserve the right not to submit any Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters if we believe that they do not comply with the Charter, Bylaws or the DGCL. If we believe that your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and/or Verification Letter does not so comply, or the Company notifies us of such non-compliance, we expect to contact you.

Procedures for Submitting Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters . Executed Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters should be delivered by mail to D.F. King using the enclosed postage-paid envelope.

Procedures for Arranging for Execution of Cede & Co. Meeting Requests and Verification Letters . Shareholders should direct their DTC participant(s) through which they hold their shares to:

(1) complete and sign the DTC Instruction Letter included as Exhibit B-1 hereto for the same aggregate number of shares as the DTC participant holds of record for such shareholder;

(2) complete the Cede & Co. Meeting Request included as Exhibit B-2 hereto for the same aggregate number of shares as the DTC participant holds of record for such shareholder;

(3) send the duly completed and signed DTC Instruction Letter and the duly completed Cede & Co. Meeting Request to DTC by email and overnight mail, thereby instructing DTC to cause Cede & Co., DTC’s nominee, to sign and return the Cede & Co. Meeting Request to the DTC participant;

(4) complete and sign the Verification Letter included as Exhibit C hereto for the same aggregate number of shares as the DTC participant holds of record for such shareholder; and

(5) upon receiving the signed Cede & Co. Meeting Request from Cede & Co., return the Cede & Co. Meeting Request executed by Cede & Co., along with the Verification Letter executed by such DTC participant, to the shareholder.

Please note that DTC will take at least 48 hours to execute and return a Cede & Co. Meeting Request. Please send the form of DTC Instruction Letter and Cede & Co. Meeting Request to your DTC participant today so that they may be processed on a timely basis. You must still complete, sign, date and return the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card by mail to D.F. King using the enclosed postage-paid envelope, regardless of whether you hold your shares through a DTC participant.

Transfer or Purchase of Stock in Record Form . Beneficial owners of shares of Company Common Stock who wish to become Proposing Persons but do not currently hold any shares of Company Common Stock in record (certificated) form must transfer into the name of such Proposing Person, or purchase in the name of such Proposing Person, at least one share of Company Common Stock.

 

19


Sales of Your Common Stock . If any portion of your shares of Company Common Stock is sold, or there is any other reduction in your Net Long Beneficial Ownership, prior to the date of the Special Meeting, your written request to hold the Special Meeting will be deemed revoked to the extent of such sale or reduction. Therefore, we request that you not sell any portion of your shares, or otherwise reduce your Net Long Beneficial Ownership, until after the date of the Special Meeting.

Updates to Your Special Meeting Request Form . All information provided or required to be provided in the Special Meeting Request Form must be true and correct as of the record date for notice of the Special Meeting and as of the date that is 10 business days prior to the date for the Special Meeting or any adjournment or postponement thereof. In accordance with Article II, Section 3(c) of the Bylaws, if there is any update that needs to be made with respect to the information you provided in your Special Meeting Request Form after your submission, you must further update and supplement the information as necessary and send it to the Secretary of the Company at the principal executive office of the Company at the address below, to be received by (i) not later than five business days after the record date for notice of the Special Meeting (in the case of the update and supplement required to be made as of such record date), and (ii) not later than eight business days prior to the date for the Special Meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the Special Meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to the date for the Special Meeting or any adjournment or postponement thereof):

Allergan, Inc.

2525 Dupont Drive

Irvine, California 92612

ATTN: Secretary

Written Request for the Special Meeting . If we receive executed Special Meeting Request Forms, WHITE Proxy Cards, Cede & Co. Meeting Requests and Verification Letters from the Requisite Holders, we will request the Secretary of the Company to promptly call the Special Meeting at such time. Please note that the delivery of the enclosed Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter will not commit you to cast any vote in respect of any Proposal to be brought before the Special Meeting . To vote on the matters to be brought before the Special Meeting, you must vote by proxy or in person at the Special Meeting.

Revocation Procedure . Shareholders who have executed and delivered a WHITE Proxy Card may revoke it at any time before the proxy is exercised by delivering an instrument revoking the earlier WHITE Proxy Card, or a duly executed later dated WHITE Proxy Card for the same shares, to D.F. King, our proxy solicitor, at 48 Wall Street, New York, New York 10005.

You may revoke your Special Meeting Request Form at any time prior to the date of the Special Meeting by delivering a written revocation to the Company’s Secretary at the address above. Such a revocation must clearly state that your Special Meeting Request Form is no longer effective. Although such revocation is effective if delivered to the Secretary of the Company or to such other recipient as the Company may designate as its agent, we request that either the original or photostatic copies of all revocations be mailed or faxed to the Requesting Shareholder, care of D.F. King, so that we will be aware of all revocations and can more accurately determine if and when enough Special Meeting Request Forms have been received from shareholders.

Delivery Procedures for Direct and Beneficial Owners . Please sign, date and mail the enclosed Special Meeting Request Form and the accompanying WHITE Proxy Card as soon as possible.

If any of your shares of Company Common Stock are held in the name of a brokerage firm, bank nominee or other institution, please arrange to have your DTC participant complete and return the executed Cede & Co. Meeting Request and their executed Verification Letter to you by following the procedures set forth in the section of this Solicitation Statement titled “Procedures for Arranging for Execution of Cede & Co. Meeting Requests and Verification Letters” above.

 

20


Your Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter, as applicable, are important, no matter how many or how few shares you own. Please send all four documents to the address set forth on the enclosed envelope as promptly as possible. The failure to sign and return the Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter, as applicable, will have the same effect as opposing the call of a Special Meeting.

If you have any questions about completing, executing and dating your Special Meeting Request Form or WHITE Proxy Card, causing your Cede & Co. Meeting Request or Verification Letter to be executed and returned to you or delivering each of the four documents to D.F. King, or otherwise require assistance, please contact:

D.F. King & Co., Inc.

48 Wall Street

New York, NY 10005

Toll-free: (800) 859-8511

Banks and brokers: (212) 269-5550

By delivering the enclosed Special Meeting Request Form, WHITE Proxy Card, Cede & Co. Meeting Request and Verification Letter to D.F. King, you are not committing to cast any vote in respect of, nor are you granting us any proxy to vote on, any Proposal to be brought before the Special Meeting.

SOLICITATION OF REQUESTS AND PROXIES; EXPENSES

The Requesting Shareholder will bear the entire expense of preparing and mailing this Solicitation Statement and any other soliciting material and the total expenditures relating to the solicitation of revocable proxies to empower us to deliver to the Company’s Secretary Special Meeting Request Forms and Cede & Co. Meeting Requests to call the Special Meeting, along with Verification Letters, as applicable, including, without limitation, costs, if any, related to advertising, printing, fees of attorneys, financial advisors, solicitors and accountants, public relations, transportation and litigation. We may solicit your proxy by telephone, email, facsimile, and personal solicitation, in addition to mail. We will reimburse the reasonable out-of-pocket expenses of banks, brokerage houses, and other custodians, nominees, and fiduciaries in connection with the forwarding of solicitation material to the beneficial owners of Company Common Stock that such institutions hold.

D.F. King, our proxy solicitation firm, has been retained to assist in this solicitation and will receive customary fees for its services, plus reimbursement of reasonable out-of-pocket expenses. D.F. King will be indemnified against certain liabilities and expenses, including certain liabilities under the federal securities laws. The firm will utilize approximately 30 persons in its solicitation efforts.

The Requesting Shareholder currently estimates that its solicitation expenses will amount to not less than $1,750,000. The Requesting Shareholder does not intend to seek reimbursement from Allergan for the costs and expenses incurred in connection with this Solicitation Statement or any subsequent proxy solicitation.

CERTAIN INFORMATION REGARDING THE COMPANY

The Company is a Delaware corporation with its principal executive offices at 2525 Dupont Drive, Irvine, California.

The Company is subject to the informational filing requirements of the Exchange Act and in accordance therewith it files periodic reports, proxy statements and other information with the SEC. Reports, proxy statements and other information filed by the Company with the SEC can be inspected and copied at the public

 

21


reference facilities maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Information regarding the public reference facilities may be obtained from the SEC by calling (202) 551-8090. The Company’s filings with the SEC are also available to the public without charge on the SEC’s website ( http://www.sec.gov ).

Except as otherwise noted herein, the information concerning the Company contained in this Solicitation Statement has been taken from or based upon publicly available documents and records on file with the SEC and other public sources. Although we do not have any knowledge that would indicate that any statement contained herein based upon such documents and records is untrue, we have not independently verified the accuracy or completeness of such information and do not take any responsibility for the accuracy or completeness of the information contained in such documents and records, or for any failure by the Company to disclose events that may affect the significance or accuracy of such information. For information regarding the security ownership of the directors and the management of the Company, please refer to Annex A attached to this Solicitation Statement.

INFORMATION REGARDING THE NOMINEES

In the event that the Special Meeting is called and held and the Company’s shareholders approve the proposal to remove from office, without cause, the following six members of the current Board: Deborah Dunsire, M.D., Michael R. Gallagher, Trevor M. Jones, Ph.D., Louis J. Lavigne, Jr., Russell T. Ray and Henri A. Termeer, and any person or persons appointed by the Board without shareholder approval after the 2014 annual meeting and up to and including the date of the Special Meeting, Proposal 2 requests that the Board appoint or elect the Group Nominees. We reserve the right to request the appointment or election of substitute persons for any of the Group Nominees named herein. The information herein regarding a particular Group Nominee has been furnished to the Requesting Shareholder by such Group Nominee.

Name, Address, Age and Employment History . Set forth below are the name, age, business address, present principal occupation, and employment and material occupations, positions, offices, or employments for the past five years of each of the proposed Group Nominees.

 

Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

Betsy Atkins

 

Business Address:

 

10 Edgewater Drive

Coral Gables, Florida 33133-6966

   61    Betsy Atkins has been the Chief Executive Officer of Baja LLC, an independent venture capital firm focused on technology, renewable sciences and life sciences, since 1994. She was formerly Chief Executive Officer and Chairman of Clear Standards, Inc., an on-demand enterprise energy management sustainability software company, from 2008-2009, at which time it was acquired by SAP AG.
     

 

Ms. Atkins has co-founded successful high tech and consumer companies, including Ascend Communications (formerly NASDAQ: ASDN). She is the former Chairman of the Board of Directors of Third Screen Media, a company that enables advertising on mobile phones and was eventually sold to AOL. Ms. Atkins was the CEO of NeutraCeutical Ingredients Pte. Ltd., a food manufacturer creating functional food products, from 1991 through 1993. She has also served on the Board of Directors of Human Genome Sciences Inc. (NASDAQ: HGSI), HealthSouth Corporation (NYSE: HLS), Vonage Holdings Inc., Towers Watson & Co. (NYSE: TW), Reynolds American Inc. (NYSE: RAI), SunPower Corporation (NASDAQ: SPWR) and Chico’s FAS, Inc. (NYSE: CHS).

 

22


Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

     

Ms. Atkins has served as a director of Polycom, Inc. (NASDAQ: PLCM) since April 1999 and is currently Chairman of the Compensation Committee and a member of the Nominating and Governance Committee. She has been a director of Schneider Electric, SA. since April 2011. Ms. Atkins has also served as a director for HD Supply Holdings, Inc. (NASDAQ: HDS) since September 2013 and is a member of the Compensation Committee. Ms. Atkins served as a director for Wix.com Ltd. (NASDAQ: WIX) through July 2014, where she was a member of the Audit Committee and Chair of the Compensation Committee since October 2013. Ms. Atkins is also a director for Ciber Inc. (NYSE: CBR) since July 2014 and is a member of the Compensation and Governance Committee.

 

Ms. Atkins is a member of the Council on Foreign Relations as well as a member of the Florida International University Medical School Board of Trustees. Ms. Atkins received her bachelor’s degree from the University of Massachusetts and also studied at Trinity College Oxford.

Cathleen P. Black

 

Business Address:

 

110 East 25th Street

New York, NY 10010

   70    Cathleen P. Black has served as a Senior Advisor at RRE Ventures LLC, an early stage venture capital firm, since 2011. She has served on the boards of two of RRE Ventures LLC’s portfolio companies, Yieldbot Inc. and Bark & Co, Inc. as an independent board member and is also a board member of PubMatic, Inc., an advertising technology platform. Prior to that, Ms. Black served as President of Hearst Magazines, a division of the Hearst Corporation and one of the world’s largest publishers of monthly magazines, from January 1996 until late 2010. Ms. Black also served as a director of the Hearst Corporation from January 1996 until late 2010. Moreover, Ms. Black served as President of USA Today from October 1983 until June 1991 and was a board member of the parent company, Gannett Co., Inc. (NYSE:GCI).
      In addition, Ms. Black served as a director of Vibrant Media Inc., a global leader of in-content contextual technology, from October 2012 until 2013, served as an independent director of International Business Machines Corp. (NYSE: IBM) from 1995 until 2010 and served as a director of The Coca-Cola Company (NYSE: KO) from 1992 until 2010.
      Further, Ms. Black served as a director of NYC2012 Inc., a non-profit organization created to promote New York City as a location for the 2012 Summer Olympics and as President of the Newspaper Association of America. Between January 2011 and April 2011, Ms. Black also served New York City as Chancellor of New York City Schools.
      Ms. Black is a member of the National Council of Foreign Relations, a trustee emeritus of The University of Notre Dame and a trustee of the Kent School.

 

23


Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

      Ms. Black holds a bachelor’s degree from Trinity College in Washington, D.C.

Fredric N. Eshelman

 

Business Address:

 

6814 Towles Road

Wilmington, NC 28409

   65    Dr. Fredric N. Eshelman is a principal at Eshelman Ventures, LLC, which is a fund that invests primarily in early-stage healthcare. He served as Founding Chairman of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development company, from its founding in 2009 until the sale of the company to Forest Laboratories LLC in July 2014. Mr. Eshelman also founded Pharmaceutical Product Development, Inc. (NASDAQ: PPDI), an international contract research organization. He served as the Chief Executive Officer of Pharmaceutical Product Development, Inc. until 1989 and from July 1990 until July 2009, Vice Chairman of its board of directors from July 1993 until July 2009 and Executive Chairman from July 2009 until its sale to private equity in 2011. From 1989 until he rejoined Pharmaceutical Product Development, Inc. in 1990, Dr. Eshelman was Senior Vice President of Development at Glaxo, Inc. and served on the board of the United States subsidiary of Glaxo Holdings plc. Dr. Eshelman also currently serves as director on several private company boards. Dr. Eshelman also served on the board of Princeton Pharma Holdings LLC from February 2008 until May 2010, when it was acquired by Valeant Pharmaceuticals International, Inc.
      Dr. Eshelman serves on the University of North Carolina System Board of Governors, including its Audit Committee. He also serves as a director of the North Carolina Biotechnology Center. Moreover, Dr. Eshelman serves on the University of North Carolina at Wilmington Board of Trustees and has served as an adjunct professor at University of North Carolina at Chapel Hill.
      He has received numerous awards including the Davie and the Outstanding Service Awards from University of North Carolina at Chapel Hill, the NC Biotechnology Award, and the Outstanding Alumnus awards from both the University of North Carolina and University of Cincinnati Schools of Pharmacy. The University of North Carolina Eshelman School of Pharmacy was so named to reflect his many contributions to the University of North Carolina and the profession of pharmacy.
      Mr. Eshelman received his bachelor’s degree in pharmacy from University of North Carolina at Chapel Hill and his doctor of pharmacy (Pharm.D.) from the University of Cincinnati. He completed his hospital residency at Cincinnati General Hospital and completed the Owner/President Management program at Harvard Business School.

Steven J. Shulman

 

Business Address:

 

1433 Nighthawk Pointe

Naples, FL 34105

   63    Steven J. Shulman serves as the Managing Director of Shulman Ventures Inc., a private equity investment firm. Mr. Shulman has also served as a strategic advisor to Water Street Healthcare Partners, a private equity firm focused exclusively on health care, since 2008.

 

24


Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

      Mr. Shulman has served as Chairman of CareCentrix, Inc. since 2008, Access MediQuip, LLC since 2009 and Accretive Health, Inc. (NYSE: AH) since 2014. Mr. Shulman has also served as a director of HealthMarkets, Inc. since 2006, Facet Technologies since 2011, Oasis Outsourcing since 2012, MedImpact since 2013 and Quantum Health since 2013. Mr. Shulman has previously served on numerous other privately held company boards.
      Mr. Shulman served as Chairman of Health Management Associates Inc. (NYSE: HMA) from 2013 until January 2014. He also served as Chairman and Chief Executive Officer of Magellan Health Services, Inc. (NASDAQ: MGLN) from 2003 until 2009.
      Mr. Shulman founded and served as Chairman and Chief Executive Officer at Internet Healthcare Group, LLC, an early stage health care services and technology venture fund, from 1999 until 2003. Mr. Shulman also served as the Chairman, President and Chief Executive Officer of Prudential Healthcare, Inc. from 1997 until 1999.
      Mr. Shulman co-founded and served as a director of Value Health, Inc. (NYSE: VH), a specialty managed care company in 1987, which went public in 1991 and was sold in 1997. During this time, he served in a number of senior operating positions including President of Pharmacy & Disease Management Group.
      Earlier in his career, Mr. Shulman held various leadership positions at Cigna Corporation (NYSE: CI) from 1983 to 1987 and at Kaiser Permanente from 1974 to 1983.
      Mr. Shulman served on the Board of Trustees of the Crohn’s and Colitis Foundation of America as well as the University of Hartford’s Art School. In addition, he serves on the Deans Council at SUNY at Stony Brook and as an incorporator at Hartford Hospital.
      Mr. Shulman received his bachelor’s degree in economics and his masters in health services administration from the State University of New York at Stony Brook. He also completed the Advanced Management program at Stanford University Graduate School of Business.

David A. Wilson

 

Business Address:

 

4551 Gulf Shore Blvd.

N Unit 402,

Naples, FL 34103

   73    David A. Wilson is the former President and Chief Executive Officer of the Graduate Management Admission Council, a not-for-profit education association dedicated to creating access to graduate management and professional education that provides the Graduate Management Admission Test (GMAT), which position he held from 1995 through December 2013. Mr. Wilson served as Senior Advisor to the Graduate Management Admission Council from December 2013 until June 2014.
     

 

Mr. Wilson has served as a director of CoreSite Realty Corporation (NYSE: COR), an owner-developer and operator of strategically located data centers, since 2010, and is a member of the Compensation Committee and chair of the Audit Committee. He has also served Barnes & Noble, Inc. (NYSE: BKS) as a director and as chair of its Audit Committee since October 2010.

 

25


Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

      Mr. Wilson served as a director at Terra Industries Inc. (formerly NYSE: TRA), a producer and marketer of nitrogen products, from November 2009 until April 2010 where he served as member of the Audit Committee. Mr. Wilson also served as a director at Laureate Education, Inc. (formerly Sylvan Learning Systems, Inc.) (NASDAQ: LAUR), an operator of an international network of licensed campus-based and online universities and higher education institutions, from 2002 until 2007, where he served on the Audit Committee.
      From 1978 to 1994, Mr. Wilson worked in various capacities for Ernst & Young LLP (and its predecessor, Arthur Young & Company), including Audit Principal, Audit Partner, Managing Partner, National Director of Professional Development, Chairman of Ernst & Young’s International Professional Development Committee and as a director of the Ernst & Young Foundation. Mr. Wilson has had full responsibility for managing teams responsible for the planning, review and execution of audit engagements.
      Mr. Wilson served as a faculty member at Queen’s University (1968 to 1970), the University of Illinois at Urbana Champaign (1970 to 1972), the University of Texas (1972 to 1978), where he was awarded tenure, and Harvard University’s Graduate School of Business (1976 to 1977).
      Mr. Wilson has a Bachelor of Commerce from Queen’s University Canada, a Masters of Business Administration (M.B.A.) from the University of California, Berkeley and a doctorate in accounting (PhD) from the University of Illinois. Mr. Wilson has also been a Chartered Accountant (Ontario), a Fellow Chartered Accountant (Ontario) and a Certified Public Accountant (Texas), although he no longer holds a license to practice accounting. Mr. Wilson remains a member in good standing with American Institute of Certified Public Accountants and the Institute of Chartered Accountants of Ontario.
      Mr. Wilson beneficially owns 50 shares of Allergan, Inc., of which he has sole voting and investment power, all of which were purchased on April 16, 2014. Mr. Wilson has Net Long Beneficial Ownership of such shares, as such term is defined in the Bylaws.

John J. Zillmer

 

Business Address:

 

30 Basset Hunt Lane

Glenmoore, PA 19343

   58    John J. Zillmer is the former Executive Chairman of Univar, Inc., a leading global distributor of industrial and specialty chemicals and related services, which position he held from May 2012 to December 2012. He served as director, President and Chief Executive Officer of Univar, Inc. from September 2009 to May 2012.
     

 

Prior to joining Univar, Inc., Mr. Zillmer was Chairman and Chief Executive Officer of Allied Waste Industries, Inc., the nation’s second-largest waste management company, from May 2005 until December 2008, at which time Allied Waste Industries, Inc. merged with Republic Services, Inc. (NYSE: RSG).

     

 

From May 2000 to January 2004, Mr. Zillmer served as Executive Vice President of ARAMARK Corporation (NYSE: ARMK), a

 

26


Name (Citizenship); Business Address

   Age   

Present Principal Occupation or Employment;

Five Year Employment History

      leading foodservice, facilities and uniforms provider. From 1995 to 2000, Mr. Zillmer served in various management positions in roles of increasing responsibility with ARAMARK Corporation.
      Mr. Zillmer has served as a director of Reynolds American Inc. (NYSE: RAI), the second-largest tobacco company in the United States, since July 2007. He has been the Chair of its Governance and Nominating Committee since 2011, and served on its Compensation Committee from 2008 until 2010.
      Mr. Zillmer has served as a director of Ecolab Inc. (NYSE: ECL), the global leader in water, hygiene and energy technologies and services, since May 2006. He has been a member of its Governance Committee since 2007 to, its Compensation Committee since 2011 and on its Audit Committee from 2007 to 2010. Mr. Zillmer has also served as director and Chair of the Compensation and Governance Committee of Veritiv Corporation (NYSE: VRTV), a North American leader in business-to-business distribution solutions, since June 2014. He has also served as director of Liberty Capital Partners, Investment Arm, a private equity and venture capital firm specializing in startups, early stage, growth equity, buyouts, and acquisitions, since June 2004.
      Mr. Zillmer received his Master of Business Administration (M.B.A.) from Northwestern University.

Additional Information About the Group Nominees . Each Group Nominee named herein is independent under the Board’s independence guidelines, the applicable rules of the NYSE, and the independence standards applicable to the Company under paragraph (a)(1) of Item 407 of Regulation S-K under the Exchange Act. Furthermore, all of the six candidates are independent of and unaffiliated with PS Fund 1, Pershing Square and Valeant.

Each Group Nominee named herein has consented to be named in this Solicitation Statement and to serve as a director of the Company, if elected. The consent of each Group Nominee is attached to this Solicitation Statement as Exhibits F-1 through F-6. If these Group Nominees are elected, they have indicated that intend to discharge their duties as directors of the Company consistent with all applicable legal requirements, including the general fiduciary obligations imposed upon corporate directors. If elected, each of these Group Nominees would serve as a director until the Company’s annual meeting in 2015 and until a successor has been duly elected.

The Requesting Shareholder does not intend to compensate the Group Nominees in connection with their nomination. If elected, the Group Nominees will be entitled to such compensation from the Company as may be determined by the Company for non-employee directors, and which is described in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on March 26, 2014 for its 2014 annual meeting (the “Company Proxy Statement”). We expect that, if elected, the Group Nominees will be indemnified for service as a director of the Company to the same extent indemnification is provided to the current directors of the Company and that the Group Nominees will be covered by the Company’s director and officer liability insurance.

Information regarding the amount of each class of securities of the Company beneficially owned by the participants in this solicitation and certain other matters is set forth in the section of the Solicitation Statement titled “Certain Information Regarding the Participants.” Except as set forth in this Solicitation Statement, none of the Group Nominees beneficially own any shares of capital stock or other securities of the Company. Information regarding purchases and sales in the securities of the Company effected during the past two years by participants

 

27


in this solicitation is set forth in Annex B attached to this Solicitation Statement. Except as set forth in Annex B, there have been no purchases and sales in the securities of the Company in the past two years by any Group Nominee.

In connection with the Special Meeting, the Requesting Shareholder has entered into customary indemnification agreements with each Group Nominee with respect to the nomination of such individual as a director of the Company. The indemnification agreement provides, among other things, that (i) the Requesting Shareholder will reimburse each Group Nominee for reasonable out-of-pocket expenses arising from or in connection with such person’s participation in this solicitation; and (ii) the Requesting Shareholder will, subject to limited exceptions and to the extent permitted by applicable law, indemnify and hold each Group Nominee harmless from and against all losses, claims, damages, liabilities and expenses (including, without limitation, attorneys’ fees) incurred by such Group Nominee and also advance expenses in the event such person becomes a party to litigation arising out of or relating to this solicitation (but not in such Group Nominee’s capacity as a director of the Company if elected).

Other than as disclosed herein, there are no agreements, arrangements or understandings between any Group Nominee and the Requesting Shareholder or any other person or persons with respect to the nomination of such Group Nominee.

Other than as disclosed herein, (i) no Group Nominee or any associate of a Group Nominee is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries in any material proceeding, (ii) there is no event that occurred during the past 10 years with respect to any of the Group Nominees that is required to be described under Item 401(d) or 401(f) of Regulation S-K, and (iii) no Group Nominee has any Disclosable Interest as such term is defined in Article II, Section 3 of the Bylaws (except that the term “Proposing Person” where it appears in sections (A)(1) and (2) of Section 3 of the Bylaws shall be deemed to refer to such Group Nominee).

The Company has published non-binding Guidelines on Significant Corporate Governance Issues (the “Guidelines”), which in part state that when a Board member reaches the age of 73, he shall not be eligible for renomination to the Board and shall retire from the Board effective immediately prior to the Company’s first annual meeting of shareholders following such Board member’s 73rd birthday. One of the Group Nominees, Mr. David Wilson, is currently 73 years old. In accordance with the Guidelines and without any waiver thereof, he is eligible for election at a special meeting because he turned 73 years old in June of 2014, and accordingly would have been eligible for re-nomination at the 2014 annual meeting of Allergan shareholders held in May 2014 had he been a director and would have been eligible to serve as a director of the Company if elected until the 2015 annual meeting of Allergan shareholders. Also, the age limitation in the Guidelines only applies to renomination and not to an initial election. Finally, the Guidelines can be amended or waived. Indeed the Guidelines state that “[t]hese guidelines are not rigid rules. Nor is it intended that publication of these guidelines be interpreted as a representation that they will be strictly followed in each instance. The Board will continue to assess the appropriateness and efficacy of these guidelines and it is likely that changes or exceptions to these Guidelines will be considered from time to time.” If the Group Nominees are elected prior to the 2015 annual meeting of Allergan shareholders, the Board may choose to waive or amend the Guidelines as they relate to Mr. Wilson. If the Board chooses to maintain the Guidelines and apply the age limit with respect to Mr. Wilson, his service on the Board would terminate at the 2015 annual meeting of Allergan shareholders.

Filling of Vacancies . The Charter and the Bylaws currently permit the Company’s shareholders to remove its directors with or without cause, but further provide that any vacancies on the Board will be filled solely by the affirmative vote of a majority of the remaining directors then in office, and do not permit the Company’s shareholders to fill any vacancies on the Board. Therefore, the Board’s action is necessary to effect the shareholders’ request to appoint or elect the Group Nominees, but the Board has no obligation to take any action with respect to such request. However, in the event that, at the time of filling any board vacancy, the directors then in office constitute less than a majority of the whole board, Section 223(c) of the DGCL provides that the Delaware Court of Chancery may, upon the application of any shareholder or shareholders holding at least 10

 

28


percent of the voting stock at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or to replace the directors chosen by the directors then in office. If the Board ignores the request to fill vacancies as contemplated in Proposal 2, Pershing Square reserves its right to petition the Delaware Court of Chancery under Section 223(c) of the DGCL to order a new election. In addition, we are proposing the amendments to the Bylaws described in Proposal 4 that would facilitate the shareholders’ right to call a special meeting to elect the replacements of the removed directors in the event that, at the time of filling any board vacancy, the directors then in office constitute less than a majority of the whole Board, as contemplated by Section 223(c) of the DGCL. In the event we choose to pursue our rights under Section 223(c) of the DGCL, we will join with other Allergan shareholders to meet the 10 percent requirement of Section 223(c) of the DGCL in a manner consistent with the court order effecting the settlement of litigation relating to Allergan’s shareholder rights plan, between Pershing Square and Allergan dated as of June 28, 2014.

 

29


CERTAIN INFORMATION REGARDING THE PARTICIPANTS

The Requesting Shareholder and certain other persons listed below are participants in this solicitation.

The business address of the Pershing Square Participants (as defined below) is 888 Seventh Avenue, 42nd Floor, New York, NY 10019. The business address of Valeant is 2150 St. Elzéar Blvd. West Laval, Quebec, Canada, H7L 4A8, and the business address of Valeant USA is 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807. The business address of the Valeant Officer Participants (as defined below) is 2150 St. Elzéar Blvd. West Laval, Quebec, Canada, H7L 4A8. The business address of each Group Nominees in set forth in the section this Solicitation Statement titled “Information Regarding the Nominees.”

PS Fund 1 and Valeant have been shareholders of the Company since February 25, 2014 and May 7, 2014, respectively. As of July 11, 2014, the amount of each class of securities of the Company beneficially owned by each of the participants in this solicitation is as follows:

 

     Ownership of
Company
Common
Stock
    Percent of
Class(1)
 

Pershing Square Capital Management, L.P.

     28,878,638 (2)      9.7

PS Management GP, LLC

     28,878,638 (2)      9.7

PS Fund 1, LLC

     28,878,638 (2)      9.7

William A. Ackman

     28,878,638 (2)      9.7

William F. Doyle

     0        0   

Ben Hakim

     0        0   

Jordan H. Rubin

     0        0   

Roy J. Katzovicz

     0        0   

Valeant Pharmaceuticals International, Inc.

     28,878,638 (2)      9.7

Valeant Pharmaceuticals International

     28,878,638 (2)      9.7

J. Michael Pearson

     0        0   

Howard B. Schiller

     0        0   

Ari S. Kellen

     0        0   

Laurie W. Little

     0        0   

Betsy Atkins

     0        0   

Cathleen P. Black

     0        0   

Fredric N. Eshelman

     0        0   

Steven J. Shulman

     0        0   

David A. Wilson

     50        0.0

John J. Zillmer

     0        0   

Total

     28,878,688 (2)      9.7

 

(1) Based on 296,824,582 shares of Company Common Stock outstanding as of June 20, 2014 (exclusive of 10,035,841 shares of Company Common Stock held in treasury) as reported in the Company 14D-9.
(2) The total number of shares beneficially owned by the Pershing Square Participants and the Valeant Participants include 28,878,538 shares of Common Stock owned by PS Fund 1, LLC and 100 shares of Common Stock owned by Valeant USA.

 

30


Pershing Square Participants

Pershing Square serves as investment advisor to PS Fund 1 with respect to 28,878,538 shares of Company Common Stock held for the accounts of this fund and may be deemed to have beneficial ownership of such shares of Company Common Stock for purposes of Rule 13d-3 under the Exchange Act (“Rule 13d-3”).

Pershing Square is an investment adviser founded in 2003 and registered with the SEC. Pershing Square is a concentrated, research-intensive, fundamental value investor in the public markets.

PS Management GP, LLC, a Delaware limited liability company (“PS Management”), serves as the general partner of Pershing Square and may be deemed to be the beneficial owner of such shares of Company Common Stock owned by Pershing Square for purposes of Rule 13d-3. William A. Ackman is the Chief Executive Officer of Pershing Square and managing member of PS Management and may be deemed to be the beneficial owner of such shares of Company Common Stock owned by Pershing Square for purposes of Rule 13d-3.

PS Fund 1 is a Delaware limited liability company formed by Pershing Square to purchase certain securities of the Company. Valeant USA contributed $75.9 million of its working capital to PS Fund 1 for such purpose and, together with the capital contributions from the Pershing Square Funds, PS Fund 1 acquired 28,878,538 shares of Company Common Stock.

In addition, William A. Ackman, William F. Doyle, Ben Hakim, Jordan H. Rubin and Roy J. Katzovicz (together with Pershing Square, PS Management, and PS Fund 1, the “Pershing Square Participants”), may be deemed “participants” under SEC rules in this solicitation. All five of these individuals are presently employed at Pershing Square, located at 888 7th Avenue, 42nd Floor, New York, NY 10019, and their titles are as follows: William A. Ackman, Founder and CEO; William F. Doyle, Senior Advisor; Ben Hakim, Partner; Jordan H. Rubin, Partner; Roy J. Katzovicz, Partner and Chief Legal Officer.

Valeant Participants

Valeant is a corporation continued under the laws of British Columbia, Canada. Valeant USA is a Delaware corporation and a wholly owned subsidiary of Valeant. Valeant and Valeant USA are multinational, specialty pharmaceutical and medical device companies that develop, manufacture, and market a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

In addition, J. Michael Pearson, Chairman and Chief Executive Officer of Valeant, Howard B. Schiller, Director, Executive Vice President and Chief Financial Officer of Valeant, Ari S. Kellen, Executive Vice President and Company Group Chairman of Valeant, and Laurie W. Little, Senior Vice President, Investor Relations of Valeant (the “Valeant Officer Participants” and, together with Valeant and Valeant USA, the “Valeant Participants”), may be deemed “participants” under SEC rules in this solicitation.

Group Nominees

Each of the Group Nominees may be deemed “participants” under SEC rules in this this solicitation. The name and present principal occupation or employment of each Group Nominee is set forth in the section this Solicitation Statement titled “Information Regarding the Nominees.” David A. Wilson, a Group Nominee, beneficially owns 50 shares of the Company Common Stock, of which he has sole voting and investment power, that were purchased on April 16, 2014.

Section 13(d) Group

Each of Pershing Square, PS Management, PS Fund 1, William A. Ackman, Valeant and Valeant USA, as a member of a “group” for the purposes of Rule 13d-5(b)(1) under the Exchange Act, is deemed to be a beneficial owner of the 28,878,638 shares of Company Common Stock held by each of the members of the group

 

31


combined, or 9.7% of the issued and outstanding Company Common Stock based on 296,824,582 shares of Company Common Stock outstanding as of June 20, 2014 as reported in the Company 14D-9, and each entity or individual may be deemed to beneficially own the shares of each other entity or individual in the reporting group. Each member of the group disclaims beneficial ownership of such shares of Company Common Stock, except to the extent it exercises voting or dispositive power with respect to those shares. Such shares include 100 shares of Company Common Stock with respect to which Valeant exercises sole voting and dispositive power.

Transactions in the Securities of the Company

For information regarding purchases and sales of securities of the Company during the past two years by the participants in this solicitation, please refer to Annex B attached to this Solicitation Statement. Except as set forth on Annex B, there have been no purchases or sales in the securities of the Company in the past two years by such parties.

Additional Information Regarding the Participants

Except as set forth in this Solicitation Statement (including the annexes, exhibits and any other attachments hereto), (i) during the past 10 years, no participant in this solicitation has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no participant in this solicitation owns beneficially, directly or indirectly, any securities of the Company; (iii) no participant in this solicitation owns any securities of the Company of record but not beneficially; (iv) no participant in this solicitation has purchased or sold any securities of the Company during the past two years; (v) no part of the purchase price or market value of the securities of the Company owned by any participant in this solicitation is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities; (vi) no participant in this solicitation is, or within the past year was, a party to any contract, arrangements or understandings with any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; (vii) no associate of any participant in this solicitation owns beneficially, directly or indirectly, any securities of the Company; (viii) no participant in this solicitation owns beneficially, directly or indirectly, any securities of any subsidiary of the Company; (ix) no participant in this solicitation or any of his, her or its associates or immediate family members was a party to, or had a direct or indirect material interest in, any transaction, or series of similar transactions, since the beginning of the Company’s last fiscal year, or is a party to any currently proposed transaction, or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000; (x) no participant in this solicitation or any of his, her or its associates has any arrangement or understanding with any person with respect to any future employment by the Company or its affiliates, or with respect to any future transactions to which the Company or any of its affiliates will or may be a party; (xi) no participant in this solicitation has a substantial interest, direct or indirect, by securities holdings or otherwise in any matter to be acted on at the Special Meeting; and (xii) no participant in this solicitation has a family relationship with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer.

For the purposes of the foregoing, (i) the term “associates” shall have the meaning ascribed to that term in Rule 14a-1 of Regulation 14A under the Exchange Act and (ii) the terms “immediate family member” and “family relationship” shall have the meanings ascribed to those terms in Item 404(a) and Item 401(d), respectively, of Regulation S-K under the Exchange Act.

 

32


CERTAIN EFFECTS RELATED TO THIS SOLICITATION

According to the Company 10-Q, Allergan had approximately $2.815 billion of cash and cash equivalents on its balance sheet for the fiscal period ended March 31, 2014 and long-term debt of approximately $2.095 billion, for a net cash position of approximately $720 million.

Based upon a review of the Company’s public filings with the SEC, pursuant to the Company’s Amended and Restated Credit Agreement, dated as of October 28, 2011 (the “Credit Agreement”), the Proposals could potentially result in an Event of Default (as defined in the Credit Agreement), which includes a change in the majority of the Board, unless approved by the original Board members in office on the effective date of the Credit Agreement and/or their successors. An Event of Default would permit Lenders (as defined in the Credit Agreement) holding more than 50% of the commitments under the Credit Agreement to terminate the commitments under the Credit Agreement and to declare the outstanding principal and accrued interest due and payable. The Company could also seek a waiver of such Event of Default which would require the approval of the Lenders. As reported in the Company 10-Q, the Company had no borrowings under the Credit Agreement.

Based upon a review of the Company’s public filings with the SEC, the Proposals could potentially result in a Change in Control (as defined in the respective agreements) under a number of agreements with the Company’s named executive officers (“NEOs”) and other management level employees. Under the 2014 Management Bonus Plan and the Executive Bonus Plan (applicable only to David Pyott), upon a Change in Control, participants will be paid a bonus prorated to the effective date of such Change in Control, with the Company’s performance being deemed to be the greater of (i) 100% of the underlying target goals and (ii) the prorated actual year-to-date performance. The NEOs’ target bonus amounts are: for Mr. Pyott, 135% of his base salary ($1,365,000); for Jeffrey Edwards, 75% of his base salary ($645,000); for Scott Whitcup, 75% of his base salary ($645,000); for Julian Gangolli, 60% of his base salary ($556,000), and for Douglas Ingram, 77.5% of his base salary ($700,000). We note, however, that the target bonus amount for Mr. Pyott and Mr. Ingram and each of the base salary amounts provided herein are based on information filed with the SEC with respect to the 2013 fiscal year.

With respect to awards granted in 2010 and thereafter under the 2008 Incentive Award Plan and with respect to unvested option, restricted stock unit (“RSU”), and restricted stock awards granted under the Company’s 2011 Incentive Award Plan, awards will be subject to “double trigger” change in control vesting in the event of a termination without cause or a resignation for good reason within two years after the Change in Control, provided, however, the Company may decide to cancel and cash-out the outstanding equity awards, in which case, such awards will “single-trigger” vest upon the Change in Control (with performance-based RSUs vesting to the extent that the Company achieves the underlying performance objectives on an abbreviated basis). Based on information filed with the SEC, the NEOs’ respective unvested holdings are: 477,000 options and 165,000 performance-based RSUs for Mr. Pyott; 99,000 options for Mr. Ingram; 106,750 options for Mr. Edwards; 133,500 options for Mr. Whitcup; and 97,000 options and 3,000 shares of restricted stock for Mr. Gangolli. More generally, as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as of December 31, 2013, there were 12,051,000 unvested options and 875,000 unvested “restricted share” awards (which amount includes restricted stock and RSUs).

The Company’s Change in Control Policy provides employees at the vice president level or above with certain severance entitlements in the event of a termination without cause or a resignation for good reason within two years after a Change in Control of the Company (a “Qualifying Termination”). Under the Change in Control Policy, upon such a Qualifying Termination, participants at the CEO, President and Executive Vice President level (including the NEOs) are eligible to receive (A) a lump sum cash payment equal to three times the sum of (i) the participant’s highest annual salary rate within the five-year period preceding the termination and (ii) the participant’s target annual bonus for the year in which the Qualifying Termination occurs (the “Cash Severance Payment”) and (B) continued participation (at no cost to the participant) in medical, dental and vision benefit programs for the three-year period following the termination and outplacement benefits of a type and duration generally provided to employees at the participant’s level (the “Continued Employee Benefits”). Based on information filed with the SEC, upon a Qualifying Termination as of December 31, 2013, each NEO would be

 

33


entitled to receive a Cash Severance Payment under the Company’s Change in Control Policy in an amount as follows: $9,623,250 for Mr. Pyott; $3,624,000 for Mr. Ingram; $3,386,250 for Mr. Edwards; $3,386,250 for Mr. Whitcup; and $2,668,800 for Mr. Gangolli and each NEO would be entitled to receive Continued Employee Benefits with a value as follows: $80,389 for Mr. Pyott; $80,410 for Mr. Ingram; $76,049 for Mr. Edwards; $36,487 for Mr. Whitcup; and $77,002 for Mr. Gangolli.

In the event of a Change in Control, each participant in the Company’s Supplemental Executive Benefit Plan and the Supplemental Retirement Income Plan will be entitled to receive a lump sum payment in lieu of accrued benefits under each respective plan, with such lump sum payment calculated using a more favorable discount rate of 3.6%. Under the Company’s Executive Deferred Compensation Plan, in the event of a Change in Control, each participant will become vested in the unvested portion of his or her plan account. Based on the Company’s public filings, we understand that all five NEOs are participants in the Supplemental Executive Benefit Plan and that Messrs. Whitcup and Gangolli were the only NEOs who participated in the Executive Deferred Compensation Plan in 2013. We are unable to confirm from the Company’s public filings with the SEC to what extent any individuals are currently receiving benefits under these plans (though no NEOs are currently receiving any such benefits).

We have not independently verified if the copies of the agreements discussed above (collectively, the “Filed Agreements”) and publicly filed by the Company with the SEC are the same as the executed copies of the Filed Agreements, and the analyses above are based on our review of the Company’s public SEC filings. While we are not aware of any, there may be other compensation or vesting provisions with other Company employees or directors may be triggered by a change in control. The discussion of the potential impact of the Proposals is based entirely upon our review of the Filed Agreements and the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. If the Company’s shareholders approve the Proposals, prior to the acceleration of vesting of any Company equity awards (which will occur if the Company decides to cancel and cash-out the outstanding equity awards) or the payment of any compensation described above, we expect to review with counsel the original copies of all relevant agreements, award documentation and Company records associated with the creation of the potential obligations upon a change in control.

YOUR SUPPORT IS IMPORTANT

NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN, WE ARE SEEKING YOUR SUPPORT. PLEASE COMPLETE, EXECUTE AND DATE THE ENCLOSED SPECIAL MEETING REQUEST FORM AND THE ACCOMPANYING WHITE PROXY CARD AS SOON AS POSSIBLE. IF YOU HOLD ANY OF YOUR SHARES THROUGH A BROKERAGE FIRM, BANK NOMINEE OR OTHER INSTITUTION, PLEASE ARRANGE TO HAVE SUCH DTC PARTICIPANT(S) RETURN THE EXECUTED CEDE & CO. MEETING REQUEST ALONG WITH THEIR EXECUTED VERIFICATION LETTER TO YOU BY FOLLOWING THE PROCEDURES SET FORTH IN THE SECTION OF THIS SOLICITATION STATEMENT TITLED “PROCEDURES FOR ARRANGING FOR EXECUTION OF CEDE & CO. MEETING REQUESTS AND VERIFICATION LETTERS”. YOU SHOULD MAIL YOUR EXECUTED SPECIAL MEETING REQUEST FORM, WHITE PROXY CARD, CEDE & CO. MEETING REQUEST AND VERIFICATION LETTER TO D.F. KING IN THE ENCLOSED POSTAGE-PAID ENVELOPE (TO THE ADDRESS SET FORTH ON THE ENVELOPE, WHICH IS SAME AS THE ADDRESS AT THE BOTTOM OF THIS PAGE).

 

34


WHOM YOU CAN CALL IF YOU HAVE QUESTIONS

If you have any questions or require any assistance, please contact D.F. King, proxy solicitors for the Requesting Shareholder, at the following address and toll free telephone number:

D.F. King & Co., Inc.

48 Wall Street

New York, NY 10005

Toll-free: (800) 859-8511

Banks and brokers: (212) 269-5550

IT IS IMPORTANT THAT YOU COMPLETE, EXECUTE AND DATE YOUR SPECIAL MEETING REQUEST FORM AND WHITE PROXY CARD PROMPTLY, ARRANGE FOR THE RETURN TO YOU BY YOUR DTC PARTICIPANT OF THE EXECUTED CEDE & CO. MEETING REQUEST AND THEIR EXECUTED VERIFICATION LETTER, AND SEND ALL FOUR DOCUMENTS TO D.F. KING IN THE ENCLOSED ENVELOPE TO AVOID UNNECESSARY EXPENSE AND DELAY. NO POSTAGE IS NECESSARY.

THE REQUESTING SHAREHOLDER

July 11, 2014

 

35


ANNEX A

SECURITY OWNERSHIP OF DIRECTORS AND MANAGEMENT OF THE COMPANY

AND PRINCIPAL SHAREHOLDERS

Security Ownership of Directors and Executive Officers

The following information is based solely on the Company Proxy Statement and the Company 10-Q, and the Requesting Shareholder makes no representation regarding its accuracy or completeness. The Company indicated in the Company Proxy Statement that, to the Company’s knowledge, the following table summarizes information as of March 11, 2014 with respect to ownership of the outstanding shares of Company Common Stock by (i) each director, (ii) the Chief Executive Officer, Chief Financial Officer, and each of the Company’s three other most highly compensated executive officers for the year ended December 31, 2013, and (iii) all directors and executive officers of the Company as a group. Unless otherwise indicated, each person in the table has sole voting and investment power of the shares listed as owned by such person. The percentages in the following table are based on 296,824,582 shares of Company Common Stock outstanding as of June 20, 2014 as reported in the Company 14D-9.

 

     Vested Shares
of Company
Common
Stock
Owned(1)
     Rights to
Acquire
Shares of
Company
Common
Stock(2)
     Unvested
Shares of
Restricted
Stock/Units
     Total Shares
of Company
Common
Stock
Beneficially
Owned
     Percent of
Class(3)
 

Directors:

              

Deborah Dunsire, M.D.

     29,111         65,123         0         94,234          

Michael R. Gallagher

     36,400         61,750         0         98,150          

Trevor M. Jones, Ph.D.

     200         54,476         0         54,676          

Louis J. Lavigne, Jr.

     14,421         3,102         0         17,523          

Peter J. McDonnell, M.D.

     0         3,102         0         3,102          

Timothy D. Proctor

     0         3,261         0         3,261          

David E.I. Pyott

     234,168         2,265,200         165,000         2,664,368          

Russell T. Ray

     22,810         57,702         0         80,512          

Henri A. Termeer(4)

     0         0         0         0          

Other Named Executive Officers:

              

Douglas S. Ingram

     30,101         527,700         0         557,801          

Jeffrey L. Edwards

     20,259         207,850         0         228,109          

Scott M. Whitcup, M.D.

     20,849         556,200         0         577,049          

Julian S. Gangolli

     20,590         140,500         3,000         164,090          

All current directors and executive officers (as a group 17 persons, including those named above)

     454,077         4,348,166         178,700         4,980,943         1.678   

 

* Beneficially owns less than 1% of the outstanding Company Common Stock.
(1) In addition to shares held in the individual’s sole name, this column includes: (1) shares held by the spouse of the named person and shares held in various trusts; and (2) for executive officers, shares held in trust for the benefit of the named employee in the Company’s Savings and Investment Plan and Employee Stock Ownership Plan as of March 11, 2014.
(2)

This column also includes shares which the person or group has the right to acquire within 60 days of March 11, 2014 as follows: (1) for executive officers, these shares include shares that may be acquired upon the exercise of stock options and vesting of restricted stock units; and (2) for non-employee directors, these shares include shares that may be acquired upon the exercise of stock options and vesting of restricted stock units, as well as shares accrued under the Company’s Deferred Directors’ Fee Program as of March 11, 2014. Under the Company’s Deferred Directors’ Fee Program, participants may elect to defer all or a portion of their retainer and meeting fees until termination of their status as a director. Deferred amounts are

 

A-1


  treated as having been invested in Company Common Stock such that on the date of deferral the director is credited with a number of phantom shares of Company Common Stock equal to the amount of fees deferred divided by the market price of a share of Company Common Stock as of the date of deferral. Upon termination of the director’s service on the Board, the director will receive shares of Company Common Stock equal to the number of phantom shares of Company Common Stock credited to such director under the Deferred Directors’ Fee Program.
(3) Based on 296,824,582 shares of Company Common Stock outstanding as of June 20, 2014, as reported in the Company 14-D9.
(4) Mr. Termeer was appointed to the Board on January 24, 2014.

Security Ownership of Certain Principal Shareholders

Set forth below is the name and stock ownership of each person or group of persons known by the Company to beneficially own more than 5% of the outstanding shares of Company Common Stock, and is based on the Company Proxy Statement and information provided by the beneficial owner in subsequent public filings made with the SEC.

 

Name and Address of Beneficial Owners

   Shares
Beneficially
Owned
    Percent of
Class(1)
 

Capital Research Global Investors
40 East 52nd Street
New York, NY 10022

     17,472,533 (2)      5.89

BlackRock, Inc.
40 East 52nd Street
New York, NY 10022

     17,416,972 (3)      5.87

Pershing Square Capital Management, L.P.
888 Seventh Avenue, 42nd Floor
New York, NY 10019

     28,878,638 (4)      9.73

PS Management GP, LLC
888 Seventh Avenue, 42nd Floor
New York, NY 10019

     28,878,638 (4)      9.73

William A. Ackman
888 Seventh Avenue, 42nd Floor
New York, NY 10019

     28,878,638 (4)      9.73

Valeant Pharmaceuticals International, Inc.
2150 St. Elzéar Blvd.
West Laval, Quebec, Canada, H7L 4A8

     28,878,638 (5)      9.73

Valeant Pharmaceuticals International
400 Somerset Corporate Boulevard
Bridgewater, New Jersey 08807

     28,878,638 (5)      9.73

 

(1) Based on 296,824,582 shares outstanding as of June 20, 2014 , as reported in the Company 14D- 9.
(2) Based on information provided pursuant to a statement on a Schedule 13G filed with the SEC on February 10, 2014 by Capital Research Global Investors, a division of Capital Research and Management Company. Capital Research Global Investors reported that it has sole voting power with respect to 17,472,533 shares and sole dispositive power with respect to 17,472,533 shares.
(3) Based on information provided pursuant to a statement on a Schedule 13G/A filed with the SEC on January 28, 2014 by BlackRock, Inc. BlackRock reported that it has sole voting power with respect to 14,470,789 shares and sole dispositive power with respect to 17,416,972 shares.
(4) Based on information provided pursuant to a statement on a Schedule 13D/A filed with the SEC on May 12, 2014 by Pershing Square Capital Management, L.P., PS Management GP, LLC and William A. Ackman, pursuant to which the three parties reported that they have shared beneficial ownership with respect to 28,878,638 shares and shared voting power with respect to 28,878,538 shares.

 

A-2


(5) Based on information provided pursuant to a statement on a Schedule 13D/A filed with the SEC on May 5, 2014 by Valeant Pharmaceuticals International, Inc. and Valeant Pharmaceuticals International, pursuant to which the two parties reported that they have shared beneficial ownership with respect to 28,878,538 shares and shared voting power with respect to 28,878,538 shares, and on information provided pursuant to a statement on a Schedule 13D/A filed with the SEC on May 12, 2014 by Pershing Square Capital Management, L.P., PS Management GP, LLC and William A. Ackman, which reported that Valeant has sole voting power with respect to 100 shares.

 

A-3


ANNEX B

ADDITIONAL INFORMATION REGARDING PARTICIPANTS IN THE SOLICITATION:

PURCHASES AND SALES IN THE COMPANY COMMON STOCK DURING THE PAST TWO YEARS

 

Common Stock Name

   Trade Date    Buy/
Sell
   No. of Shares /
Quantity
     Security  

PS Fund 1, LLC

   February 25, 2014    Buy      94,182         Common Stock   

PS Fund 1, LLC

   February 25, 2014    Buy      25,000         Common Stock   

PS Fund 1, LLC

   February 25, 2014    Buy      55,454         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      5,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      4,197         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      540         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      5,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      5,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      75,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      5,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      10,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      100,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      35,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      21,634         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      75,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      25,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      20,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      13,629         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      10,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      10,000         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      2,500         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      250         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      40         Common Stock   

PS Fund 1, LLC

   February 26, 2014    Buy      5         Common Stock   

David A. Wilson

   April 16, 2014    Buy      50         Common Stock   

PS Fund 1, LLC

   May 1, 2014    Buy      1,239,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      863,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      779,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,416,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,353,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      2,130,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      2,578,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,733,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,046,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,191,107         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      2,523,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      2,184,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,843,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      2,233,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      1,720,000         Common Stock

PS Fund 1, LLC

   May 1, 2014    Buy      3,450,000         Common Stock ** 

Valeant Pharmaceuticals International, Inc.

   May 7, 2014    Buy      100         Common Stock   

 

* Shares purchased represents the exercise of the relevant (previously purchased) American-style call option transactions.
** Shares purchased represents the early termination of the relevant (previously purchased) forward purchase contract.

 

B-1


Options (all of which have been exercised as of the date hereof):

 

Name

   Trade Date    Buy/
Sell
   No. of Options /
Quantity
     Security  

PS Fund 1, LLC

   March 3, 2014    Buy      1,239,000         OTC Call Option   

PS Fund 1, LLC

   March 6, 2014    Buy      863,000         OTC Call Option   

PS Fund 1, LLC

   March 11, 2014    Buy      779,000         OTC Call Option   

PS Fund 1, LLC

   March 14, 2014    Buy      1,416,000         OTC Call Option   

PS Fund 1, LLC

   March 19, 2014    Buy      1,353,000         OTC Call Option   

PS Fund 1, LLC

   March 24, 2014    Buy      2,130,000         OTC Call Option   

PS Fund 1, LLC

   March 27, 2014    Buy      2,578,000         OTC Call Option   

PS Fund 1, LLC

   April 1, 2014    Buy      1,733,000         OTC Call Option   

PS Fund 1, LLC

   April 4, 2014    Buy      1,046,000         OTC Call Option   

PS Fund 1, LLC

   April 8, 2014    Buy      1,191,107         OTC Call Option   

PS Fund 1, LLC

   April 11, 2014    Buy      2,523,000         OTC Call Option   

PS Fund 1, LLC

   April 14, 2014    Buy      2,184,000         OTC Call Option   

PS Fund 1, LLC

   April 15, 2014    Buy      1,843,000         OTC Call Option   

PS Fund 1, LLC

   April 16, 2014    Buy      2,233,000         OTC Call Option   

PS Fund 1, LLC

   April 17, 2014    Buy      1,720,000         OTC Call Option   

Forward (which has been early terminated and physically settled as of the date hereof):

 

Name

   Trade Date      Buy/
Sell
   No. of Options /
Quantity
     Security  

PS Fund 1, LLC

     April 21, 2014       Buy      3,450,000         OTC Equity Forward   

 

B-2


EXHIBIT A

SPECIAL MEETING REQUEST FORM

ALLERGAN, INC.

2525 Dupont Drive

Irvine, CA 92612

Attention: Matthew J. Maletta

Associate General Counsel and Secretary

 

  Re: Request for Special Meeting of Shareholders of Allergan, Inc. (the “Company”)

Ladies and Gentlemen:

Pursuant to Article 10 of the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”) and Article II, Section 3 of the Company’s Amended and Restated Bylaws (the “ Bylaws ”), this letter constitutes a Special Meeting Request (as defined in the Bylaws) of the undersigned Proposing Person (as defined in the Bylaws) requesting the Secretary of the Company to call a special meeting of the Company’s shareholders (the “ Special Meeting ”) for the purposes of considering and voting upon the proposals (collectively, the “ Proposals ”) set forth in full under “Plans for the Special Meeting” in the solicitation statement filed by PS Fund 1, LLC (“ PS Fund 1 ”) on , 2014 (the “ Solicitation Statement ”), which Proposals are incorporated herein by reference as if set forth in full herein.

The Proposing Person is making this request because the Proposing Person believes adoption of the Proposals will enhance shareholder value. The Proposing Person requests that the Special Meeting be held as soon as possible, and in any event within 45 days, after Special Meeting Requests from holders with a Net Long Beneficial Ownership (as defined in the Bylaws) of at least 25% of the outstanding shares of common stock of the Company (“ Company Common Stock ”) are delivered to the Company’s Secretary.

The information in Attachment A and Appendix 1 , as they may be updated, amended or supplemented from time to time, is incorporated herein by reference as if set forth in full herein. In addition, the information in the Solicitation Statement (including its Annexes and Exhibits) and in Special Meeting Requests submitted by other Proposing Persons, as they may be updated, amended or supplemented from time to time, is incorporated herein by reference as if set forth in full herein, although the Proposing Person notes that it did not prepare that information and thus takes no responsibility for its accuracy or completeness.

The Proposing Person hereby represents that it intends to continuously hold the Subject Shares (as defined in Attachment A) through the date of the Special Meeting contemplated by this Special Meeting Request (and through any date to which such Special Meeting is postponed or adjourned). The Proposing Person remains free to sell any or all of the Subject Shares on or before the date of the Special Meeting, but it acknowledges that any reduction in its Net Long Beneficial Ownership with respect to which this Special Meeting Request relates following the delivery of this Special Meeting Request to the Company’s Secretary shall constitute a revocation of this Special Meeting Request to the extent of such reduction.

The Proposing Person further represents that it (a) is a holder of record of stock of the Company entitled to vote at the Special Meeting, (b) does not intend to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to approve or adopt the Proposals or otherwise to solicit proxies from shareholders in support of the Proposals (although it understands that PS Fund 1 intends to do so) and (c) intends to appear by a qualified representative 1 at the Special Meeting to propose the Proposals.

 

1   The Proposing Person intends to authorize PS Fund 1 representatives to act as proxy for the Proposing Person to present the Proposals at the Special Meeting, and thus act as the Proposing Person’s qualified representative.


Any claim by the Company or its advisors that this Special Meeting Request is in any way deficient, and all further correspondence from the Company or its advisors on this matter, should be addressed in a timely fashion to:

 

    Edward McCarthy

D.F. King & Co., Inc.

48 Wall Street, New York, NY 10005

(212) 269-5550

emccarthy@dfking.com

with copies to:

 

    Roy J. Katzovicz

Pershing Square Capital Management, L.P.

888 Seventh Avenue, 42nd Floor, New York, NY 10019

(212) 813-3700

rjk@persq.com

and

 

    Richard Brand

Kirkland & Ellis LLP

601 Lexington Avenue, New York, NY 10022

(212) 446-6454

richard.brand@kirkland.com

[Signature page follows]

 

2


Sincerely yours,
[insert signature blocks for the persons or entities within the Proposing Person 2 that collectively own (beneficially or of record) the shares covered by this Special Meeting Request]

Date:

 

 

[Signature Page to Special Meeting Request]

 

2   For this purpose, the Proposing Person is:

 

    the stockholder of record (on the books of the Company’s transfer agent, Wells Fargo Bank Shareowner Services) of at least one share of Company Common Stock who or which signs this Special Meeting Request;

 

    any other beneficial owners of the shares covered by this Special Meeting Request (including any person or entity who or which has or shares the power to vote or direct the voting of or the power to dispose or direct the disposition of those shares);

 

    any other person or entity who or which has or shares the economic incidents of ownership of those shares (other than merely through an investment in an entity that signs this Special Meeting Request) (any such shareholder, beneficial owner, other person or entity, an “ Owner ”);

 

    (a) any corporation or organization of which any Owner is an officer or partner or is, directly or indirectly, the beneficial owner of 10 percent or more of any class of equity securities, (b) any trust or other estate in which any Owner has a substantial beneficial interest or as to which any Owner serves as trustee or in a similar fiduciary capacity, and (c) any relative or spouse of any Owner, or any relative of such spouse, who has the same home as that Owner or who is a director or officer of the Company or any of its subsidiaries; and

 

    any other person or entity who or which is a participant (as defined in (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder of record in the solicitation seeking the Special Meeting or Acting in Concert (as defined in the Bylaws) with any of the foregoing.

Each of the foregoing persons and entities should sign this Special Meeting Request in the space indicated above.

Note about participants and persons Acting in Concert : the typical Proposing Person will have no person or entity falling within the final bullet that refers to participants and Acting in Concert.

 

3


INSTRUCTION SHEET

If you want to complete and submit a Special Meeting Request, you should fill out Attachment A and Appendix 1 (which directly follow this Instruction Sheet), sign and date the Special Meeting Request on the page preceding this Instruction Sheet, and complete the following steps:

1. Arrange for the DTC participant holding your shares of Company Common Stock to:

 

    fill out a DTC Instruction Letter and Cede & Co. Meeting Request with respect to your shares (in the forms attached as Exhibits B-1 and B-2 to the Solicitation Statement),

 

    sign and date the DTC Instruction Letter and deliver it (along with the filled out Cede & Co. Meeting Request) to DTC,

 

    once Cede & Co. executes the Cede & Co. Meeting Request, have it delivered back to you and

 

    complete, sign and date a Verification Letter with respect to your shares (in the form attached as Exhibit C to the Solicitation Statement) and deliver it to you.

2. Submit the following items to D.F. King & Co., Inc. (“D.F. King & Co.”), proxy solicitor for PS Fund 1, at 48 Wall Street, New York, NY 10005, Toll-free: (800) 859-8511:

 

    this signed and dated Special Meeting Request with Attachment A and Appendix 1 completed,

 

    the completed, signed and dated Cede & Co. Meeting Request received as discussed above,

 

    the completed, signed and dated Verification Letter received as discussed above,

 

    a photocopy of a stock certificate (or a statement of ownership from the Company’s transfer agent, Wells Fargo Bank Shareholder Services) showing you are a stockholder of record (on the books of the Company’s transfer agent) of at least one share of Company Common Stock 3 and

 

    a completed, signed and dated WHITE Proxy Card in the form attached as Exhibit D to the Solicitation Statement.

D.F. King & Co. will gather all such documents and coordinate the submission of such materials on behalf of Proposing Persons to the Company.

If you have questions on how to fill out this Special Meeting Request or how to answer any of the questions in Attachment A or Appendix 1 below, please contact either of the individuals listed below:

Edward McCarthy

D.F. King & Co., Inc.

(212) 269-5550

emccarthy@dfking.com

Richard Brand

Kirkland & Ellis LLP

(212) 446-6454

richard.brand@kirkland.com

 

3   If you are not already a stockholder of record and want to submit a Special Meeting Request, you must first arrange (through transfer or purchase) to become a stockholder of record of at least one share of Company Common Stock. If you need assistance in doing that, please contact Edward McCarthy at D.F. King & Co., (212) 269-5550, emccarthy@dfking.com

 

4


ATTACHMENT A

PROPOSING PERSON INFORMATION

ALLERGAN, INC. PROPOSING PERSON INFORMATION

TO BE DELIVERED AS PART OF A SPECIAL MEETING REQUEST

 

1. The name and address of each person or entity included in the Proposing Person is set forth below. 4

(Please make sure that the Proposing Person signing this Special Meeting Request includes a stockholder of record of at least one share of Company Common Stock and that the name and address you use for that shareholder below is exactly as the name and address appears on the books of the transfer agent, Wells Fargo Bank Shareholder Services.)

In addition, the Proposing Person notes that shares of Company Common Stock held beneficially but not of record by the Proposing Person are held by Cede & Co., c/o DTC – Transfer Operation Dept, 570 Washington Blvd FL 1, Jersey City 08857.

 

2. The number of shares of Company Common Stock owned beneficially and of record by the Proposing Person is set forth below.

(Include for this purpose any shares you have a right to acquire, whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both.)

The Proposing Person beneficially owns                 shares of Company Common Stock and owns of record                 shares of Company Common Stock (collectively, the “ Subject Shares ”).

 

3. The Net Long Beneficial Ownership of the Proposing Person is shares of Company Common Stock.

The Bylaws define “ Net Long Beneficial Ownership ” as those shares of Company Common Stock of the Company as to which the Proposing Person possesses (i) the sole power to vote or direct the voting, (ii) the sole economic incidents of ownership (including the sole right to profits and the sole risk of loss), and (iii) the sole power to dispose of or direct the disposition.

The definition of Net Long Beneficial Ownership does not include any Synthetic Equity Position (as defined in Item 5 below); however, shares underlying derivatives would normally not be included in the calculation of Net Long Beneficial Ownership in any event because clauses (i) and (iii) above would normally not be satisfied with respect to shares underlying derivatives and thus this exclusion will normally not be relevant even if the Proposing Person owns derivatives.

 

4. The following is a description of any agreements, arrangements or understandings with respect to or in connection with the Proposals or the Special Meeting Request between or among the Proposing Person signing this Special Meeting Request and any other Proposing Persons, record holders or beneficial owners of shares of Company Common Stock or Group Nominees named in the Solicitation Statement:

 

5. Disclosable Interests of the Proposing Person:

 

  (i) State the full notional amount of any securities that, directly or indirectly, underlie any “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a “call equivalent position” (as such term is defined in Rule 16a-1(b) under the Exchange Act) (“ Synthetic Equity Position ”) and that is, directly or indirectly, held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Company. For purposes of this Special Meeting Request, “ Exchange Act ” means the Securities Exchange Act of 1934, as amended.

Note that, for purposes of the definition of Synthetic Equity Position, the term “ derivative security ” also includes any security or instrument that would not otherwise constitute a “derivative security” as a result of any feature that would make any conversion, exercise or similar right or privilege of such

 

4   In this Attachment A, references to the Proposing Person are, where the context requires, references to each person or entity included within the Proposing Person.

 

5


security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable will be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination.

In addition, note that if the Proposing Person satisfies the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than solely by reason of Rule 13d-1(b)(1)(ii)(E)), the Proposing Person will not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic Equity Position held by the Proposing Person as a hedge with respect to a bona fide derivatives trade or position of the Proposing Person arising in the ordinary course of the Proposing Person’s business as a derivatives dealer.

Full notional amount computed as described above:

 

  (ii) State any rights to dividends on the shares of Company Common Stock owned beneficially by the Proposing Person that are separated or separable from the underlying shares:

 

  (iii) State any material pending or threatened action, suit or proceeding (whether civil, criminal, investigative, administrative or otherwise) in which the Proposing Person is, or is reasonably expected to be made, a party or material participant involving the Company or any of its officers, directors or employees, or any affiliate of the Company, or any officer, director or employee of such affiliate:

 

  (iv) State any other material relationship between the Proposing Person, on the one hand, and the Company, any affiliate of the Company, any officer, director or employee of the Company or any affiliate thereof, or any principal competitor of the Company, on the other hand.

Principal competitors of the Company would include, without limitation: Akorn, Inc., Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Genentech/Hoffman La Roche AG, Merck & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Seiyaku, US WorldMeds, Ipsen Ltd., Galderma, a joint venture between Nestle and L’Oréal Group, Syntaxin, Merz, Q-Med, Anteis, Filorago, Teoxane, Stiefel Laboratories, Inc., a division of GlaxoSmithKline, Novartis AG, L’Oréal Group, Pfizer Inc., Actavis Inc., Warner Chilcott, Astellas Pharma US, Inc., Mentor, Sientra, Inc., Silimed, Eurosilicone, Nagor, Polytech and several Chinese breast implant manufacturers (and, in each case, subsidiaries of any of the foregoing).

 

  (v) State any direct or indirect material interest in any material contract or agreement of the Proposing Person with the Company, any affiliate of the Company or any principal competitor of the Company (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement).

See (iv) above for a listing of the principal competitors of the Company.

 

  (vi) State the Proposing Person’s present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is carried on.

 

  (vii) State whether or not, during the past ten years, the Proposing Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and, if so, give dates, nature of conviction, name and location of court, and penalty imposed or other disposition of the case. A negative answer need not be included.

 

  (viii) State the amount of each class of securities of the Company which the Proposing Person owns beneficially, directly or indirectly.

 

  (ix) State the amount of each class of securities of the Company (if any) which the Proposing Person owns of record but not beneficially.

 

  (x) Appendix 1 (which is incorporated herein by reference as if set forth in full herein) sets forth information with respect to all securities of the Company purchased or sold by the Proposing Person within the past two years.

 

6


  (xi) If any part of the purchase price or market value of any of the shares referred to in Appendix 1 is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities, so state and indicate the amount of the indebtedness as of the latest practicable date. If such funds were borrowed or obtained otherwise than pursuant to a margin account or bank loan in the regular course of business of a bank, broker or dealer, briefly describe the transaction, and state the names of the parties.

 

  (xii) State whether or not the Proposing Person is, or was within the past year, a party to any contract, arrangements or understandings with any person with respect to any securities of the Company, including, but not limited to joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies. If so, name the parties to such contracts, arrangements or understandings and give the details thereof.

 

  (xiii) State the amount of securities of the Company owned beneficially, directly or indirectly, by each of the Proposing Person’s associates and the name and address of each such associate. For purposes of this Special Meeting Request, “ associate ” means (a) any corporation or organization of which any the Proposing Person (or any person or entity within the Proposing Person) is an officer or partner or is, directly or indirectly, the beneficial owner of 10 percent or more of any class of equity securities, (b) any trust or other estate in which the Proposing Person (or any person or entity within the Proposing Person) has a substantial beneficial interest or as to which the Proposing Person (or any person or entity within the Proposing Person) serves as trustee or in a similar fiduciary capacity, and (c) any relative or spouse of the Proposing Person (or any person or entity within the Proposing Person), or any relative of such spouse, who has the same home as the Proposing Person (or any person or entity within the Proposing Person) or who is a director or officer of the Company or any of its parents or subsidiaries.

 

  (xiv) State the amount of each class of securities of any subsidiary of the Company which the Proposing Person owns beneficially, directly or indirectly.

 

  (xv) Describe any transaction, since January 1, 2013, or any currently proposed transaction, in which the Company was or is to be a participant and the amount involved exceeds $120,000, and in which the Proposing Person or any of its associates had or will have a direct or indirect material interest. If there are any such transactions, disclose the information that would be required by Item 404(a) of Regulation S-K under the Exchange Act with respect to those transactions.

 

  (xvi) State whether or not the Proposing Person or any associates of the Proposing Person have any arrangement or understanding with any person –

(A) with respect to any future employment by the Company or its affiliates; or

(B) with respect to any future transactions to which the Company or any of its affiliates will or may be a party.

If so, describe such arrangement or understanding and state the names of the parties thereto.

 

  (xvii) Describe briefly any substantial interest, direct or indirect, by security holdings or otherwise, of the Proposing Person in any matter to be acted upon at the Special Meeting to the extent not already disclosed elsewhere herein.

Important: To assure this Special Meeting Request remains valid, you must update and supplement the information contained herein, if necessary, so that the information provided or required to be provided herein is true and correct as of the record date for notice of the Special Meeting and as of the date that is ten business days prior to the Special Meeting or any adjournment or postponement thereof . Please make sure that you deliver any required update or supplement to D.F. King & Co. as soon as possible, and in any event in time so that D.F. King & Co. can deliver it to the Company not later than five business days after the record date for notice of the Special Meeting (in the case of the update and supplement required to be made as of such record date) and not later than eight business days prior to the date for the Special Meeting (in the case of the update and supplement required to be made as of the date of the Special Meeting).

 

7


APPENDIX 1

PURCHASES AND SALES OF COMPANY SECURITIES BY THE PROPOSING PERSON

The following is a summary of all purchases and sales of Company securities by the Proposing Person over the last two years.

 

Trade Date

   Buy/Sell    Quantity    Security
        
        
        

 

8


EXHIBIT B-1

DTC INSTRUCTION LETTER

REQUEST TO CALL A SPECIAL MEETING

[Participant Letterhead]

Date:                     

The Depository Trust Company

55 Water Street

New York, NY 10041

Attn: Proxy Department

 

  RE: Allergan, Inc. Common Stock, $0.01 Par Value (CUSIP number 018490102) (DTC Participant account number:             )

Gentlemen:

Please cause your nominee, Cede & Co., to sign the attached written request to call a special meeting of shareholders (the “Cede & Co. Meeting Request”), with respect to                 shares of the above-referenced securities credited to our DTC Participant account at             , 2014.

In addition to acknowledging that this request is subject to the indemnification provided for in DTC Rule 6, the undersigned certifies to DTC and Cede & Co. that the information and facts set forth in the attached Cede & Co. Meeting Request are true and correct, including the following:

 

  1. The number of shares credited to our DTC Participant account that are beneficially owned by our customer.

 

  2. There have been no prior requests to DTC and Cede & Co. for the execution of a request similar to the attached Cede & Co. Meeting Request with respect to the shares referred to herein credited to our DTC participant for such customer; and

 

  3. The purposes for the call of the special meeting are as stated in the attached Cede & Co. Meeting Request.

Please make the Cede & Co. Meeting Request available for pick-up by our contact              or Federal Express to (contact:            ). Our Federal Express account number is            .


EXHIBIT B-1

 

Very truly yours,
PARTICIPANT NAME:

 

By:  

 

  (manual signature of authorized person)
Name:  

 

Title:  

 

Medallion Stamp


EXHIBIT B-2

CEDE & CO. MEETING REQUEST

Cede & Co.

c/o The Depository Trust Company

55 Water Street

New York, NY 10041

Date                    

Allergan, Inc.

2525 Dupont Drive

Irvine, CA 92612

Attn: Corporate Secretary

Cede & Co., the nominee of The Depository Trust Company (“DTC”), is a holder of record of shares of common stock of Allergan, Inc. (the “Company”). DTC is informed by its Participant,                     (the “Participant”), that on the date hereof                      of such shares (the “Shares”) credited to Participant’s DTC account are beneficially owned by                     , a customer of Participant.

At the request of Participant, on behalf of                     , a customer of Participant, Cede & Co., as a holder of record of the Shares, hereby requests that you call a special meeting of the shareholders of the Company (the “Special Meeting”) for the purposes of considering and voting upon the resolutions set forth in full under “Plans for the Special Meeting” in the solicitation statement filed by PS Fund 1, LLC on July 11, 2014, which resolutions are incorporated herein by reference as if set forth in full herein.

The undersigned further requests that the Special Meeting be held as soon as possible, and in any event within 45 days, after Special Meeting Requests from the holders of at least 25% of the outstanding shares of common stock of the Company are delivered to the Company’s Secretary.

While Cede & Co. is furnishing this request as the shareholder of record of the Shares, it does so only at the request of Participant and only as a nominee for the true party in interest,                     , a customer of Participant. Cede & Co., has no interest in this matter other than to take those steps which are necessary to ensure that                     , a customer of the Participant, is not denied its rights as the beneficial owner of the Shares, and Cede & Co. assumes no further responsibility in this matter.

 

      Very truly yours,
      Cede & Co
Dated:  

 

    BY:  

 


EXHIBIT C

VERIFICATION LETTER

[BROKERAGE FIRM, BANK NOMINEE OR

OTHER INSTITUTION LETTERHEAD]

[Month] [Day], 2014

To whom it may concern:

This is to confirm that [Brokerage Firm, Bank Nominee or Other Institution] (the “DTC Participant”) currently serves as a Custodian for [Investor Name]. As is typical of a custodian relationship, [Investor Name] can terminate its relationship with [Name of Brokerage Firm, Bank Nominee or other Institution] at any time or appoint other custodians.

As of [Month] [Day], 2014, [Investor Name] held [Number of Shares] shares of Allergan Inc. (CUSIP 018490102) in record name as Cede & Co. through one or more of [DTC Participant’s Name]’s Depository Trust Company account(s).

Please feel free to contact me should you have any questions.

Sincerely,

[Representative Name]

[Name of Brokerage Firm, Bank Nominee or Other Institution]

This letter is specifically limited to the information provided herein relating to each of [Investor Name]’s accounts with [Name of Brokerage Firm, Bank Nominee or Other Institution] as of the date specified. The Investor may also be involved in other transactions with [Name of Brokerage Firm, Bank Nominee or Other Institution] outside of this relationship. The information contained above is provided in good faith by [Name of Brokerage Firm, Bank Nominee or Other Institution] for informational purposes only.

The data presented is static and does not take into account unsettled trades or other client activity that could affect balance information on a particular date. This information does not reflect any securities our client may have at other broker/dealers. Vendor pricing feeds used to aggregate the account value could contain errors that would affect the overall computation of a client’s balance. [Name of Brokerage Firm, Bank Nominee or Other Institution] shall not be held liable for any decisions, transactions, or other business undertaken in reliance of this information.


EXHIBIT D

WHITE PROXY CARD

WHITE PROXY CARD

THIS PROXY IS BEING SOLICITED BY THE REQUESTING SHAREHOLDER AND NOT

BY ALLERGAN OR THE BOARD OF DIRECTORS OF ALLERGAN

Please sign and date your WHITE proxy card and return it in the postage-paid envelope provided or return it to:

D.F. King & Co., Inc.

48 Wall Street, 22 nd Floor

New York, NY 10005

Attn: Gordon Algernon


WHITE PROXY CARD

ALLERGAN, INC.

SOLICITATION OF WRITTEN REQUEST FOR SPECIAL MEETING

IN CONNECTION WITH THE

CALLING OF A SPECIAL MEETING OF SHAREHOLDERS

THIS PROXY IS SOLICITED ON BEHALF OF PS FUND 1, LLC.

THE BOARD OF DIRECTORS OF ALLERGAN, INC. IS NOT SOLICITING THIS PROXY

 

x PLEASE MARK AS IN THIS EXAMPLE.

 

¨ The undersigned Proposing Person (as defined in the attached Special Meeting Request) hereby appoints PS Fund 1, LLC proxy, with full power of substitution, to submit the attached Special Meeting Request, along with the related Cede & Co. Meeting Request, Verification Letter and proof of record ownership as contemplated by the Special Meeting Request, to the Company’s Secretary on behalf of the undersigned Proposing Person.

Proposing Person:

[insert same signature blocks for the Proposing Person that are used in the Special Meeting Request]

Date:                    


EXHIBIT F-1

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ Betsy Atkins

Name:   Betsy Atkins

July 6, 2014


EXHIBIT F-2

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ Cathleen P. Black

Name:   Cathleen P. Black

July 6, 2014


EXHIBIT F-3

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ Fredric N. Eshelman

Name:   Fredric N. Eshelman

July 6, 2014


EXHIBIT F-4

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ Steven J. Shulman

Name:   Steven J. Shulman

July 6, 2014


EXHIBIT F-5

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ David A. Wilson

Name:   David A. Wilson

July 6, 2014


EXHIBIT F-6

CONSENT

I hereby consent (i) to be named in the Solicitation Statement filed by PS Fund 1, LLC on July 7, 2014, and in all amendments or supplements thereto, as a nominee for director of Allergan, Inc., a Delaware corporation, and to all references to me in such capacity, and (ii) to serve as a director of Allergan, Inc. if appointed or elected.

 

/s/ John J. Zillmer

Name:   John J. Zillmer

July 6, 2014


LOGO

ADVANCING ALLERGAN
Home
Webcast
Nominees
Shareholder Materials
News Releases
Proposed By-Laws
Media Contacts
July 11, 2014
PERSHING SQUARE FILES DEFINITIVE SOLICITATION STATEMENT
July 7, 2014
Pershing Square Announces Director Slate For Allergan Board
June 27, 2014
Pershing Square enters into a settlement with Allergan
June 19, 2014
Delaware Court of Chancery rules in favor of expediting Pershing Square’s request
June 12, 2014
Pershing Square seeks clarification on Allergan poison pill in court.
June 11, 2014
Allergan responds to PSCM letter
June 6, 2014
PSCM seeks clarification from Allergan
June 2, 2014
Pershing Square seeks to hold a special shareholder meeting
May 19, 2014
Pershing Square urges Allergan to hire independent counsel
April 22, 2014
Valeant and Pershing Square announce partnership to acquire Allergan
© 2014 Pershing Square Capital Management


EXHIBIT E

ALLERGAN, INC.

a Delaware Corporation

AMENDED AND RESTATED BYLAWS 1

(As Amended and Restated Effective             , 2014)

ARTICLE I: Offices

SECTION 1. Registered Office. The registered office of Allergan, Inc. (the “Corporation”) shall be at The Prentice-Hall Corporation System, Inc., 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, State of Delaware 19808, and the name of the registered agent in charge thereof shall be The Prentice-Hall Corporation System, Inc.

SECTION 2. Principal Office. The principal office for the transaction of the business of the Corporation shall be at such place as the Board of Directors of the Corporation (the “Board”) may determine. The Board is hereby granted full power and authority to change said principal office from one location to another.

SECTION 3. Other Offices. The Corporation may also have an office or offices at such other place or places, either within or without the State of Delaware, as the Board may from time to time determine or as the business of the Corporation may require.

ARTICLE II: Meetings of Stockholders

SECTION 1. Place of Meetings. All annual meetings of stockholders and all other meetings of stockholders shall be held either at the principal office of the Corporation or at any other place within or without the State of Delaware that may be designated by the Board pursuant to authority hereinafter granted to the Board.

SECTION 2. Annual Meetings. Annual meetings of stockholders of the Corporation for the purpose of electing directors and for the transaction of such other proper business as may come before such meetings may be held at such time and place and on such date as the Board shall determine by resolution.

SECTION 3. Special Meetings.

Section 3. (A) Special meetings of the stockholders of the Corporation (i) may be called by the Chairman of the Board, the Chief Executive Officer or the Board, at any time and for any purpose or purposes, and (ii) shall be called by the Secretary upon the written request of the holders of record of at least twenty-five percent (25%) of the outstanding shares of common stock of the Corporation (the “Requisite Percentage”), subject to and in compliance with Article 10 of the Amended and Restated Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Restated Certificate of Incorporation”), or any successor provision thereto , and this Section 3 . Any special meeting of stockholders of the Corporation shall be held at such place, date and hour as may be fixed by the Board in compliance with applicable law; provided, however , that in the case of a meeting called pursuant to clause (ii) of the preceding sentence, the place, date and hour shall be as specified in the written request described in that clause (and in accordance with applicable law) and the Secretary shall mail the notice of such meeting to stockholders (specifying such place, date , and hour) as provided in Section 4 of this Article II (and the date of such meeting shall be publicly announced) no later than five business days after the date of receipt of such written request.

(A) In order for a special meeting to be called upon stockholder request (“Stockholder Requested Special Meeting”), one or more requests for a special meeting (each, a “Special Meeting Request” and, collectively, the “Special Meeting Requests”), in the form required by this section (A) of this Section 3, must be signed by Proposing Persons (as defined below) that have a combined Net Long Beneficial Ownership (as defined below) of at least the Requisite Percentage. Only Proposing Persons who are stockholders of record at the time the

 

1   In this Exhibit E, language struck through illustrates deletions from and underlined language illustrates additions to the current Bylaws.


Special Meeting Requests representing the Requisite Percentage are validly delivered pursuant to this Section 3 shall be entitled to sign a Special Meeting Request. In determining whether a Stockholder Requested Special Meeting has been properly requested by Proposing Persons that have a combined Net Long Beneficial Ownership of at least the Requisite Percentage, multiple Special Meeting Requests delivered to the Secretary will be considered together only if (i) each Special Meeting Request identifies the same purpose or purposes of the Stockholder Requested Special Meeting and the same matters proposed to be acted on at such meeting (in each case as determined in good faith by the Board), and (ii) such Special Meeting Requests have been dated and delivered to the Secretary within sixty (60) days of the earliest dated Special Meeting Request. To be in proper form, such Special Meeting Request(s) shall comply with, and shall include and set forth, the following:

(1) As to each Proposing Person, (a) the name and address of each Proposing Person (including, if applicable, the name and address as they appear on the Corporation’s books), (b) the class and number of shares of the Corporation which are owned beneficially and of record by such Proposing Person (with evidence of such ownership attached), except that such Proposing Person shall be deemed for such purpose to beneficially own any shares of any class or series of capital stock of the Corporation as to which such Proposing Person has the right to acquire (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both), (c) a representation that such Proposing Person intends to hold the shares of the Corporation described in the immediately preceding clause (b) through the date of the Stockholder Requested Special Meeting and (d) an acknowledgement by the Proposing Person that any reduction in such Proposing Person’s Net Long Beneficial Ownership with respect to which a Special Meeting Request relates following the delivery of such Special Meeting Request to the Secretary shall constitute a revocation of such Special Meeting Request to the extent of such reduction;

(2) As to each Proposing Person, any Disclosable Interests (as defined below) of such Proposing Person;

(3) As to the purpose or purposes of the Stockholder Requested Special Meeting, a reasonably brief statement of the specific purpose or purposes of the Stockholder Requested Special Meeting, the matter(s) proposed to be acted on at the Stockholder Requested Special Meeting and the reasons for conducting such business at the Stockholder Requested Special Meeting, and the text of any proposal or business to be considered at the Stockholder Requested Special Meeting (including the text of any resolutions proposed to be considered and, in the event that such business includes a proposal to amend the Bylaws, the language of the proposed amendment); and

(4) Such other information and representations as would be required by Article 12 of the Restated Certificate of Incorporation and Section 9 of Article II of these Bylaws if incorporated in this Section 3, including, without limitation, all such information regarding any material interest of the Proposing Person in the matter(s) proposed to be acted on at the Stockholder Requested Special Meeting, all agreements, arrangements or understandings between or among any Proposing Person and any other record holder or beneficial owner of shares of any class or series of capital stock of the Corporation in connection with the Special Meeting Record Date Request, the Special Meeting Request, or the matter(s) proposed to be brought before the Stockholder Requested Special Meeting.

(5) Definitions.

(a) “Proposing Person” shall mean (i) each stockholder of record that signs a Special Meeting Request pursuant section (A) of this Section 3, (ii) the beneficial owner or beneficial owners, if different, on whose behalf such Special Meeting Request is made, (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation or associate (within the meaning of Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for purposes of these Bylaws) of such stockholder or beneficial owner, and (iv) any other person with whom such stockholder or such beneficial owner (or any of their respective associates or other participants in such solicitation) is Acting in Concert.

 

2


(b) A person shall be deemed to be “Acting in Concert” with another person for purposes of these Bylaws if such person knowingly acts (whether or not pursuant to an express agreement, arrangement or understanding) in concert or in parallel with, or towards a common goal with such other person, relating to changing or influencing the control of the Corporation or in connection with or as a participant in any transaction having that purpose or effect, where (i) each person is conscious of the other person’s conduct and this awareness is an element in their decision-making processes and (ii) at least one additional factor suggests that such persons intend to act in concert or in parallel, which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions, or making or soliciting invitations to act in concert or in parallel; provided, that a person shall not be deemed to be Acting in Concert with any other person solely as a result of the solicitation or receipt of (x) revocable proxies or consents from such other person in response to a solicitation made pursuant to, and in accordance with, Section 14(a) of the Exchange Act by way of a proxy or consent solicitation statement filed on Schedule 14A or (y) tenders of securities from such other person in a public tender or exchange offer made pursuant to, and in accordance with, Section 14(d) of the Exchange Act by means of a tender offer statement filed on Schedule TO. A person Acting in Concert with another person shall be deemed to be Acting in Concert with any third party who is also Acting in Concert with such other person.

(c) “Net Long Beneficial Ownership” shall mean those shares of common stock of the Corporation as to which the stockholder or Proposing Person, as applicable, possesses (i) the sole power to vote or direct the voting, (ii) the sole economic incidents of ownership (including the sole right to profits and the sole risk of loss), and (iii) the sole power to dispose of or direct the disposition; provided that the number of shares calculated in accordance with clauses (i), (ii) and (iii) shall not include any Synthetic Equity Position.

(d) “Disclosable Interests” shall mean (i) the full notional amount of any securities that, directly or indirectly, underlie any “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a “call equivalent position” (as such term is defined in Rule 16a-1(b) under the Exchange Act) (“Synthetic Equity Position”) and that is, directly or indirectly, held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Corporation; provided that, for the purposes of the definition of “Synthetic Equity Position,” the term “derivative security” shall also include any security or instrument that would not otherwise constitute a “derivative security” as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination; and, provided, further, that any Proposing Person satisfying the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than a Proposing Person that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely by reason of Rule 13d-1(b)(1)(ii)(E)) shall not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic Equity Position held by such Proposing Person as a hedge with respect to a bona fide derivatives trade or position of such Proposing Person arising in the ordinary course of such Proposing Person’s business as a derivatives dealer, (ii) any rights to dividends on the shares of any class or series of capital stock of the Corporation owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, (iii) any material pending or threatened action, suit or proceeding (whether civil, criminal, investigative, administrative or otherwise) in which such Proposing Person is, or is reasonably expected to be made, a party or material participant involving the Corporation or any of its officers, directors or employees, or any affiliate of the Corporation, or any officer, director or employee of such affiliate, (iv) any other material relationship between such Proposing Person, on the one hand, and the Corporation, any affiliate of the Corporation, any officer, director or employee of the Corporation or any affiliate thereof, or any principal competitor of the Corporation, on the other hand, (v) any direct or indirect material interest in any material contract or agreement of such Proposing Person with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement) and (vi) any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with

 

3


solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting; provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the Special Meeting Record Date Request or Special Meeting Request required by Article 10 of the Restated Certificate of Incorporation or these Bylaws on behalf of a beneficial owner.

(B) Notwithstanding anything to the contrary in this Section 3:

(1) The Secretary shall not accept, and shall consider ineffective, a Special Meeting Request if (a) such Special Meeting Request does not comply with Article 10 of the Restated Certificate of Incorporation, these Bylaws, or relates to an item of business that is not a proper subject for stockholder action under applicable law, (b) the Special Meeting Request is received by the Corporation during the period commencing ninety (90) days prior to the first anniversary of the date of the immediately preceding annual meeting of stockholders and ending on the date of the final adjournment of the next annual meeting of stockholders, (c) an identical or substantially similar item (a “Similar Item”) to that included in the Special Meeting Request was presented at any meeting of stockholders held within one year prior to receipt by the Corporation of such Special Meeting Request, (d) the Board calls an annual or special meeting of stockholders (in lieu of calling the Stockholder Requested Special Meeting) in accordance with section (B)(3) of this Section 3, (e) a Similar Item is already included in the Corporation’s notice as an item of business to be brought before a meeting of the stockholders that has been called but not yet held, or (f) such Special Meeting Request was made in a manner that involved a violation of Regulation 14A under the Exchange Act, or other applicable law.

(2) Business transacted at any Stockholder Requested Special Meeting shall be limited to the purpose stated in the valid Special Meeting Request; provided, however, that nothing herein shall prohibit the Board from submitting matters to the stockholders at any Stockholder Requested Special Meeting. If none of the Proposing Persons who submitted the Special Meeting Request appears at or sends a qualified representative to the Stockholder Requested Special Meeting to present the matters to be presented for consideration that were specified in the Stockholder Meeting Request, the Corporation need not present such matters for a vote at such meeting. A “qualified representative” of a Proposing Person shall be, if such Proposing Person is (a) a general or limited partnership, any general partner or person who functions as a general partner of the general or limited partnership or who controls the general or limited partnership, (b) a corporation, a duly appointed officer of the corporation, (c) a limited liability company, any manager or officer (or person who functions as an officer) of the limited liability company or any officer, director, manager or person who functions as an officer, director or manager of any entity ultimately in control of the limited liability company or (d) a trust, any trustee of such trust.

(3) If a Special Meeting Request is made that complies with this Section 3 and Article 10 of the Restated Certificate of Incorporation, the Board may (in lieu of calling the Stockholder Requested Special Meeting) present a Similar Item for stockholder approval at any other meeting of stockholders that is held within one hundred twenty (120) days after the Corporation receives such Special Meeting Request.

(4) Any Proposing Person may revoke a Special Meeting Request by written revocation delivered to, or mailed and received by, the Secretary at any time prior to the date of the Stockholder Requested Special Meeting. In the event any revocation(s) are received by the Secretary after the Secretary’s receipt of a valid Special Meeting Request(s) from the holders of the Requisite Percentage of stockholders or any Special Meeting Request is deemed to be revoked as a result of section (A)(1)(d) of this Section 3, and as a result of such revocation(s), there no longer are valid unrevoked Special Meeting Request(s) from the Requisite Percentage of stockholders to call a special meeting, the Board shall have the discretion to determine whether or not to proceed with the Stockholder Requested Special Meeting.

(5) Notwithstanding anything in these Bylaws to the contrary, the Secretary shall not be required to call a special meeting except in accordance with Article 10 of the Restated Certificate of Incorporation and this

 

4


Section 3. If the Board shall determine that any Special Meeting Request was not properly made in accordance with Article 10 of the Restated Certificate of Incorporation or these Bylaws, or shall determine that the stockholder or stockholders submitting such Special Meeting Request have not otherwise complied with Article 10 of the Restated Certificate of Incorporation or these Bylaws, then the Board shall not be required to take any action in connection with the Stockholder Requested Special Meeting, and the Secretary shall not be required to call such meeting. In addition to the requirements of this Section 3, each Proposing Person shall comply with all requirements of applicable law, including all requirements of the Exchange Act, with respect to any request to fix a Special Meeting Request.

(C) In connection with a Stockholder Requested Special Meeting called in accordance with this Section 3, each Proposing Person that signed and delivered a Special Meeting Request shall further update and supplement the information previously provided to the Corporation in connection with such request, if necessary, so that the information provided or required to be provided in such request pursuant to this Section 3 shall be true and correct as of the record date for notice of the Stockholder Requested Special Meeting and as of the date that is ten (10) business days prior to the Stockholder Requested Special Meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for notice of the special meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8) business days prior to the date for the special meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the special meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the Stockholder Requested Special Meeting or any adjournment or postponement thereof). As used herein, the term “business day” shall mean any day that is not a Saturday or Sunday or a day on which banks in the city of the Corporation’s principal place of business are required or permitted to close.

(D) (B) Any special meeting of stockholders, including any Stockholder Requested Special Meeting, shall be held at such date and time as may be fixed by the Board in accordance with these Bylaws and in compliance with applicable law. The Chief Executive Officer or Secretary shall, within five business days after the earlier of (i) the first date on which the Corporation shall have no directors in office and (ii) the date on which the Court of Chancery issues an order requiring the Corporation to hold an election pursuant to Section 223 of the General Corporation Law of the State of Delaware, call a special meeting of stockholders of the Corporation for the election of directors and mail notice of such meeting as provided in Section 4 of this Article II. Any special meeting of stockholders of the Corporation so called shall be held at the place, date and hour specified in the notice of such meeting and in accordance with applicable law (or, in the case of an election ordered by the Court of Chancery, at such other place, date and hour as may be specified by the Court of Chancery).

SECTION 4. Notice of Meetings. Except as otherwise required by law, notice of each meeting of stockholders, whether annual or special, shall be given not less than ten (10) days nor more than sixty (60) days before the date of the meeting to each stockholder of record entitled to vote at such meeting by delivering a typewritten or printed notice thereof to such stockholder personally, or by depositing such notice in the United States mail, in a postage prepaid envelope, directed to such stockholder at such stockholder’s post office address furnished by such stockholder to the Secretary of the Corporation for such purpose, or, if such stockholder shall not have furnished an address to the Secretary for such purpose, then at such stockholder’s post office address last known to the Secretary, or by transmitting a notice thereof to such stockholder at such address by electronic transmission in accordance with Section 232 of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”). Except as otherwise expressly required by law, no publication of any notice of a meeting of stockholders shall be required. Every notice of a meeting of stockholders shall state the place, date and hour of the meeting and, in the case of a special meeting, shall also state the purpose for which the meeting is called. Notice of any meeting of stockholders shall not be required to be given to any stockholder to whom notice may be omitted pursuant to applicable law or who shall have waived such notice, and such notice shall be deemed waived by any stockholder who shall attend such meeting in person or by proxy, except a stockholder who shall attend such meeting for the express purpose of objecting, at the beginning of the meeting,

 

5


to the transaction of any business because the meeting is not lawfully called or convened. Except as otherwise expressly required by law, notice of any adjourned meeting of stockholders need not be given if the time and place thereof are announced at the meeting at which the adjournment is taken.

SECTION 5. Quorum. Except as otherwise required by law, the holders of record of a majority in voting interest of the shares of stock of the Corporation entitled to be voted thereat, present in person or by proxy, shall constitute a quorum for the transaction of business at any meeting of stockholders of the Corporation or any adjournment thereof. Subject to the requirement of a larger percentage vote contained in the Restated Certificate of Incorporation, these Amended and Restated Bylaws (these “Bylaws”) or by statute, the stockholders present at a duly called or held meeting at which a quorum is present may continue to do business until adjournment, notwithstanding any withdrawal of stockholders that may leave less than a quorum remaining, if any action taken (other than adjournment) is approved by at least a majority of the shares required to constitute a quorum. In the absence of a quorum at any meeting or any adjournment thereof, a majority in voting interest of the stockholders present in person or by proxy and entitled to vote thereat or, in the absence therefrom of all the stockholders, any officer entitled to preside at, or to act as secretary of, such meeting may adjourn such meeting from time to time. At any such adjourned meeting at which a quorum is present, any business may be transacted that might have been transacted at the meeting as originally called.

SECTION 6. Voting.

Each stockholder shall, at each meeting of stockholders, be entitled to vote in person or by proxy each share of stock of the Corporation that has voting rights on the matter in question and that shall have been held by such stockholder and registered in such stockholder’s name on the books of the Corporation:

(A) on the date fixed pursuant to Article VI, Section 5 of these Bylaws as the record date for the determination of stockholders entitled to notice of and to vote at such meeting; or

(B) if no such record date shall have been so fixed, then (i) at the close of business on the day immediately preceding the day upon which notice of the meeting shall be given or (ii) if notice of the meeting shall be waived, at the close of business on the day immediately preceding the day upon which the meeting shall be held. Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors in such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum purposes. Persons holding stock of the Corporation in a fiduciary capacity shall be entitled to vote such stock. Persons whose stock is pledged shall be entitled to vote, unless in the transfer by the pledgor on the books of the Corporation the pledgor shall have expressly empowered the pledgee to vote thereon, in which case only the pledgee, or the pledgee’s proxy, may represent such stock and vote thereon. Stock having voting power standing of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety or otherwise, or with respect to which two (2) or more persons have the same fiduciary relationship, shall be voted in accordance with the provisions of the Delaware General Corporation Law.

Any such voting rights may be exercised by the stockholder entitled thereto in person or by such stockholder’s proxy appointed by an instrument in writing (or in such manner prescribed by the Delaware General Corporation Law) by such stockholder or by such stockholder’s attorney thereunto authorized and delivered to the secretary of the meeting; provided, however, that no proxy shall be voted or acted upon after three (3) years from its date unless said proxy shall provide for a longer period. The attendance at any meeting of a stockholder who may theretofore have given a proxy shall not have the effect of revoking the same unless such stockholder shall in writing so notify the secretary of the meeting prior to the voting of the proxy. At any meeting of stockholders, all matters, except as otherwise provided in the Restated Certificate of Incorporation, in these Bylaws or by law, shall be decided by the vote of a majority in voting interest of the stockholders present in person or by proxy and entitled to vote thereat and thereon, a quorum being present. The vote at any meeting of stockholders on any question need not be by ballot, unless so directed by the chairman of the meeting. On a vote by ballot, each ballot shall be signed by the stockholder voting, or by such stockholder’s proxy, if there be such proxy, and it shall state the number of shares voted.

 

6


SECTION 7. List of Stockholders. The Secretary of the Corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of such stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, in such manner as prescribed by the Delaware General Corporation Law. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

SECTION 8. Judges. If at any meeting of stockholders a vote by written ballot shall be taken on any question, the chairman of such meeting may appoint a judge or judges to act with respect to such vote. Each judge so appointed shall first subscribe an oath faithfully to execute the duties of a judge at such meeting with strict impartiality and according to the best of such judge’s ability. Such judges shall decide upon the qualification of the voters and shall report the number of shares represented at the meeting and entitled to vote on such question, shall conduct and accept the votes, and, when the voting is completed, shall ascertain and report the number of shares voted respectively for and against the question. Reports of judges shall be in writing and subscribed and delivered by them to the Secretary of the Corporation. The judges need not be stockholders of the Corporation, and any officer of the Corporation may be a judge on any question other than a vote for or against a proposal in which such officer shall have a material interest.

SECTION 9. Notice of Stockholder Business and Nominations. In addition to the provisions governing a A stockholder’s notice of nominations of persons for election to the Board , or the proposal of other business to be considered by the stockholders provided for in , at any annual meeting of stockholders must comply with the applicable procedures set forth in Articles 11 and 12 of the Restated Certificate of Incorporation : .

(A) Such stockholder’s notice shall also set forth: (i) as to each person whom the stockholder proposes to nominate for election as a director, (a) such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected, (b) any Disclosable Interests of such person (except that the term “Proposing Person” where it appears in sections (A)(1) and (2) of Section 3 shall be deemed to refer to such nominee) and (c) a description of any agreement, arrangement or understanding with any Noticing Person (defined below); (ii) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting and any interest in such business of such stockholder or the beneficial owner, if any, on whose behalf the proposal is made; and (iii) as to all Noticing Persons giving the notice (a) a description of any agreement, arrangement or understanding with respect to the nomination or proposal the Noticing Persons of such person (except that the term “Proposing Person” where it appears in sections (A)(1) and (2) of Section 3 shall be deemed to refer to the Noticing Person), (b) a description of any Disclosable Interests, (c) a representation that the stockholder of record submitting the notice is a holder of record of stock of the Corporation entitled to vote at such meeting, intends to continuously hold such stock of the Corporation through such meeting and intends to appear in person or by a qualified representative at the meeting to propose such business or nomination, and (d) a representation as to whether the stockholder of record submitting the notice or any Noticing Person intends (1) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve or adopt the proposal or elect the nominee and/or (2) otherwise to solicit proxies from stockholders in support of such proposal or nomination. The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Corporation.

The term “Noticing Person” shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made, (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation or

 

7


associate (within the meaning of Rule 12b-2 under the Exchange Act for purposes of these Bylaws) of such stockholder or beneficial owner, and (iv) any other person with whom such stockholder or such beneficial owner (or any of their respective associates or other participants in such solicitation) is Acting in Concert.

(B) A Noticing Person shall update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 9 shall be true and correct as of the record date for notice of the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for notice of the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof).

(C) The foregoing notice requirements of this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation shall be deemed satisfied by a stockholder with respect to business other than a nomination if the stockholder has notified the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with applicable rules and regulations promulgated under the Exchange Act and such stockholder’s proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting.

(D) Only such persons who are nominated in accordance with the procedures set forth in this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation shall be eligible to be elected at an annual meeting of stockholders of the Corporation to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation. The only matters that may be brought before a special meeting of stockholders are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting pursuant Section 3 of these Bylaws, and stockholders shall not otherwise be permitted to nominate directors or propose business to be brought before a special meeting of stockholders. Except as otherwise provided by law, the chairman of the meeting shall have the power and duty:

(i) to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation (including whether the stockholder or beneficial owner, if any, on whose behalf the nomination or proposal is made solicited (or is part of a group which solicited) or did not so solicit, as the case may be, proxies in support of such stockholder’s nominee or proposal in compliance with such stockholder’s representation as required by clause (A)(iii)(d) of this Section 9) and (ii) if any proposed nomination or business was not made or proposed in compliance with this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation, to declare that such nomination shall be disregarded or that such proposed business shall not be transacted. Notwithstanding the foregoing provisions of this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear in person at the annual meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 9, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.

 

8


(E) Notwithstanding the foregoing provisions of this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation; provided, however, that any references in these Bylaws or in the Restated Certificate of Incorporation to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit any requirements applicable to nominations or proposals as to any business to be considered pursuant to this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation and compliance with this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation shall be the exclusive means for a stockholder to make nominations or submit other business (other than, as provided in clause (B) of this Section 9, matters brought properly under and in compliance with Rule 14a-8 of the Exchange Act. Nothing in this Section 9 and Articles 11 and 12 of the Restated Certificate of Incorporation shall be deemed to affect any rights (i) of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to applicable rules and regulations promulgated under the Exchange Act or (ii) of the holders of any series of preferred stock to elect directors pursuant to any applicable provisions of the Restated Certificate of Incorporation.

ARTICLE III: Board of Directors

SECTION 1. General Powers. Subject to any requirements in the Restated Certificate of Incorporation, these Bylaws, and of the Delaware General Corporation Law as to action which must be authorized or approved by the stockholders, any and all corporate powers shall be exercised by or under the authority of, and the business and affairs of the Corporation shall be under the direction of, the Board to the fullest extent permitted by law. Without limiting the generality of the foregoing, it is hereby expressly declared that the Board shall have the following powers, to wit:

(A) to select and remove all of the officers, agents and employees of the Corporation, prescribe such powers and duties for them as may not be inconsistent with law, the Restated Certificate of Incorporation or these Bylaws, fix their compensation, and require from them security for faithful service;

(B) to conduct, manage and control the affairs and business of the Corporation, and to make such rules and regulations therefor not inconsistent with law, the Restated Certificate of Incorporation or these Bylaws, as it may deem best;

(C) to change the location of the registered office of the Corporation in Article I, Section 1 hereof; to change the principal office for the transaction of the business of the Corporation from one location to another as provided in Article I, Section 2 hereof; to fix and locate from time to time one or more subsidiary offices of the Corporation within or without the State of Delaware as provided in Article I, Section 3 hereof; to designate any place within or without the State of Delaware for the holding of any meeting or meetings of stockholders; and to adopt, make and use a corporate seal, and to prescribe the forms of certificates of stock, and to alter the form of such seal and of such certificates from time to time, and in its judgment as it may deem best, provided such seal and such certificate shall at all times comply with the provisions of law;

(D) to authorize the issuance of shares of stock of the Corporation from time to time, upon such terms and for such considerations as may be lawful;

(E) to borrow money and incur indebtedness for the purposes of the Corporation, and to cause to be executed and delivered therefor, in the corporate name, promissory notes, bonds, debentures, deeds of trust and securities therefor; and

(F) by resolution adopted by a majority of the authorized number of directors, to designate an executive and other committees, each consisting of one or more directors, to serve at the pleasure of the Board, and to prescribe the manner in which proceedings of such committee or committees shall be conducted.

 

9


SECTION 2. Number and Term of Office. The authorized number of directors of the Corporation shall be not less than five (5) nor more than fifteen (15) until this Section 2 is amended by a resolution duly adopted by the Board or by the stockholders of the Corporation. The exact number of directors shall be fixed from time to time within the limits specified by resolution of the Board or the stockholders nine (9) . Directors need not be stockholders. Each of the directors of the Corporation shall hold office until such director’s successor shall have been duly elected and shall qualify or until such director shall resign or shall have been removed in the manner provided for in the Restated Certificate of Incorporation. At all times a majority of the directors shall be Independent Directors (as defined below). If a director ceases to be an Independent Director, and such change causes the majority of directors not to be Independent Directors, the Board shall take such action as it deems prudent and necessary to cause the Board to consist of directors, a majority of whom are Independent Directors.

SECTION 3. Election of Directors. Each director to be elected by the stockholders of the Corporation shall be elected by the affirmative vote of a majority of the votes cast with respect to such director by the shares represented and entitled to vote therefor at a meeting of the stockholders for the election of directors at which a quorum is present (an “Election Meeting”); provided, however, that if the Board determines that the number of nominees exceeds the number of directors to be elected at such meeting (a “Contested Election”), and the Board has not rescinded such determination by the record date of the Election Meeting as initially announced, each of the directors to be elected at the Election Meeting shall be elected by the affirmative vote of a plurality of the votes cast by the shares represented and entitled to vote at such meeting with respect to the election of such director.

For purposes of this Section 3, a “majority of the votes cast” means that the number of votes cast “for” a candidate for director exceeds the number of votes cast “against” that director (with “abstentions” and “broker non-votes” not counted as votes cast as either “for” or “against” such director’s election). In an election other than a Contested Election, stockholders will be given the choice to cast votes “for” or “against” the election of directors. In a Contested Election, stockholders will be given the choice to cast “for” or “withhold” votes for the election of directors and shall not have the ability to cast any other vote with respect to such election of directors. In the event an Election Meeting involves the election of directors by separate votes by class or classes or series, the determination as to whether an election constitutes a Contested Election shall be made on a class by class or series by series basis, as applicable.

SECTION 4. Resignations. Any director of the Corporation may resign at any time upon notice given in writing or by electronic transmission to the Board or to the Secretary of the Corporation. Any such resignation shall take effect at the time specified therein, or, if the time be not specified, it shall take effect immediately upon receipt; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

SECTION 5. Vacancies. Except as otherwise provided in the Restated Certificate of Incorporation, and subject to the rights, if any, of the holders of shares of Preferred Stock then outstanding, newly created directorships resulting from any increase in the number of directors or any vacancy on the Board resulting from death, resignation, disqualification, removal or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum, or by a sole remaining director. Each director so chosen to fill a vacancy shall hold office until such director’s successor shall have been elected and shall qualify or until such director shall resign or shall have been removed.

No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director’s term of office.

SECTION 6. Place of Meeting. The Board or any committee thereof may hold any of its meetings at such place or places within or without the State of Delaware as the Board or such committee may from time to time by resolution designate or as shall be designated by the person or persons calling the meeting or in the notice or a waiver of notice of any such meeting. Directors may participate in any regular or special meeting of the Board or

 

10


any committee thereof by means of conference telephone or similar communications equipment pursuant to which all persons participating in the meeting of the Board or such committee can hear each other, and such participation shall constitute presence in person at such meeting.

SECTION 7. First Meeting. The Board shall meet as soon as practicable after each annual election of directors, and notice of such first meeting shall not be required.

SECTION 8. Regular Meetings. Regular meetings of the Board may be held at such times as the Board shall from time to time by resolution determine. If any day fixed for a regular meeting shall be a legal holiday at the place where the meeting is to be held, then the meeting shall be held at the same hour and place on the next succeeding business day that is not a legal holiday. Except as provided by law, notice of regular meetings need not be given.

SECTION 9. Special Meetings. Special meetings of the Board for any purpose or purposes shall be called at any time by the Chairman of the Board or, if the Chairman of the Board is absent or unable or refuses to act, by the Chief Executive Officer or the President. Except as otherwise provided by law or by these Bylaws, special meetings of the Board shall be held upon at least four (4) days written notice or two (2) hours notice given personally, by telephone or by electronic transmission. Any such notice shall be addressed or delivered to each director at such director’s address as is shown upon the records of the Corporation or as may have been given to the Corporation by the director for purposes of notice or, if such address is not shown on such records or is not readily ascertainable, at the place in which the meetings of the directors are regularly held. Notice by mail shall be deemed to have been given at the time such notice is deposited in the United States mails, postage prepaid. Any other written notice shall be deemed to have been given at the time it is personally delivered to the recipient or is delivered to a common carrier for delivery or transmission. Notice by electronic transmission shall be deemed to have been given at the time it is actually transmitted by the person giving the notice by electronic means to the recipient. Oral notice shall be deemed to have been given at the time it is communicated, in person or by telephone or similar means of communication, to the recipient or to a person at the office of the recipient whom the person giving the notice has reason to believe will promptly communicate it to the recipient. Except where otherwise required by law or these Bylaws, notice of the purpose of a special meeting need not be given. Notice of any meeting of the Board shall not be required to be given to any director who is present at such meeting, except a director who shall attend such meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

SECTION 10. Quorum and Manner of Acting. Except as otherwise provided in these Bylaws, the Restated Certificate of Incorporation or by applicable law, the presence of a majority of the authorized number of directors shall be required to constitute a quorum for the transaction of business at any meeting of the Board, and all matters shall be decided at any such meeting, a quorum being present, by the affirmative vote of a majority of the directors present. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, provided any action taken is approved by at least a majority of the required quorum for such meeting. In the absence of a quorum, a majority of directors present at any meeting may adjourn the same from time to time until a quorum shall be present. Notice of any adjourned meeting need not be given. The directors shall act only as a Board, and the individual directors shall have no power as such.

SECTION 11. Action by Consent. Any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting if consent in writing or by electronic transmission is given thereto by all members of the Board or of such committee, as the case may be, and such consent, electronic transmission or transmissions are filed with the minutes of proceedings of the Board or of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

SECTION 12. Compensation. Directors who are not employees of the Corporation or any of its subsidiaries may receive an annual fee for their services as directors in an amount fixed by resolution of the Board, and, in

 

11


addition, a fixed fee, with or without expenses of attendance, may be allowed by resolution of the Board for attendance at each meeting, including each meeting of a committee of the Board. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity as an officer, agent, employee, or otherwise, and receiving compensation therefor.

SECTION 13. Committees. The Board may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. Any such committee, to the extent provided in the resolution of the Board and subject to any restrictions or limitation on the delegation of power and authority imposed by applicable law, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it. Any such committee shall keep written minutes of its meetings and report the same to the Board at the next regular meeting of the Board. Unless the Board or these Bylaws shall otherwise prescribe the manner of proceedings of any such committee, meetings of such committee may be regularly scheduled in advance and may be called at any time by the chairman of the committee or by any two (2) members thereof; otherwise, the provisions of these Bylaws with respect to notice and conduct of meetings of the Board shall govern.

SECTION 14. Definition of Independent Director. For purposes of this Article III, the term “Independent Director” shall mean:

(A) for purposes of determining whether a director is qualified to serve as a member of the audit committee of the Board, a director who meets the qualification requirements for being an independent director under applicable securities laws, including the Securities Exchange Act of 1934, as amended , applicable rules and regulations of the U.S. Securities and Exchange Commission and applicable rules and regulations of any stock exchange or securities market applicable to the Corporation; and

(B) for all other purposes, a director who meets the qualification requirements for being an independent director under applicable rules and regulations of any stock exchange or securities market applicable to the Corporation.

SECTION 15. Interpretation and Application of this Article. The Board shall have the exclusive right and power to interpret and apply the provisions of this Article, including, without limitation, the adoption of written definitions of terms used in and guidelines for the application of this Article (any such definitions and guidelines shall be filed with the Secretary, and such definitions and guidelines as may prevail shall be made available to any stockholder upon written request). Any such definitions or guidelines and any other interpretation or application of the provisions of this Article made in good faith shall be binding and conclusive upon the stockholders, provided that, in the case of any interpretation or application of this Article by the Board to a specific person which results in such person being classified as an Independent Director, the Board shall have determined that such person is independent of management and free from any relationship that, in the opinion of the Board, would interfere with such person’s exercise of independent judgment as a Board member.

ARTICLE IV: Officers

SECTION 1. Officers. The officers of the Corporation shall be a Chairman of the Board, a Chief Executive Officer, a President, one or more Vice Presidents (the number thereof and their respective titles to be determined by the Board), a Secretary, a Treasurer and such other officers as may be appointed at the discretion of the Board in accordance with the provisions of Section 3 of this Article IV. At the discretion of the Board, from time to time, the Chairman of the Board may be a director of the Corporation who is not an officer of the Corporation.

SECTION 2. Election. The officers of the Corporation, except such officers as may be appointed or elected in accordance with the provisions of Section 3 or Section 5 of this Article IV, shall be chosen annually by the Board at the first meeting thereof, and each officer shall hold office until such officer shall resign or shall be removed or otherwise disqualified to serve, or until such officer’s successor shall be elected and qualified.

 

12


SECTION 3. Other Officers. In addition to the officers chosen annually by the Board at its first meeting, the Board also may appoint or elect such other officers as the business of the Corporation may require, each of whom shall have such authority and perform such duties as are provided in these Bylaws or as the Board may from time to time specify, and shall hold office until such officer shall resign or shall be removed or otherwise disqualified to serve, or until such officer’s successor shall be elected and qualified.

SECTION 4. Removal and Resignation. Any officer may be removed, either with or without cause, by resolution of the Board passed by a majority of the directors at the time in office, at any regular or special meeting of the Board, or except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.

SECTION 5. Vacancies. A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in these Bylaws for regular appointment to such office.

SECTION 6. Chairman of the Board. The Chairman of the Board shall preside at all meetings of stockholders and at all meetings of the Board. The Chairman of the Board shall be a member of such committees, if any, and shall have such other powers and duties as may be prescribed by the Board or these Bylaws.

SECTION 7. Chief Executive Officer. The Chief Executive Officer shall, subject to the control of the Board, have general supervision, direction and control of the business and affairs of the Corporation.

SECTION 8. President. The President shall have such powers and perform such duties with respect to the administration of the business and affairs of the Corporation as may from time to time be assigned by the Chief Executive Officer or the Board, or as may be prescribed by these Bylaws.

SECTION 9. Vice President. Each Vice President shall have such powers and perform such duties with respect to the administration of the business and affairs of the Corporation as may from time to time be assigned to such Vice President by the Chief Executive Officer, the President or the Board, or as may be prescribed by these Bylaws.

SECTION 10. Secretary. The Secretary shall keep, or cause to be kept, at the principal office of the Corporation, or such other place as the Board may order, a book of minutes of all meetings of directors and stockholders, with the time and place of holding, whether regular or special, and if special, how authorized and the notice thereof given, the names of those present at meetings of directors, the number of shares present or represented at meetings of stockholders, and the proceedings thereof.

The Secretary shall keep, or cause to be kept, at the principal office of the Corporation’s transfer agent, a share register, or a duplicate share register, showing the name and address of each stockholder, the number of shares of each class held by such stockholder, the number and date of certificates issued for certificated shares, the number and date of issuance of uncertificated shares, and the number and date of cancellation of certificated shares surrendered for cancellation or for uncertificated shares.

The Secretary shall give, or cause to be given, notice of all meetings of stockholders and of the Board required by these Bylaws or by law to be given, and shall keep the seal of the Corporation in safe custody and, if necessary or appropriate, shall affix and attest the seal to all documents to be executed on behalf of the Corporation under its seal, and shall have such other powers and perform such other duties as may be prescribed by these Bylaws or assigned by the Board, the Chairman of the Board or any officer of the Corporation to whom the Secretary may report. If for any reason the Secretary shall fail to give notice of any special meeting of the Board called by one or more of the persons identified in Article III, Section 9 hereof, then any such person or persons may give notice of any such special meeting.

SECTION 11. Treasurer. The Treasurer shall supervise, have custody of and be responsible for all funds and securities of the Corporation. The Treasurer shall deposit all moneys and other valuables in the name and to the

 

13


credit of the Corporation with such depositories as may be designated by the Board or in accordance with authority delegated by the Board. The Treasurer shall disburse the funds of the Corporation as may be ordered or authorized by the Board, shall render to the Board and the Chairman of the Board whenever they request it, an account of all of the Treasurer’s transactions, and shall have such other powers and perform such other duties as may be prescribed by these Bylaws or assigned by the Board, the Chairman of the Board or any officer of the Corporation to whom the Treasurer may report.

ARTICLE V: Contracts, Checks, Drafts, Bank Accounts, Etc.

SECTION 1. Execution of Contracts. The Board, except as otherwise provided in these Bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances; and unless so authorized by the Board or by these Bylaws, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or in any amount.

SECTION 2. Checks, Drafts, Etc. All checks, drafts, or other orders for payment of money, notes or other evidence of indebtedness, issued in the name of or payable to the Corporation, shall be signed or endorsed by such person or persons and in such manner as, from time to time, shall be determined by resolution of the Board. Each such officer, assistant, agent or attorney shall give such bond, if any, as the Board may require.

SECTION 3. Deposits. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust companies or other depositories as the Board may select, or as may be selected by any officer or officers, assistant or assistants, agent or agents, or attorney or attorneys of the Corporation to whom such power shall have been delegated by the Board. For the purpose of deposit and for the purpose of collection for the account of the Corporation, the Chairman of the Board, the Chief Executive Officer, the President, any Vice President, the Treasurer or the Secretary (or any other officer or officers, assistant or assistants, agent or agents, or attorney or attorneys of the Corporation who shall from time to time be determined by the Board) may endorse, assign and deliver checks, drafts and other orders for the payment of money which are payable to the order of the Corporation.

SECTION 4. General and Special Bank Accounts. The Board may from time to time authorize the opening and keeping of general and special bank accounts with such banks, trust companies or other depositories as the Board may select or as may be selected by any officer or officers, assistant or assistants, agent or agents, or attorney or attorneys of the Corporation to whom such power shall have been delegated by the Board. The Board may make such special rules and regulations with respect to such bank accounts, not inconsistent with the provisions of these Bylaws, as it may deem expedient.

ARTICLE VI: Shares and Their Transfer

SECTION 1. Certificates for Stock. The shares of stock of the Corporation may be certificated or uncertificated, as provided under Delaware law. Every holder of stock represented by certificates shall be entitled to have a certificate or certificates, to be in such form as the Board shall prescribe, certifying the number and class of shares of the stock of the Corporation owned by such holder. The certificates representing certificated shares of such stock shall be numbered in the order in which they shall be issued and shall be signed in the name of the Corporation by the Chairman of the Board, the Chief Executive Officer, the President or any Vice President, and by the Secretary or the Treasurer. Any or all of the signatures on the certificates may be a facsimile. In case any officer, transfer agent or registrar who has signed, or whose facsimile signature has been placed upon, any such certificate, shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, such certificate may nevertheless be issued by the Corporation with the same effect as though the person who signed such certificate, or whose facsimile signature shall have been placed thereupon, were such officer, transfer agent or registrar at the date of issue. Every certificate surrendered to the Corporation

 

14


for exchange or transfer shall be canceled, and no new certificate or certificates or uncertificated shares shall be issued in exchange for any existing certificate until such existing certificate shall have been so canceled, except in cases provided for in Section 4 of this Article VI.

SECTION 2. Transfers of Stock. Transfers of shares of stock of the Corporation shall be made only on the books of the Corporation by the registered holder thereof, or by such holder’s attorney thereunto authorized by power of attorney duly executed and filed with the Secretary, or with a transfer clerk or a transfer agent appointed as provided in Section 3 of this Article VI, and, if such shares are represented by a certificate, upon surrender of the certificate or certificates for such shares properly endorsed and the payment of all taxes thereon. The person in whose name shares of stock stand on the books of the Corporation shall be deemed the owner thereof for all purposes with regard to the Corporation. Whenever any transfer of shares shall be made for collateral security, and not absolutely, such fact shall be so expressed in the entry of transfer if, when the certificate or certificates shall be presented to the Corporation for transfer or uncertificated shares are requested to be transferred, both the transferor and the transferee request the Corporation to do so.

SECTION 3. Regulations. The Board may make such rules and regulations as it may deem expedient, not inconsistent with these Bylaws, concerning the issue, transfer and registration of certificates for shares of the stock of the Corporation. It may appoint, or authorize any officer or officers to appoint, one or more transfer clerks or one or more transfer agents and one or more registrars, and may require all certificates for stock to bear the signature or signatures of any of them.

SECTION 4. Lost, Stolen, Destroyed, and Mutilated Certificates. In any case of loss, theft, destruction, or mutilation of any certificate of stock, another certificate or uncertificated shares may be issued in its place upon proof of such loss, theft, destruction, or mutilation and upon the giving of a bond of indemnity to the Corporation in such form and in such sum as the Board may direct; provided, however, that a new certificate or uncertificated shares may be issued without requiring any bond when, in the judgment of the Board, it is proper so to do.

SECTION 5. Fixing Date for Determination of Stockholders of Record.

(A) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any other change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than 60 nor less than 10 days before the date of such meeting , nor more than 60 days prior to any other action. If in any case involving the determination of stockholders for any purpose other than notice of or voting at a meeting of stockholders the Board shall not fix such a record date, then the record date for determining stockholders for such purpose shall be the close of business on the day on which the Board shall adopt the resolution relating thereto . A determination of stockholders entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of such meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.

(B) The record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be fixed in the manner provided for in the Restated Certificate of Incorporation.

(B) (C) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted and which record date shall not be more than 60 days prior to such action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be the close of business on the day on which the Board adopts the resolution relating thereto.

 

15


ARTICLE VII: Miscellaneous

SECTION 1. Seal. The Board shall adopt a corporate seal, which shall be in the form of a circle and shall bear the name of the Corporation and words showing that the Corporation was incorporated in the State of Delaware.

SECTION 2. Waiver of Notices. Whenever notice is required to be given by these Bylaws or the Restated Certificate of Incorporation or by law, the person entitled to said notice may waive such notice in writing, either before or after the time stated therein, and such waiver shall be deemed equivalent to notice.

SECTION 3. Amendments. Except as otherwise provided herein or in the Restated Certificate of Incorporation, these Bylaws or any of them may be altered, amended, repealed or rescinded and new Bylaws may be adopted by the Board or by the stockholders at any annual or special meeting of stockholders, provided that notice of such proposed alteration, amendment, repeal, re s ci s sion or adoption is given in the notice of such meeting.

SECTION 4. Representation of Other Corporations. The Chairman of the Board, the Chief Executive Officer, the President, the Secretary or any Vice President of the Corporation is authorized to vote, represent and exercise on behalf of the Corporation all rights incident to any and all shares of any other corporation or corporations standing in the name of the Corporation. The authority herein granted to said officers to vote or represent on behalf of the Corporation any and all shares held by the Corporation in any other corporation or corporations may be exercised either by such officers in person or by any person authorized so to do by proxy or power of attorney duly executed by such officers.

 

16


LOGO

ADVANCING ALLERGAN
Home
Webcast
Nominees
Shareholder Materials
News Releases
Proposed By-Laws
Media Contacts
Frequently Asked Questions
Why is Pershing Square asking shareholders to call a special meeting?
What are you asking me to do?
What Steps Must an Allergan Shareholder Take to Help Request a Special Meeting?
What steps must each DTC Participant take?
What is the record date for the calling of a special meeting?
How many shares do you need to call a special meeting?
If I choose to become a Proposing Person, am I accepting Valeant’s offer?
What do I need to do to become a Proposing Person?
When will the special meeting be held?
Are you asking me to remove any Allergan directors?
How do I become a holder of record?
When do I need to submit my forms by?
If I become Proposing Person, do I have to own my shares through the date of the special meeting?
If I become a proposing Person, what happens if I sell my shares?
When does the tender offer for Valeant expire?
Why is Pershing Square asking shareholders to call a special meeting?
Pershing Square is asking shareholders to call a special meeting in order to vote on the eight proposals discussed below.
The proposals seek to (1) remove from office as directors certain members of the Allergan board of directors that Pershing Square believes lack the objectivity necessary to act in the best interests of shareholders with respect to Valeant’s proposal to acquire Allergan, (2) request that the Allergan board elect or appoint (irrespective of whether proposal 1 is passed) six new directors to the Allergan board, (3) amend the Allergan bylaws to simplify the mechanics for calling a special meeting, (4) amend the Allergan bylaws to provide mechanics for calling a special meeting if no directors or less than a majority of directors are then in office, (5) amend the Allergan bylaws to provide simplified mechanics for nominating directors or proposing business at any annual meeting, (6) amend the Allergan bylaws to fix the authorized number of directors at nine directors, (7) repeal any bylaws adopted without shareholder approval after Allergan’s 2014 annual meeting and up to and including the date of the special meeting (other than any amendment approved at the special meeting) and (8) pass a non-binding resolution encouraging the Board to promptly engage in good faith discussions with Valeant regarding Valeant’s offer to merge with Allergan without in any way precluding discussions the Board may choose to engage in with other parties potentially offering higher value.
If Pershing Square is successful in calling the special meeting, shareholders would have the ability to vote for, against or abstain from voting on each of the proposals. For proposal 1, the shareholders would have the ability to vote to remove all, some or none of the six members of the Allergan board of directors that Pershing Square is seeking to remove. For proposal 2, the shareholders would have the ability to recommend that the Allergan board elect or appoint all, some or none of the six new directors that Pershing Square is seeking to have elected or appointed.
Back to top


LOGO

What are you asking me to do?
We are asking you to (1) either transfer or purchase at least one share of Allergan common stock and register in your name on the books of Allergan’s transfer agent, Wells Fargo Bank, (2) complete, sign and date your Special Meeting Request Form, (3) complete, sign and date your WHITE Proxy Card, (4) arrange for the execution of the Cede & Co. Meeting Request, and (5) arrange for the execution of the Verification Letter, as applicable, and return each of them to D.F. King & Co. Each of these documents and instructions for completing these documents may be found here. What do I need to do to become a Proposing Person?
Back to top
What Steps Must an Allergan Shareholder Take to Help Request a Special Meeting?
First, you should either transfer or purchase at least one share of Allergan common stock and register in your name on the books of Allergan’s transfer agent, Wells Fargo Bank.
Second, you should complete, sign and date your Special Meeting Request Form and your WHITE Proxy Card.
Third, to effect the execution of the Cede & Co. Meeting Request and Verification Letter, you will need to:
arrange for your DTC participant(s) to instruct DTC to cause Cede & Co., as nominee of DTC, to sign and return the Cede & Co. Meeting Request to your DTC participant(s);
arrange for your DTC participant(s) to sign the Verification Letter with respect to your shares of Allergan common stock.
Fourth, once you receive the executed Cede & Co. Meeting Request and executed Verification Letter from your DTC participant, you should send the Cede & Co. Meeting Request and Verification Letter, along with the executed Special Meeting Request Form, WHITE Proxy Card and the record holder verification (copy of certificate or statement of ownership from Wells Fargo Bank, Allergan’s transfer agent), to D.F. King.
If you have any questions about completing, executing and dating your Special Meeting Request Form or WHITE Proxy Card, causing your Cede & Co. Meeting Request or Verification Letter to be executed and returned to you or delivering each of the four documents to D.F. King, or otherwise require assistance, please contact D.F. King at the address and telephone numbers below:
D.F. King & Co., Inc.
48 Wall Street
New York, NY 10005
Toll-free: (800) 859-8511
Banks and brokers: (212) 269-5550
Back to top
What steps must each DTC Participant take?
First, once a DTC Participant is contacted by an Allergan shareholder, the DTC Participant should: instruct DTC to cause Cede & Co., as nominee of DTC, to sign and return the Cede & Co. Meeting Request; sign the Verification letter with respect to that shareholder’s shares of Allergan common stock. Second, upon receiving the executed Cede & Co. Meeting Request from Cede & Co., the DTC participant should return the executed Cede & Co. Meeting Request and executed Verification Letter to the shareholder.
If you have any questions about completing, executing and dating your Special Meeting Request Form or WHITE Proxy Card, causing your Cede & Co. Meeting Request or Verification Letter to be executed and returned to you or delivering each of the four documents to D.F. King, or otherwise require assistance, please contact D.F. King at the address and telephone numbers below:


LOGO

D.F. King & Co., Inc.
48 Wall Street
New York, NY 10005
Toll-free: (800) 859-8511
Banks and brokers: (212) 269-5550
Back to top
What is the record date for the calling of a special meeting?
The record date for determining shareholders entitled to notice of, and to vote at, the special meeting has not been established yet. The record date will be at the close of the business day immediately preceding the day on which notice of the meeting is given to shareholders, unless the Allergan board sets a different record date in accordance with the Allergan bylaws and Delaware law. In any event, the record date will not be more than 60 days nor less than 10 days before the date of the special meeting.
Back to top
How many shares do you need to call a special meeting?
Under the Allergan bylaws, holders of record with Net Long Beneficial Ownership (as defined in the Allergan bylaws) of at least 25% of the outstanding shares of common stock of Allergan at the time the special meeting request is validly submitted must complete and deliver the necessary paperwork.
Based on on 296,910,449 shares of Allergan common stock outstanding as of June 30, 2014, as reported in Allergan’s Preliminary Revocation Solicitation Statement on Schedule 14A, as filed with the Securities and Exchange Commission on July 14, 2014, the request of record holders with Net Long Beneficial Ownership of approximately 74,227,612 shares will be necessary to call the special meeting.
Back to top
If I choose to become a Proposing Person, am I accepting Valeant’s offer?
No, if you choose to become a Proposing Person, you are simply supporting Pershing Square’s effort to call a special meeting of Allergan’s shareholders to vote on the proposals summarized above.
Back to top
What do I need to do to become a Proposing Person?
You must own at least one share of Allergan stock beneficially and in record form on the books and records of Allergan’s transfer agent, Wells Fargo Bank. Beneficial owners of shares who wish to become Proposing Persons but do not currently hold any shares of Allergan common stock in record form must transfer into the name of such Proposing Person, or purchase in the name of such Proposing Person, at least one share of Allergan common stock. Proposing Persons must then (1) complete, sign and date your Special Meeting Request Form, (2) complete, sign and date your WHITE Proxy Card (3) arrange for the execution of the Cede & Co. Meeting Request, (4) arrange for the execution of the Verification Letter, as applicable, and return each of them to D.F. King & Co. by following the instructions set forth in the question, “What are you asking me to do?”
Back to top
When will the special meeting be held?
The Special Meeting will be held at such date and time as the Allergan board may determine in accordance with the bylaws and applicable law.


LOGO

Back to top
Are you asking me to remove any Allergan directors?
Pershing Square is seeking to remove six of Allergan’s current directors and requesting that the Allergan board elect or appoint six new directors. Allergan shareholders may vote for, against or abstain from voting on any of the proposals submitted for a vote of Allergan shareholders at the special meeting. At the special meeting the shareholders would have the ability to vote to remove all, some or none of the six members of the Allergan board of directors that Pershing Square is seeking to remove. Shareholders would also have the ability to recommend that the Allergan board elect or appoint all, some or none of the six new directors that Pershing Square is seeking to have elected or appointed.
Back to top
How do I become a holder of record?
Beneficial owners of shares of Allergan common stock who wish to become Proposing Persons but do not currently hold any shares of Allergan common stock in record form on the books and records of Allergan’s transfer agent, Wells Fargo Bank, you must transfer into the name of such Proposing Person, or purchase in the name of such Proposing Person, at least one share of Allergan common stock.
Back to top
When do I need to submit my forms by?
We are asking shareholders who wish to become Proposing Persons to submit their forms as promptly as possible.
Back to top
If I become Proposing Person, do I have to own my shares through the date of the special meeting?
No. While the Participating Person must represent that it intends to continuously hold the shares through the date of the special meeting, the proposing person remains free to sell any or all of its shares on or before the date of the special meeting, but any reduction in Net Long Beneficial Ownership will constitute a revocation of the special meeting request to the extent of such reduction.
Back to top
If I become a proposing Person, what happens if I sell my shares?
If you become a Proposing Person and you sell your shares, any reduction in your Net Long Beneficial Ownership (as defined in Allergan’s bylaws) with respect to which your special meeting request relates will constitute a revocation of your special meeting request to the extent of such reduction.
Back to top
When does the tender offer for Valeant expire?
As disclosed in the Offer to Exchange contained within the Form S-4 Valeant filed with the SEC on June 18, 2014, Valeant’s exchange offer for Allergan shares will expire at 5:00 pm New York City time on August 15, 2014, unless the offer is extended.
Back to top
© 2014 Pershing Square Capital Management


LOGO

ADVANCING ALLERGAN
HOME WEBCAST NOMINEES SHAREHOLDER MATERIALS NEWS RELEASES PROPOSED BY-LAWS MEDIA CONTACTS
Timeline
VALEANT AND PERSHING SQUARE ANNOUNCE BID TO ACQUIRE ALLERGAN
Valeant and Pershing Square announce bid to acquire Allergan ($48.3 + 0.83 share of VRX) Pershing Square’s Presentation. Allergan adopts a poison pill and, based on media reports, subsequently seeks competing offers from Johnson & Johnson and Sanofi.
May 13, 2014 April 22, 2014
ALLERGAN REJECTS VALEANT’S BID
Allergan rejects Valeant’s bid, Pershing Square seeks list of Allergan stockholders and the next days files preliminary proxy to launch process to hold informal shareholder referendum on the bid.
May 19, 2014
PERSHING SQUARE URGES ALLERGAN INDEPENDENT DIRECTORS TO HIRE INDEPENDENT COUNSEL
Pershing Square urges allergen independent directors to hire independent counsel, arguing Allergan’s CEO is conflicted because he will lose his leadership rule at the company and likely his job as a result of the transaction and cannot independently represent the company in the merger.
Read WAA’s publicly released letter
May 28, 2014
VALEANT INCREASES ITS OFFER TO ACQUIRE ALLERGAN
Valeant increases its offer to acquire Allergan ($38.30 shares/ +0.83 share of VRX) to $166.16/share and adds contingent Value Right for DARPin of up to $25.00/share in value.


LOGO

VALEANT INCREASES ITS OFFER TO ACQUIRE ALLERGAN TO $180.90/ SHARE
Valeant increases its offer to acquire Allergan by increasing the cash component to $72 per shares. New offer prompted by PSCM based on shareholder feedback, which agrees to take all VRX stock (and no cash) for its AGN shares at a fixed exchange ratio.
PSCM SEEKS CLARITICATION FROM ALLERGAN
PSCM seeks clarification from Allergan on what actions would trigger poision pill.
ALERGAN RESPONDS TO PSCM LETTER
Allergan responds to PSCM letter but does not provide complete answers.
May 30, 2014
PERSHING SQUARE SEEKS TO HOLD A SPECIAL SHAREDHOLDER MEETING
Pershing 5quare, having dropped its request for an informal shareholders referendum, seeks to hold a special shareholder meeting to oust six of the nine Allergan directors.
Click to View Filling
June 6, 2014
ALLERGAN REJECTS VALEANT’S INCREASED BID
Allergan rejects Valeant’s increased bid
June 11, 2014
PERSHING SQUARE SEEKS CLARIFICATION ON ALLERGAN POISON PILL IN COURT.
PSCM sure Allergan in Delaware Court of Chancery seeking clarification on whether efforts to hold special shareholders meeting will trigger Allergan’s poison pill.
View Complaint
Pershing 5quare asks the court expedite the hearing on the matter.


LOGO

June 17, 2014
VALEANT HOSTS WEBINAR
Valeant hosts webinar to respond to misleading facts made by Allergan
June 18, 2014
VALEANT LAUNCHES EXCHANGE OFFER
Valeant launches exchange offer for Allergan.
June 19, 2014
DELAWARE COURT OF CHANCERY RULES IN FAVOR OF EXPEDITING PERSHING SQUARE’S REQUEST
Delaware Court of Chancery rules in favor of expediting Pershing Square’s request to seek clarity on trigger for poison pill. Hearing set for July 7.
June 23, 2014
ALLERGAN BOARD DECLARES VALEANT’S UNSOLICITED EXCHANGE OFFER INADEQUATE
Allergan board declares Valeant’s unsolicited exchange offer in adequate. Valeant Posts Facts-Based Answers to Refute Allergan’s Misleading Statements.
June 27, 2014
PERSHING SQUARE ENTERS INTO A SETTLEMENT WITH ALLERGAN
Pershing Square enters into a settlement with Allergan resolving the poison pill litigation before the Delaware Court of Chancery. The settlement provides the clarification sought by Pershing Square that its actions in connection with the solicitation and receipt of recoverable proxies to call a special meeting of shareholders of Allergan will not trigger Allergan’s recently adopted poison pill. The settlement paves the way for Perishing Square to soon begin actively soliciting proxies to call the special meeting. Link to Press Release


LOGO

July 7, 2014 PERSHING SQUARE ANNOUNCES DIRECTOR SLATE FOR ALLERGAN BOARD
Pershing Square announces a state of six independent directors for the board of Allergan. The six members of the state are: Betsy Atkins, Cathleen P. Black, Fredric N. Eshelman, Steven J. Shulman, David A. Wilson and John J. Zillmer. Read Announcement
PERSHING SQUARE FILES DEFINITIVE SOLICITATION STATEMENT
Pershing Square files definitive solicitation statement with the Securities and Exchange Commission, permitting it to actively solicit support for the calling of a special meeting. July 11, 2014
August 15, 2014 VALEANT’S EXCHANGE OFFER EXPIRES UNLESS EXTENDED


LOGO

ADVANCING ALLERGAN
HOME
WEBCAST
NOMINEES
SHAREHOLDER MATERIALS
NEWS RELEASES
PROPOSED BY-LAWS
MEDIA CONTACTS
Media Contacts
CAROLYN SARGENT
Rubenstein Associates
212 843-8030
(M) 917 838-8514
csargent@rubenstein.com
STEVE MURRAY
Rubenstein Associates
212 843 8293
(M) 631 697 5621
smurray@rubenstein.com
FRAN MCGILL
Rubenstein Associates
212-843-9353
(M) 610-506-7559
fmcgill@rubenstein.com
© 2014 Pershing Square Capital Management


LOGO

HOME WEBCAST NOMINEES SHAREHOLDER MATERIALS NEWS RELEASES PROPOSED BY-LAWS MEDIA CONTACTS
Disclaimer
LEGAL NOTICE, DISCLAIMER AND FORWARD-LOOKING INFORMATION
This website is provided by Pershing Square Capital Management, L.P. and certain of its affiliates (collectively “Pershing Square”, “we” or “our”) and contains information made previously publicly available by or on behalf of Pershing Square and Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with Pershing Square’s solicitation of written requests to call a special meeting of shareholders of Allergan, Inc. (“Allergan”) in furtherance of a proposal which Valeant has made for a business combination transaction with Allergan and, in connection therewith, an exchange offer which Valeant has made to Allergan stockholders. The information contained in this website is provided on an “as is” basis, which is given as of the specific dates of the particular content or in respect of the specific periods referenced.
No representation or warranty, express or implied, is made as to the accuracy (currently or historically) or completeness of any information contained in this website, whether derived or obtained from filings made with regulatory authorities, from any third party or otherwise. The information contained in this website should not be relied upon as an accurate or complete source of current information or events. As a visitor to this website, you acknowledge and agree that any reliance on or use of this website shall be solely at your own risk, and we are not responsible in any manner for any harm, loss or damage whatsoever arising from your use of this website or the information contained herein. Copies of the various filings with the Securities and Exchange Commission (“SEC”), letters to shareholders, shareholder materials, presentations, press releases and other statements issued by or on behalf of Pershing Square or its principals or Valeant contained in this website have previously been made publicly available in accordance with applicable U.S. corporate and securities laws, and are accessible on the Electronic Data Gathering, Analysis and Retrieval system on the SEC*s website at www.sec.gov.
In addition, some of the content on this website contains references or links to information published or otherwise made publicly available by third parties. Pershing Square has not sought or obtained and Valeant did not seek or obtain consent from any third party to use any statement or information contained in the content available on this website obtained or derived from statements made or published by third parties, and nor has Pershing Square or Valeant independently verified the accuracy (currently or historically) of such information. Pershing Square does not and Valeant when it published the content did not assume liability or responsibility for the content, accuracy (currently or historically) or appropriateness of the third party information.
The information contained in this website is made available by Pershing Square and not by or on behalf of Allergan or its affiliates or subsidiaries or any other person. While certain funds managed by Pershing Square and its affiliates have invested in common shares of Allergan, Pershing Square is not an affiliate of Allergan and neither Pershing Square nor its principals or representatives are authorized to disseminate any information for or on behalf of Allergan, and nor do we purport to do so. It is also possible that there will be developments in the future that cause Valeant or Pershing Square to change their positions regarding Allergan. Pershing Square hereby disclaims any duty to provide any updates or changes to the information contained in this website, except as required by and in accordance with applicable laws.
Forward-looking Statements
This website contains forward-looking information that was prepared as of the specific dates and/or for the specific periods referenced in the materials contained or referred to in this website. All information contained in this website that is not clearly historical in nature or that necessarily depends on future or subsequent events is forward-looking information prepared as of the specific dates and for the specific periods referenced in the applicable document contained or referred to in this website, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking information as of such date(s). Such forward-looking information was based on the expectations of Pershing Square and Valeant and information available at the time of initial publication or dissemination of such information. They were not, and are not, guarantees of future performance, events or results, involve various risks and uncertainties that are difficult to predict and are based upon assumptions as to future events, performance or results that were believed to be reasonable at the time such information was initially made available but may not prove to be accurate and, in most cases, have been superseded, modified or replaced by subsequent information, events or developments. While Pershing Square may elect to update forward-looking information contained in this website at some point in the future, we do not assume any obligation to update any such forward-looking information, except as required by and in accordance with applicable laws.
ADDITIONAL INFORMATION
This website does not constitute an offer to buy or solicitation of an offer to sell any securities. This website relates to Pershing Square’s solicitation of written requests to call a special meeting of shareholders of Allergan in connection with the proposal which Valeant has made for a business combination transaction with Allergan. In furtherance of this proposal, Pershing Square has filed a definitive solicitation statement with the SEC on July 11, 2014 (the “solicitation statement”), Valeant has filed a registration statement on Form S-4 (the “Form S-4”) and a tender offer statement on Schedule TO (including the offer to exchange, the letter of election and transmittal and other related offer materials) with the SEC on June 18, 2014 (together with the Form S-4, as amended and supplemented the “Schedule TO”), and a preliminary proxy statement on June 24, 2014 with respect to a meeting of Valeant shareholders. Valeant and Pershing Square (and, if a negotiated transaction is agreed, Allergan) may file one or more other solicitation statements, proxy statements, registration statements, tender or exchange offer documents or other documents with the SEC. This website is not a substitute for the solicitation statement, the Schedule TO or any other solicitation statement, proxy statement, registration statement, prospectus, tender or exchange offer document or other document Valeant, Pershing Square and/or Allergan may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF VALEANT AND ALLERGAN ARE URGED TO READ THE SOLICITATION, THE SCHEDULE TO AND ANY OTHER SOLICITATION STATEMENT, PROXY STATEMENT, REGISTRATION STATEMENT, PROSPECTUS, TENDER OR EXCHANGE OFFER DOCUMENTS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any other definitive solicitation statement or proxy statement or definitive tender or exchange offer documents (if and when available) will be mailed to stockholders of Allergan and/or Valeant, as applicable. Investors and security holders may obtain free copies of the solicitation statement and the Schedule TO, and will be able to obtain free copies of these other documents (if and when available) and other documents filed with the SEC by Valeant and/or Pershing Square through the web site maintained by the SEC at http://www.sec.gov.
Information regarding the names and interests in Allergan and Valeant of Pershing Square and persons related to Pershing Square who may be deemed participants in any solicitation of Allergan or Valeant shareholders in respect of a Valeant proposal for a business combination with Allergan is available in the solicitation statement. Information regarding the names and interests in Allergan and Valeant of Valeant and persons related to Valeant who may be deemed participants in any solicitation of Allergan or Valeant shareholders in respect of a Valeant proposal for a business combination with Allergan is available in the additional definitive proxy soliciting materials in respect of Allergan filed with the SEC by Valeant on April 21, 2014 and May 28, 2014. The additional definitive proxy soliciting material referred to in this paragraph and the solicitation statement can be obtained free of charge from the sources indicated.
This website may employ cookies. The publicly accessible areas of this website do not automatically gather any personal information, and such information will not be collected unless information such as your name, phone number or e-mail address is provided voluntarily. However, we reserve the right to gather non-personal information and perform statistical analysis of user behavior and patterns of this website.
© 2014 Pershing Square Capital Management

Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Valeant Pharma Charts.